UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-K

(Mark One)

☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the Fiscal Year Ended December 31, ~~2022~~2023

☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

For the Transition Period From ____________ to ____________

Commission File Number: 000-55753

Can B̅ Corp.

(f/k/a Canbiola, Inc.)

(Exact name of registrant as specified in its charter)

Florida

20-3624118

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification Number)

960 South Broadway, Suite 120, Hicksville NY 11801

(Address of principal executive offices)

516-595-9544

Registrant’s telephone number, including area code:

None

Securities Registered Pursuant to Section 12(b) of the Act:

Tile of each class		Trading Symbol(s)		Name of each exchange on which registered
None		CANB		N/A

Securities Registered Pursuant to Section 12(g) of the Act:

Common Stock, Nil par value per share

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Large accelerated filer	☐	Accelerated filer	☐
Non-accelerated filer	☒	Smaller reporting company	☒
Emerging Growth Company	☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☒ No

~~The~~If ~~aggregate~~securities ~~market~~are ~~value~~registered ofpursuant ~~voting~~to ~~stock~~Section ~~held~~12(b) ~~by non-affiliates~~ of the ~~registrant on June 30~~Act, ~~2022,~~indicate ~~was~~by ~~$18,546,039~~check ~~based~~mark onwhether the ~~last reported~~financial ~~sale~~statements ~~price~~ of the registrant’s included ~~Common~~in ~~Stock~~the onfiling reflect the ~~OTC~~correction ~~Markets~~of onan ~~that~~error ~~date~~to previously issued financial statements. ☐

AsIndicate by check mark whether any of ~~April~~those ~~10,~~error ~~2023,~~corrections ~~the~~are ~~registrant~~restatements ~~had~~that ~~outstanding~~required ~~5,396,682~~a ~~shares~~recovery analysis of ~~common~~incentive-based ~~stock,~~compensation received ~~$0.00~~by ~~par~~any ~~value~~of ~~per~~the ~~share~~registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

The aggregate market value of voting stock held by non-affiliates of the registrant on June 30, 2023, was $1,017,685 based on the last reported sale price of the registrant’s Common Stock on the OTC Markets on that date.

As of April 12, 2024, the registrant had outstanding 49,344,230 shares of common stock, $0.00 par value per share.

Can B̅ Corp.

~~2022~~ 2023 FORM 10-K ANNUAL REPORT

TABLE OF CONTENTS

Item No.	Description	Page
Cautionary Note Regarding Forward-Looking Statements		3
	PART I
Item 1.	Business.	4
Item 1A.	Risk Factors.	79
Item 1B.	Unresolved Staff Comments.	1719
Item 2.	Properties.	1819
Item 3.	Legal Proceedings.	1820
Item 4.	Mine Safety Disclosures.	1820
	PART II
Item 5.	Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.	1821
Item 6.	Selected Financial Data.	2123
Item 7.	Management’s Discussion and Analysis of Financial Condition and Results of Operations.	2123
Item 7A.	Quantitative and Qualitative Disclosures About Market Risk.	24
Item 8.	Financial Statements and Supplementary Data.	24
Item 9.	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.	24
Item 9A.	Controls and Procedures.	24
Item 9B.	Other Information.	25
	PART III
Item 10.	Directors, Executive Officers and Corporate Governance.	25
Item 11.	Executive Compensation.	28
Item 12.	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.	3029
Item 13.	Certain Relationships and Related Transactions, and Director Independence.	3231
Item 14.	Principal Accounting Fees and Services.	3231
	PART IV
Item 15.	Exhibits, Financial Statement Schedules.	3332
Signatures		3635

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Certain statements contained or incorporated by reference in this Annual Report on Form 10-K are considered forward-looking statements (within the meaning of the Private Securities Litigation Reform Act of 1995) concerning our business, results of operations, economic performance and/or financial condition, based on management’s current expectations, plans, estimates, assumptions and projections. Forward-looking statements are included, for example, in the discussions about:

● strategy; ● new product discovery and development; ● current or pending clinical trials; ● our products’ ability to demonstrate efficacy or an acceptable safety profile; ● actions by regulatory authorities; ● product manufacturing, including our arrangements with third-party suppliers; ● product introduction and sales; ● royalties and contract revenues; ● expenses and net income; ● credit and foreign exchange risk management; ● liquidity; ● value of assets ● asset and liability risk management; ● the outcome of litigation and other proceedings; ● intellectual property rights and protection; ● economic factors; ● competition; and ● legal risks.

Any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Forward-looking statements generally are identified by the words “expects,” “anticipates,” “believes,” “intends,” “estimates,” “aims,” “plans,” “may,” “could,” “will,” “will continue,” “seeks,” “should,” “predict,” “potential,” “outlook,” “guidance,” “target,” “forecast,” “probable,” “possible” or the negative of such terms and similar expressions. Forward-looking statements are subject to change and may be affected by risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Forward-looking statements speak only as of the date they are made, and we undertake no obligation to update any forward-looking statement in light of new information or future events, except as required by law, although we intend to continue to meet our ongoing disclosure obligations under the U.S. securities laws and other applicable laws.

We caution you that a number of important factors could cause actual results or outcomes to differ materially from those expressed in, or implied by, the forward-looking statements, and therefore you should not place too much reliance on them. These factors include, among others, those described herein, under “Risk Factors” and elsewhere in this Annual Report and in our other public reports filed with the Securities and Exchange Commission. It is not possible to predict or identify all such factors, and therefore the factors that are noted are not intended to be a complete discussion of all potential risks or uncertainties that may affect forward-looking statements. If these or other risks and uncertainties materialize, or if the assumptions underlying any of the forward-looking statements prove incorrect, our actual performance and future actions may be materially different from those expressed in, or implied by, such forward-looking statements. We can offer no assurance that our estimates or expectations will prove accurate or that we will be able to achieve our strategic and operational goals.

Forward-looking statements are based on information we have when those statements are made or management’s good faith belief as of that time with respect to future events and are subject to significant risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements.

Moreover, new risks regularly emerge, and it is not possible for our management to predict or articulate all risks we face, nor can we assess the impact of all risks on our business or the extent to which any risk, or combination of risks, may cause actual results to differ from those contained in any forward-looking statements. All forward-looking statements included in this prospectus are based on information available to us on the date of this Annual Report. Except to the extent required by applicable laws or rules, we undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the cautionary statements contained above and throughout this Annual Report.

PART I

Item 1.

Business

Recent Developments

In February 2024, our 67% owned subsidiary, Nascent Pharma, LLC (“Nascent”), acquired composition of matter and use patents covering liquid formulations of cannabis, including, among other things, beverages, tinctures, vape pen liquids and liquid filled capsules. Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders and opioid dependencies. Through Nascent, we plan to pursue opportunities to license, protect and develop uses for the patents.

An independent valuation firm valued the patents at $122,000,000 in 2020, after taking into account the present value of projected income streams, applying a 90% discount and assuming a revenue stream through August 2034. No assurance can be given that the patents will ultimately provide a revenue stream to the Company or that the value of the patents will equal the value determined by the independent valuation firm.

On March 14, 2024, an auction of the assets of our hemp division was conducted under Article 9 of the Uniform Commercial Code following allegations by certain affiliated creditors that we were in breach of our obligations under certain notes and a forbearance agreement. See “Item 3. Legal Proceedings.”

Following the auction, we have continued our hemp operations on a reduced scale using equipment provided by third parties and the services of third-party processors. Historically, revenues from our hemp division supported, in part, our durable medical equipment business conducted through Duramed, Inc. Due to reduced support from the hemp division, Duramed, Inc. is operating with reduced staff which has adversely impacted revenues. While we plan to continue our hemp and durable medical equipment operations for the near term, our primary focus will be on protecting and commercializing the cannabis patents recently acquired by Nascent.

Organization

We were originally incorporated as WrapMail, Inc. (“Wrap”) in Florida on October 11, 2005 in order to tap into a largely un-serviced segment of the web-based advertising industry. Effective January 5, 2015, WRAP acquired 100% ownership of Prosperity Systems, Inc., a New York corporation incorporated on April 2, 2008, in order to acquire Prosperity’s office productivity software suite as a complement to WRAP’s existing intellectual property. After its acquisition, the Company transferred Prosperity’s operations to WRAP; however, the Company does not currently actively operate its WRAP or Prosperity divisions.

Around the first quarter of 2017, the Company began to transition into the health and wellness space, including the development, processing and sale of hemp derived products, and now operates three distinct divisions: retail sales, R&D and manufacturing, and durable medical devices. The Company also has a hemp cultivation division which is currently non-operational.

On May 15, 2017, WRAP changed its name to Canbiola, Inc. to reflect its transition. On March 6, 2020 CANB changed its name to “Can B̅ Corp.” in order to segregate its corporate identity from its lead products branded under the Canbiola™ brand.

Effective December 27, 2010, WRAP effected a 10 for 1 forward stock split of its common stock. Effective June 4, 2013, WRAP effected a 1 for 10 reverse stock split of its common stock. On March 6, 2020, Can B̅ effected a 1 for 300 reverse stock split of its common stock. On March 13, 2022, the Company effectuated a 1 for 15 reverse split of its stock. The accompanying consolidated financial statements retroactively reflect these stock splits.

Business Divisions

Hemp is thought to contain anywhere from 60 to over 100 naturally occurring compounds (cannabinoids) thought to interact with cannabinoid receptors present on the surface of cells in various parts of the central nervous system. The effects of cannabinoids are thought to depend on the area of the brain involved. Cannabidiol (“CBD”) is probably one of the most well-known of these compounds, thought to have many beneficial uses. CBD is incorporated into many of the Company’s products; however, the Company has recently begun extracting and processing cannabinol (“CBN”), cannabigerol (“CBG”), delta-10 and delta-8 for its products and for wholesale to third-parties looking to incorporate such compounds into their products. The Company has all of its hemp based raw materials to incorporate into products tested by a 3rd party independent laboratory. The Company aims to be the premier provider of the highest quality natural hemp cannabinoid products on the market through sourcing the very best raw material and developing a variety of products it believes will improve people’s lives in a variety of areas.

I-

Pure Health Products

Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) is the Company’s manufacturing arm. PHP manufactures all of the Company’s CBD products ~~and also provides white label manufacturing and production services to third parties and performs research and development for the Company~~. ~~Through PHP, the Company is able to control the manufacturing process of its products while reducing its production costs. Pasquale Ferro is the president of PHP.~~

In December, 2018, the Company acquired 100% of the membership interests in Pure Health Products, with which it then had and currently has an exclusive production agreement, pursuant to an Acquisition Agreement (“PHP Acquisition Agreement”). In January, 2019, PHP acquired certain assets from Seven Chakras, LLC (“Seven Chakras”), a former competitor, which assets included the rights and title to (i) Seven Chakras’ proprietary formulas, methods, trade secrets, and know-how related to the production of Seven Chakras’ CBD products, (ii) Seven Chakras’ tradename, domain name, and social media sites, and (iii) other assets of Seven Chakras including but not limited to raw materials, equipment, packaging and labeling materials, mailing lists, and marketing materials.

The Company currently has two ~~four~~ in-house branded CBD products that are manufactured by PHP and sold to consumers, Canbiola™, ~~Nu Wellness™, Seven Chakras™~~ and Pure Leaf Oil™.

The Company’s Canbiola™ CBD products are sold via medical professionals under distribution agreements and directly by the Company via its website ~~and vending machines~~. The Canbiola™ assets are held directly by the Company and include tinctures, soaps, bath soaks, cryo-gel, salves, massage oils, powders, capsules, and roll-ons.

The Company’s Pure Leaf Oil™ assets are held by PHP. Pure Leaf Oil™ CBD products are sold via PHP’s website, direct to consumer via walk-in business, and through distributors and are meant for retail customers not referred through the medical community. Pure Leaf Oil™ products include massage oils, joint salves, bath salts, nano sprays, drops, and cryo-gels. PHP also holds the assets related to its Seven Chakras™ brand. Seven Chakras™ is targeted toward health clubs, spas, and beauty lines and CBD products include lotion, massage oils, roll-ons, isolate, powders, capsules, and bath soaks. Severn Chakras™ has its own internet website and direct markets to its customer base.

PHP has also created a new brand, Nu Wellness™, which it intends to market through distributors as an independent pharmacy brand targeted towards independent retail drug stores. Nu Wellness™ has yet to launch or make sales, which are intended to occur sometime in 2022.

All finished products are stored for time- quality measurement, and each batch of every product is sent to an independent third-party lab for a Certificate of Analysis (“COA”) of the finished products. These COA’s are both listed on our web site and available via the QR code on every retail package.

In the ~~4th~~3rd quarter of ~~2022~~2023, the PHP ~~signed~~assets anwere ~~agreement~~consolidated tointo ~~produce~~the ~~Superfood~~CO ~~drink~~Botanicals ~~mix~~facility ~~products~~and ~~for~~operations ~~its~~in ~~Imbibe~~Fort ~~Wellness~~Morgan, ~~Solutions LLC~~CO ~~sister~~and ~~company under~~ the ~~Longevity~~Lacey, ~~Brand~~WA ~~for~~facility was ~~Brooke Burke Body, Inc~~closed. ~~(“BBB”)~~Should ~~The~~the ~~agreement~~Superfood ~~provides~~product ~~that~~line ~~PHP~~acquire ~~will~~new ~~manufacture~~customers, ~~label,~~ ~~and~~all ~~ship~~future toproduction ~~Forever~~will ~~Brands~~be ~~customers~~from ~~across~~ the ~~USA~~Fort ~~under~~Morgan aColorado ~~subscription~~CO ~~program promoted by Forever Brands and BBB~~Botanicals facilities.

II-

Hemp Operating Division

The Company’s hemp operating division performs R&D for the Company including for CBN, CBG, delta-8 and delta-10. It also produces industrial hemp and processes hemp biomass, isolate and isomers.

Around March 17, 2021, the Company acquired assets through its newly- formed, wholly-owned subsidiary, Botanical Biotech, LLC, a Nevada limited liability company (“BB” or “Botanical Biotech”). Such assets include certain materials and manufacturing equipment and marketing or promotional designs, brochures, advertisements, concepts, literature, books, media rights, rights against any other person or entity in respect of any of the foregoing and all other promotional properties, in each case primarily used, developed or acquired by the Sellers for use in connection with the ownership and operation of the BB Assets.

Around August 12, 2021, the Company and CO Botanicals LLC, a Nevada limited liability company and wholly owned subsidiary of CANB (“COB”), acquired hemp processing assets from TWS Pharma, LLC, a Wisconsin limited liability company and L7 TWS Pharma, LLC, a Wisconsin limited liability company. COB operates out of Mead, CO.

Around August 13, 2021, the Company and TN Botanicals LLC, a Nevada limited liability company and wholly owned subsidiary of CANB (“TNB”), acquired assets from Music City Botanicals, LLC, a Wisconsin limited liability company (“MCB”) including certain equipment, inventory, and intellectual property. In late 2022 the assets from TN Botanicals LLC were moved into consolidated operations under CO Botanicals, LLC in Ft. Morgan, CO.

From its Miami lab, the Company processed ~~processes~~ hemp isolate into isomers such as CBN, CBG, delta-8 and delta-10. At its Tennessee location, the Company ~~produces~~produced industrial hemp, processes hemp biomass to isolate, processes isolate to isomers such as CBN, CBG, delta-8 and delta-10, and ~~performs~~performed research and development on cannabinoids such as such as CBN, CBG, delta-8, delta-10, CBD and CBDA. At its Colorado facilities, the Company produces industrial hemp and processes hemp biomass to isolate. The biomass and isolate processed by the Company may be produced by the Company or purchased from third parties. All of the Company’s end products contain .3% or less of THC (delta-9). In late 2022 the Company also closed its FL facility and moved the operating assets to Ft. Morgan, CO under the CO Botanicals, LLC operations.

III-

Durable Medical Equipment

Through its medical device division, Duramed, Inc. (“Duramed”) and Duramed MI LLC, a Nevada limited liability company fka DuramedNJ, LLC (“Duramed MI”), the Company serves the post-surgery medical patient arena aiming to aid in recovery and pain reduction.

In November 2018, the Company formed Duramed, Inc. to facilitate the manufacture and sale of durable medical equipment (“DME”) incorporating CBD. On January 14, 2019, Duramed entered into a Memorandum of Understanding (the “Sam MOU”) with Sam International (“Sam”) and ZetrOZ Systems LLC (“ZetrOZ” and, collectively with Sam, the “Manufacturers”). Pursuant to the Sam MOU, the Manufacturers granted Duramed the exclusive right to distribute sam® Pro 2.0 (SA271) and sam® Gel Coupling Patches (UB-14-72) within the United States for the Personal Injury Protection/No Fault Market during the term of the Sam MOU. Duramed has agreed to purchase monthly minimums from the Manufacturers at a price per Unit of $2,447. The exclusivity of the Distribution License granted to Duramed under the Sam MOU was dependent upon meeting the monthly minimum, which did not happen. In addition, Duramed was granted the right to distribute sam® Gel Capture Patches (UB-14-24). Duramed will get rebates of 2%-3% based on the volume of products sold by it. The Company did not meet the monthly minimums as contemplated by the Sam MOU and as such is currently distributing the ~~aforementioned~~ products on an at-will, non-exclusive basis.

On May 29, 2019, the Company created Duramed MI to execute the same business strategy into the no-fault insurance market in New Jersey that it had developed in New York; however, Duramed MI is not currently operating in NJ and fully developed its operations in Michigan. None of Duramed’s products are reimbursable under any federal program. Duramed has also expanded its product offerings to include certain back support braces which are sold to the doctor offices and through no-fault insurance programs.

Due to staffing and support funding, the Duramed operations are on a reduced development basis while it continues to service the existing receivables and customer base.

IV-

Green Grow Farms

Green Grow Farms, Inc., a New York corporation (“GGFI” or “Green Grow”) served as the Company’s hemp cultivation arm. Through GGFI, the Company grew its own hemp in New York and partnered with third party growers in other states whereby GGFI provided the farmers with seed and training and splits profits with the farmers. ~~GGFI was to supply the Company with all hemp needed for the Company to produce its CBD products~~Currently, ~~which hemp would be processed by a third party and shipped to the Company’s production facility in Lacey, WA. Notwithstanding the foregoing, currently,~~ it is less expensive to buy crude oil and isolate than to produce such from hemp grown by the Company. Accordingly, the Company has stopped its Green Grow operations in favor of buying raw products from third parties. If and when it makes economic sense to grow its own hemp again, the Company will resume Green Grow operations.

V-

Imbibe Wellness Solutions

On February 22, 2021, the Company entered into an agreement to purchase additional CBD brand assets from Imbibe Health Solutions, LLC, a Delaware limited liability company. The assets have been placed into the Company’s wholly owned subsidiary, Imbibe Wellness Solutions, LLC, a Nevada limited liability company (fka Radical Tactical LLC) (“Imbibe Wellness”), and include the intellectual property rights, including trademarks, logos, know how, formulations, productions procedures, copyrights, social media accounts, domain names and marketing materials ~~relating to the Imbibe™ branded products, including a muscle and joint salve, unscented fizzy bath soak,~~. ~~CALM massage oil~~Previously, ~~Me x 3 Metabolic Energy (energy and dietary supplement), and Muscle, Joints & Back CBD Cryo Gel.~~ Imbibe Wellness ~~has~~ had a ~~Purchas Order and~~ contract with Forever Brands LLC to produce Longevity Brand Superfood drink mix for Brooke Burke Body, Inc. utilizing sister company Pure Health Products , LLC as the production arm. ~~The~~In ~~Superfood~~late ~~drink is plant-based~~2023, ~~non-dairy,~~Forever ~~gluten~~Brands ~~free~~ceased ~~and~~operations ~~is produced~~thereby inending ~~a variety of flavors. Walter Hoelzel is~~ the ~~president~~Superfood ofrelationship ~~Imbibe~~and ~~Wellness~~product line.

VI.

Nascent Pharma, LLC

In February 2024, the Company’s 67% owned subsidiary, Nascent Pharma, LLC, acquired patents covering liquid formulations of cannabis. The patents relate to the extraction of pharmaceutically active components from plant materials, and more particularly to the preparation of a botanical drug substance for incorporation into a medicament and for use in pharmaceutical formulations, in particular comprising cannabinoids obtained from cannabis.

The patents include both a composition of matter patent and a method of use patent. The composition of matter patent covers liquid formulations of cannabis where the present cannabinoids are more than 95% CBD, THC, CBN, CBDa, THCa, or several combinations thereof. This patent covers beverages, tinctures, vape pen liquids and liquid filled capsules. This constitutes a considerable portion of the hemp and cannabis industry, potentially up to 50%.

Patented uses include using the liquid formulations to alleviate numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders and opioid dependencies.

An independent valuation firm valued the patents at $122,000,000 in 2020, after taking into account the present value of projected income streams, applying a 90% discount and assuming a revenue stream through August 2034. The valuation of the patents included only CBD claims and only in the U.S. No assurance can be given that the patents will ultimately provide a revenue stream to the Company or that the value of the patents will equal the value determined by the independent valuation firm. Since the date of the valuation, the patents have become effective in Canada, Australia, New Zealand, Israel and Brazil and have received additional divisional patents in the U.S. The priority date for the patents stems back to October 2013 and the patents have pending status in the European Union, India, China, Eurasia, South Korea, Mexico, Japan, and Colombia.

Of significance, the patents survived an earlier invalidity challenge in Federal Court.

Through Nascent, the Company plans to pursue opportunities to license and develop uses for the patents.

FDA DISCLAIMER

The statements found herein have not been evaluated by the Food and Drug Administration (FDA) and the Company’s products are not intended to diagnose, treat, cure or prevent any disease or medical condition.

Competitive Conditions

The CBD and cannabis markets are flooded with competition ranging from mom and pop operations to multi-million-dollar conglomerates, many with longer operating histories, more capital and/or more industry knowledge than the Company. The Company hopes to partner with or engage industry specialists to help set it apart from its numerous competitors. The Company believes that one of those points of differentiation will be its 3^rd party independent testing “Certificate of Analysis” conducted on all of the CBD isolate products it purchases and posting of those lab results on its website. The three largest CBD companies known to the Company are Elixinol LLC, a UK based company with $37 million revenue, GW Pharmaceuticals also UK based with $19 million revenue, and Aurora Cannabis based in Canada with just over $19 million revenue. The top USA companies include Medical Marijuana, CV Sciences, Gaia Herbs, and Charlotte’s Web with respective revenues of $59, $48, $45, and $17 million. Worthy of note is that Charlotte’s Web is on the shelf right next to us at Northwell Health.

Hemp biomass and its derivative products have glutted the US market, benefiting our manufacturing divisions with less expensive product but causing our hemp cultivation and processing division to become financially imprudent until the oversupply issue has resolved. Thus, we have halted operations in such division for the time being but may resume such operations should a sound opportunity present. Although we have contract farm agreements in place to grow and harvest hemp biomass, other raw materials for our finished products have at least three sources of supply in the open market and we have little risk of any ingredient supply at this time.

Intellectual Property

The Company employs, through its Pure Health Product LLC division product researchers and developers and technology experts who, ~~on a daily basis,~~ set the quality standards and new product development status and time-line agendas under the direct supervision of the Company’s management team.

~~The Company~~Other than the patents acquired by Nascent, the Company has not been granted any patents or trademarks by the USPTO or by any patent or trademark office of a foreign nation.

Employees

The Company, directly or through its subsidiaries, currently has 2012 full-time employees.

Reports to Security Holders

Our common stock is registered under the Exchange Act and we are required to file current, quarterly, and annual reports and other information with the SEC. You may read and copy any document that we file at the SEC’s public reference facilities at 100 F. Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-732-0330 for more information about its public reference facilities. Our SEC filings are available to you free of charge at the SEC’s web site at www.sec.gov. We are an electronic filer with the SEC and, as such, our information is available through the Internet site maintained by the SEC that contains reports, proxy and information statements and other information regarding issuers that file electronically with the SEC. This information may be found at www.sec.gov and posted on our website at www.canbcorp.com.

Government Regulation

The cultivation and sale of hemp and hemp products is federally regulated under the United States Farm Bill. The 2018 Farm Bill removed hemp as a Schedule 1 Substance under the Controlled Substances Act; however, rules and regulations relating to manufacture and sale of CBD and other hemp derivative products under the Farm Bill must still be promulgated and are expected to impact the Company’s operations. As the industry and our product lines expand, it is uncertain what other statutory schemes and agencies will start to regulate our products. The FDA currently still considers the addition of CBD to food products, cosmetics, or supplements to be illegal and prohibits the advertisement of CBD products with health claims. The Company must also comply with each state’s laws relating to the sale and manufacture, as applicable, of hemp-based products, with some states allowing the sale of cannabinoid products, some states limiting to medical purposes and some states banning outright. These regulations may affect, among others, the way the Company manufactures and distributes its products, the way the Company is taxed, the way the Company banks, the location of the Company’s facilities, the content and testing of the Company’s products, and the quality of the Company’s services. The Company has not sought or received approval of any of its products from the FDA or any state agency. Should the Company be sanctioned by the FDA or state agencies, it could materially, negatively impact the Company’s operations and revenue sources.

We are also subject to general business regulations and laws as well as Federal and state regulations and laws specifically governing the Internet and e-commerce. Existing and future laws and regulations may impede the growth of the Internet, e-commerce or other online services, and increase the cost of providing online services. These regulations and laws may cover sweepstakes, taxation, tariffs, user privacy, data protection, pricing, content, copyrights, distribution, electronic contracts and other communications, consumer protection, broadband residential Internet access and the characteristics and quality of services. It is not clear how existing laws governing issues such as property ownership, sales, use and other taxes, libel and personal privacy apply to the Internet and e-commerce. Unfavorable resolution of these issues may harm our business and results of operations. CBD sales are additionally state regulated for shipping and the Company maintains a current list.

Transfer Agent

We have engaged Transhare Corporation located at 2849 Executive Drive, Suite 200, Clearwater, FL 33762 as our transfer agent.

Item 1A.

Risk Factors

RISK FACTORS

Investing in our securities involves a high degree of risk. Before investing in our securities, you should carefully consider the risks and uncertainties described below, together with all of the other information in this prospectus, including our consolidated financial statements and related notes. If any of the following risks materialize, our business, financial condition, operating results and prospects could be materially and adversely affected. In that event, the price of our common stock could decline, and you could lose part or all of your investment.

Risks Related to our Common Stock

We are subject to the reporting requirements of federal securities laws, which is expensive.

We are a public reporting company in the United States and, accordingly, subject to the information and reporting requirements of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and other federal securities laws, and the compliance obligations of the Sarbanes-Oxley Act. The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders causes our expenses to be higher than they would be if we remained a privately-held company.

Our stock price may be volatile, which may result in losses to our stockholders.

The stock markets have experienced significant price and trading volume fluctuations, and the trading of our common stock has generally been very volatile and experienced sharp share-price and trading-volume changes. The trading price of our securities is likely to remain volatile and could fluctuate widely in response to many factors, including but not limited to the following, some of which are beyond our control:

	●	variations in our operating results;
	●	changes in expectations of our future financial performance, including financial estimates by securities analysts and investors;
	●	changes in operating and stock price performance of other companies in our industry;
	●	additions or departures of key personnel; and
	●	future sales of our common stock.

Domestic and international stock markets often experience significant price and volume fluctuations. These fluctuations, as well as general economic and political conditions unrelated to our performance, may adversely affect the price of our common stock.

In the past, plaintiffs have often initiated securities class action litigation against a company following periods of volatility in the market price of its securities. We may, in the future, be the target of similar litigation. Securities litigation could result in substantial costs and liabilities and could divert management’s attention and resources.

Our common stock is thinly-traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate such shares.9

Our common stock is thinly traded, and in the future, may continue to be thinly-traded, and you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate such shares.

We cannot predict the extent to which an active public market for our common stock will develop or be sustained due to a number of factors, including the fact that we are a small company that is relatively unknown to stock analysts, stock brokers, institutional investors, and others in the investment community that generate or influence sales volume, and that even if we came to the attention of such persons, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until such time as we became more seasoned and viable. As a consequence, there may be periods of several days or more when trading activity in our shares is minimal, as compared to a seasoned issuer which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on share price. We cannot give you any assurance that a broader or more active public trading market for our common stock will develop or be sustained, or that current trading levels will be sustained.

The market price for our common stock may be particularly volatile given that we are a relatively small company and have experienced losses from operations that could lead to wide fluctuations in our share price. You may be unable to sell your common stock at or above your purchase price if at all, which may result in substantial losses to you.

We do not anticipate paying any cash dividends.

We presently do not anticipate that we will pay any dividends on any of our common stock in the foreseeable future. The payment of dividends, if any, would be contingent upon our revenues and earnings, if any, capital requirements, and general financial condition. The payment of any dividends will be within the discretion of our Board of Directors (the “Board”). We presently intend to retain all earnings to implement our business plan; accordingly, we do not anticipate the declaration of any dividends in the foreseeable future.

Our common stock may be subject to penny stock rules, which may make it more difficult for our stockholders to sell their common stock.

Broker-dealer practices in connection with transactions in “penny stocks” are regulated by certain penny stock rules adopted by the SEC. Penny stocks generally are equity securities with a price of less than $5.00 per share. The penny stock rules require a broker-dealer, prior to a purchase or sale of a penny stock not otherwise exempt from the rules, to deliver to the customer a standardized risk disclosure document that provides information about penny stocks and the risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction, and monthly account statements showing the market value of each penny stock held in the customer’s account. In addition, the penny stock rules generally require that prior to a transaction in a penny stock the broker-dealer make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for a stock that becomes subject to the penny stock rules.

We may need additional capital, and the sale of additional shares or other equity securities could result in additional dilution to our stockholders.

We may require additional capital for the development and commercialization of our products and may require additional cash resources due to changed business conditions or other future developments, including any investments or acquisitions we may decide to pursue. If our resources are insufficient to satisfy our cash requirements, we may seek to sell additional equity or debt securities or obtain a credit facility. The sale of additional equity securities could result in additional dilution to our stockholders. The incurrence of additional indebtedness would result in increased debt service obligations and could result in operating and financing covenants that would restrict our operations. We cannot assure you that financing will be available in amounts or on terms acceptable to us, if at all.

810

Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.

Certain of our executive officers, directors and large stockholders own a significant percentage of our outstanding capital stock. Our executive officers, directors, holders of 5% or more of our capital stock and their respective affiliates beneficially own shares representing more than a majority of the eligible votes of the Company. Accordingly, our directors and executive officers have significant influence over our affairs due to their substantial ownership coupled with their positions on our management team and have substantial voting power to approve matters requiring the approval of our stockholders. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This concentration of ownership may prevent or discourage unsolicited acquisition proposals or offers for our common stock that some of our stockholders may believe is in their best interest.

If we are unable to implement and maintain effective internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our reported financial information and the market price of our common stock may be negatively affected.

As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal control. Section 404 of the Sarbanes-Oxley Act requires that we evaluate and determine the effectiveness of our internal control over financial reporting and provide a management report on the internal control over financial reporting. If we have a material weakness in our internal control over financial reporting, we may not detect errors on a timely basis and our consolidated financial statements may be materially misstated. We may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and testing process, if we identify one or more material weaknesses in our internal control over financial reporting, our management will be unable to conclude that our internal control over financial reporting is effective. Moreover, when we are no longer a smaller reporting company, our independent registered public accounting firm will be required to issue an attestation report on the effectiveness of our internal control over financial reporting. Even if our management concludes that our internal control over financial reporting is effective, our independent registered public accounting firm may conclude that there are material weaknesses with respect to our internal controls or the level at which our internal controls are documented, designed, implemented, or reviewed.

If we are unable to conclude that our internal control over financial reporting is effective, or when we are no longer a smaller reporting company, if our auditors were to express an adverse opinion on the effectiveness of our internal control over financial reporting because we had one or more material weaknesses, investors could lose confidence in the accuracy and completeness of our financial disclosures, which could cause the price of our common stock to decline. Internal control deficiencies could also result in a restatement of our ~~financial~~ financial results in the future. We have concluded that are internal controls have not been sufficient; however, we have begun to take steps to remediate such insufficiencies. We have communicated to our accounting review firm and audit that we have accomplished the following: (i) we have transitioned each operating subsidiary to a separate bookkeeping system (QuickBooks) and input data at each operating location on a daily basis vs. previously batching data and inputting at corporate office. Corporate then verifies data prior to accepting, (ii) we have a QuickBooks trained person with who inputs data on a real-time basis but not allowed at subsidiary level to access or make certain changes, (iii) we have installed for the hemp division companies (Botanical Biotech (Miami), TN Botanicals (TN), CoCO botanicals (CO) daily tracking procedures whereby every ounce and pound of raw materials (biomass or crude) is tracked by lot number from input to processing through to finished product, (iv) our accounts receivable tracking system, which is essentially our Duramed Division receivables, is now tracking by medical device unit number, by doctor, by location, by insurance billing company, and we have a far more refined software track and billing system than we did prior quarters, (v) we have consolidated ~~consolidate~~ banking to a master account with our primary bank (~~Investors~~ M&T Bank) by subsidiary ~~and only have one independent subsidiary bank in TN for TN Botanicals which is managed for balances through Investors Bank~~, (vi) we have instituted a new procedure for any payables which requires double ~~signatures~~confirmation to release any funds for any reason, (vii) and we have changed merchant accounts to a single user to better tie out to bank balances and accounts receivable, and (viii) Pure Health Products, LLC, our production facility in Lacey WA in mid-November just received NSF Certification (National Sanitation Foundation), the highest certification possible which now allows us to bid and product products for major national retailers but also has the highest certification and maintenance program in the food supplement industry. ~~NSF uses a sophisticated MARKOV software system to track ever incoming product and package~~, ~~manage the formulation process and makes appropriate adjustments to every material and unit down to the gram.~~

911

If securities or industry analysts do not publish research or reports about our business, or if they change their recommendations regarding our stock adversely, our stock price and trading volume could decline.

The trading market for our common stock could be influenced by the research and reports that industry or securities analysts publish about us or our business. We do not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage of us, the trading price of our stock would likely decrease. Even if we do obtain analyst coverage, if one or more of the analysts who cover us downgrade our stock, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.

We may not register or qualify our securities with any state agency pursuant to blue sky regulations.

The holders of our shares of common stock and ~~persons~~people who desire to purchase them in the future should be aware that there may be significant state law restrictions upon the ability of investors to resell our shares. We currently do not intend to and may not be able to qualify securities for resale in states which require shares to be qualified before they can be resold by our shareholders.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act, or the JOBS Act. ~~The~~ Section 107 of the JOBS Act provides that we may elect to utilize the extended transition period for complying with new or revised accounting standards and such election is irrevocable if made. As such, we have made the election to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act. Please refer to a discussion under “Risk Factors” of the effect on our financial statements of such election.

As an emerging growth company , we are exempt from Section 404(b) of the Sarbanes Oxley Act. Section 404(a) requires Issuers to publish information in their annual reports concerning the scope and adequacy of the internal control structure and procedures for financial reporting. This statement shall also assess the effectiveness of such internal controls and procedures. Section 404(b) requires that the registered accounting firm shall, in the same report, attest to and report on the assessment on the effectiveness of the internal control structure and procedures for financial reporting. As an emerging growth company, we are also exempt from Section 14A (a) and (b) of the Exchange, which require the shareholder approval of executive compensation and golden parachutes.

We have elected to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(2) of the JOBS Act, that allows us to delay the adoption of new or revised accounting standards that have different effective dates for public and private companies until those standards apply to private companies. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.

We are in default of payment obligations under certain promissory notes.

As of December 31, 2023, notes payable with principal amounts totaling $8.9 million were past due. Although only the Arena Entities have elected to pursue remedies against us, no assurance can be given that the other holders will not do so in the future. The institution of collection actions could have a material adverse effect on our business and could force us to seek relief through insolvency or other proceedings.

We could face significant penalties for our failure to comply with the terms of our outstanding convertible notes.

Our various convertible notes contain positive and negative covenants and customary events of default including requiring us in many cases to timely file SEC reports. In the event we fail to timely file our SEC reports in the future, or any other events of defaults occur under the notes, we could face significant penalties and/or liquidated damages and/or the conversion price of such notes could be adjusted downward significantly, all of which could have a material adverse effect on our results of operations and financial condition, or cause any investment in the Company to decline in value or become worthless.

1012

The issuance and sale of common stock upon conversion of our convertible notes may depress the market price of our common stock.

If sequential conversions of the convertible notes and sales of such converted shares take place, the price of our common stock may decline, and as a result, the holders of the convertible notes will be entitled to receive an increasing number of shares in connection with conversions, which shares could then be sold in the market, triggering further price declines and conversions for even larger numbers of shares, to the detriment of our investors. The shares of common stock which the convertible notes are convertible into may be sold without restriction pursuant to Rule 144. As a result, the sale of these shares may adversely affect the market price, if any, of our common stock.

We have established preferred stock which can be designated by the Company’s Board of Directors without shareholder approval.

The Company has 5,000,000 shares of preferred stock authorized. The shares of preferred stock of the Company may be issued from time to time in one or more series, each of which shall have a distinctive designation or title as shall be determined by the board of directors of the Company prior to the issuance of any shares thereof. The preferred stock shall have such voting powers, full or limited, or no voting powers, and such preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof as adopted by the board of directors. Because the board of directors is able to designate the powers and preferences of the preferred stock without the vote of a majority of the Company’s shareholders, shareholders of the Company will have no control over what designations and preferences the Company’s preferred stock will have. The issuance of shares of preferred stock or the rights associated therewith, could cause substantial dilution to our existing shareholders. Additionally, the dilutive effect of any preferred stock which we may issue may be exacerbated given the fact that such preferred stock may have voting rights and/or other rights or preferences which could provide the preferred shareholders with substantial voting control over us and/or give those holders the power to prevent or cause a change in control, even if that change in control might benefit our shareholders. As a result, the issuance of shares of preferred stock may cause the value of our securities to decrease.

Risks Related to our Business

Since we have a limited operating history in our industry, it is difficult for potential investors to evaluate our business.

Our short operating history in our industry may hinder our ability to successfully meet our objectives and makes it difficult for potential investors to evaluate our business or prospective operations. As an early -stage company, we are subject to all the risks inherent in the financing, expenditures, operations, complications and delays inherent in a new business. Accordingly, our business and success faces risks from uncertainties faced by developing companies in a competitive environment. There can be no assurance that our efforts will be successful or that we will ultimately be able to attain profitability.

We may not be able to raise capital when needed, if at all, which would force us to delay, reduce or eliminate our product development programs or commercialization efforts and could cause our business to fail.

We expect to need substantial additional funding to pursue additional product development and launch and commercialize our products. There are no assurances that future funding will be available on favorable terms or at all. If additional funding is not obtained, we may need to reduce, defer or cancel additional product development or overhead expenditures to the extent necessary. The failure to fund our operating and capital requirements could have a material adverse effect on our business, financial condition and results of operations.

If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts. Any of these events could significantly harm our business, financial condition and prospects.

1113

Our independent registered public accounting firm has expressed substantial doubt about our ability to continue as a going concern.

Our historical financial statements have been prepared under the assumption that we will continue as a going concern. Our independent registered public accounting firm has expressed substantial doubt in our ability to continue as a going concern. Our ability to continue as a going concern is dependent upon our ability to obtain additional equity financing or other capital, attain further operating efficiencies, reduce expenditures, and, ultimately, generate more revenue. The doubt regarding our potential ability to continue as a going concern may adversely affect our ability to obtain new financing on reasonable terms or at all. Additionally, if we are unable to continue as a going concern, our stockholders may lose some or all of their investment in the Company.

We depend heavily on key personnel, and turnover of key senior management could harm our business.

Our future business and results of operations depend in significant part upon the continued contributions of our senior management personnel. If we lose their services or if they fail to perform in their current positions, or if we are not able to attract and retain skilled personnel as needed, our business could suffer. Significant turnover in our senior management could significantly deplete our institutional knowledge held by our existing senior management team. We depend on the skills and abilities of these key personnel in managing the product acquisition, marketing and sales aspects of our business, any part of which could be harmed by turnover in the future. We do not have any key person insurance.

We expect to face intense competition, often from companies with greater resources and experience than we have.

The health and wellness and hemp derivative industries are highly competitive and subject to rapid change. The industry continues to expand and evolve as an increasing number of competitors and potential competitors enter the market. Many of these competitors and potential competitors have substantially greater financial, technological, managerial and research and development resources and experience than we have. Some of these competitors and potential competitors have more experience than we have in the development of hemp products, including validation procedures and regulatory matters. Moreover, some of these competitors may have patents or pending patent applications that our products infringe and for which we would need a license to become free to operate. In addition, our products compete with product offerings from large and well-established companies that have greater marketing and sales experience and capabilities than we or our collaboration partners have. If we are unable to compete successfully, we may be unable to grow and sustain our revenue.

We have substantial capital requirements that, if not met, may hinder our operations.

We anticipate that we will make substantial capital expenditures for research and product development work and acquisitions. If we cannot raise sufficient capital, we may have limited ability to expend the capital necessary to undertake or complete research and product development work and acquisitions. There can be no assurance that debt or equity financing will be available or sufficient to meet these requirements or for other corporate purposes, or if debt or equity financing is available, that it will be on terms acceptable to us. Moreover, future activities may require us to alter our capitalization significantly. Our inability to access sufficient capital for our operations could have a material adverse effect on our financial condition, results of operations or prospects.

The Russia-Ukraine and Israel-Hamas wars have disrupted global markets and my adversely impact our ability to obtain financing.

On February 24, 2022, Russian military forces invaded Ukraine, and the length, impact, and outcome of the ongoing war in Ukraine is highly unpredictable. On October 7, 2023, Hamas terrorists infiltrated Israel’s border with the Gaza Strip and conducted a series of attacks on civilian and military targets. Hamas has also launched extensive rocket attacks on Israeli population and industrial centers located along Israel’s border with the Gaza Strip and in other areas within the State of Israel. These attacks have resulted in extensive deaths, injuries and kidnapping. Following the attack, Israel’s security cabinet declared war against Hamas and a military campaign against these terrorist organizations commenced in parallel to their continued rocket and terror attacks. The intensity and duration of Israel’s current war against Hamas is similarly difficult to predict. As a result of the Russia-Ukraine and Israel-Hamas wars and other geopolitical and macroeconomic events, the global credit and financial markets have experienced volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly or more dilutive.

Current global financial conditions have been characterized by increased volatility which could negatively impact our business, prospects, liquidity and financial condition.

Current global financial conditions and recent market events have been characterized by increased volatility and the resulting tightening of the credit and capital markets has reduced the amount of available liquidity and overall economic activity. We cannot ~~guaranty~~guarantee that debt or equity financing, the ability to borrow funds or cash generated by operations will be available or sufficient to meet or satisfy our initiatives, objectives or requirements. Our inability to access sufficient amounts of capital on terms acceptable to us for our operations will negatively impact our business, prospects, liquidity and financial condition.

1214

We will need to ~~grow~~ increase the size of our organization, and we may experience difficulties in managing any growth we may achieve.

As our development and commercialization plans and strategies develop, we expect to need additional research, development, managerial, operational, sales, marketing, financial, accounting, legal, and other resources. Future growth would impose significant added responsibilities on members of management. Our management may not be able to accommodate those added responsibilities, and our failure to do so could prevent us from effectively managing future growth, if any, and successfully growing our company.

We may expend our limited resources to pursue a particular product and may fail to capitalize on products that may be more profitable or for which there is a greater likelihood of success.

Because we have limited financial and managerial resources, we have focused our efforts on particular products. As a result, we may forego or delay the pursuit of opportunities with other products that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. Any failure to improperly assess potential products could result in missed opportunities and/or our focus on products with low market potential, which would harm our business and financial condition.

We engage in transactions with related parties and such transactions present possible conflicts of interest that could have an adverse effect on us.

We have entered, and may continue to enter, into transactions with related parties for financing, corporate, business development and operational services, as detailed herein. Such transactions may not have been entered into on an arm’s-length basis, and we may have achieved more or less favorable terms because such transactions were entered into with our related parties. We rely, and will continue to rely, on our related parties to maintain these services. If the pricing for these services changes, or if our related parties cease to provide these services, including by terminating agreements with us, we may be unable to obtain replacements for these services on the same terms without disruption to our business. This could have a material effect on our business, results of operations and financial condition.

Such conflicts could cause an individual in our management to seek to advance his or her economic interests or the economic interests of certain related parties above ours. Further, the appearance of conflicts of interest created by related party transactions could impair the confidence of our investors, which could have a material adverse effect on our liquidity, results of operations and financial condition.

Any inability to protect our intellectual property rights could reduce the value of our technologies and brands, which could adversely affect our financial condition, results of operations and business.

Our business is dependent upon our trademarks, trade secrets, the patents recently acquired by Nascent and other intellectual property rights. There is a risk of certain valuable trade secrets being exposed to potential misappropriation. The efforts we have taken to protect our proprietary rights may not be sufficient or effective. Any significant impairment of our intellectual property rights could harm our business or our ability to compete. There is a risk that we may have insufficient resources to counter adequately such misappropriation or infringement through negotiation or the use of legal remedies. It may not be practicable or cost effective for us to fully protect our intellectual property rights in some countries or jurisdictions. If we are unable to successfully identify and stop unauthorized use of our intellectual property, we could lose potential revenue and experience increased operational and enforcement costs, which could adversely affect our financial condition, results of operations and business.

Our potential for rapid growth and our entry into new markets make it difficult for us to evaluate our current and future business prospects, and we may be unable to effectively manage any growth associated with these new markets, which may increase the risk of your investment and could harm our business, financial condition, results of operations and cash flow.

Our entry into the rapidly growing CBD, CBN, CBG and delta-8 markets may place a significant strain on our resources and increase demands on our executive management, personnel and systems, and our operational, administrative, and financial resources may be inadequate. We may also not be able to effectively manage any expanded operations, or achieve planned growth on a timely or profitable basis, particularly if the number of customers using our technology significantly increases or their demands and needs change as our business expands. If we are unable to manage expanded operations effectively, we may experience operating inefficiencies, the quality of our products and services could deteriorate, and our business and results of operations could be materially adversely affected.

1315

If we are unable to develop and maintain our brand and reputation for our product offerings, our business and prospects could be materially harmed.

Our business and prospects depend, in part, on developing and then maintaining and strengthening our brands and reputation in the markets we serve. If problems with our products or technologies cause customers to experience operational disruption or failure or delays, our brand and reputation could be diminished. If we fail to develop, promote and maintain our brand and reputation successfully, our business and prospects could be materially harmed.

If we or any of our suppliers or third- parties on which we rely for the development, manufacturing, marketing, or sale of our products fails to comply with regulatory requirements applicable to the development, manufacturing, marketing, and sale of our product candidates, regulatory ~~agencies~~ agencies may take action against us or them, which could significantly harm our business.

Our product candidates, along with the development process, the manufacturing processes, labeling, advertising, and promotional activities for these products, are subject to continual requirements and review by the FDA and state and foreign regulatory bodies. Regulatory authorities subject a marketed product, its manufacturer, and the manufacturing facilities to continual review and periodic inspections. We, our suppliers, third-parties on which we rely, and our and their respective contractors, suppliers and vendors, will be subject to ongoing regulatory requirements, including complying with regulations and laws regarding advertising, promotion and sales of products (including applicable anti-kickback, fraud and abuse and other health care laws and regulations), required submissions of safety and other post-market information and reports, registration requirements, Clinical Good Manufacturing Practices (cGMP) regulations (including requirements relating to quality control and quality assurance, as well as the corresponding maintenance of records and documentation), and the requirements regarding the distribution of samples to physicians and recordkeeping requirements. Regulatory agencies may change existing requirements or adopt new requirements or policies. We, our suppliers, third-parties on which we rely, and our and their respective contractors, suppliers, and vendors, may be slow to adapt or may not be able to adapt to these changes or new requirements.

Failure to comply with regulatory requirements may result in any of the following:

	●	restrictions on our product candidates or manufacturing processes;
	●	warning letters;
	●	withdrawal of the products from the market;
	●	voluntary or mandatory recall;
	●	fines;
	●	suspension or withdrawal of regulatory approvals;
	●	refusal to approve pending applications or supplements to approved applications that we submit;
	●	product seizure;
	●	injunctions; or
	●	imposition of civil or criminal penalties.

We could be subject to costly product liability claims related to our products.

Since most of our products are intended for human use, we face the risk that the use of our products may result in adverse side effects to people. We face even greater risks upon further commercialization of our products. An individual may bring a product liability claim against us alleging that one of our products causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any product liability claim brought against us, with or without merit, could result in:

	●	the inability to commercialize our products;
	●	decreased demand for our products;
	●	regulatory investigations that could require costly recalls or product modifications;

1416

	●	loss of revenue;
	●	substantial costs of litigation;
	●	liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;
	●	an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;
	●	the diversion of management’s attention from our business; and
	●	damage to our reputation and the reputation of our products.

Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, results of operations, financial condition, and prospects.

The Company could be subject to enforcement action by the FDA and certain state regulatory agencies for its products containing CBD or THC compounds.

In 2018, the federal Farm Bill removed hemp as a Schedule I drug under the Controlled Substances Act and hemp may now be grown as a commodity crop, with restrictions; however, the 2018 Farm Bill did not specifically legalize CBD. Until Congress promulgates rules and regulations relating to hemp derived cannabinoids, the “legal” status of such, or the processes the Company may have to implement (and at what expense), are still unknowns. A similar paradigm exists under various state laws with which the Company will have to comply. Further, the FDA currently considers the addition of CBD to food products, cosmetics or supplements to be illegal and also prohibits the advertisement of CBD products with health claims. In addition, the FTC under the Federal Trade Commission Act (“FTC Act”) requires that product advertising is truthful, substantiated and non-misleading. We believe that our advertising meets these guidelines; however, the FTC may bring a challenge at any time to evaluate our compliance with the FTC Act.

Further, the FDA has recently increased its review of and enforcement against CBD companies for violations of the Federal Food, Drug, and Cosmetic Act (“FCDA”), particularly with respect to the sale of food products containing CBD, claiming that CBD can treat medical conditions in humans or animals, promoting CBD products as dietary supplements, and adding CBD to human and animal foods. Should the Company become subject to enforcement action by the FDA, it could be forced to spend significant sums defending against such enforcement, pay significant fines and ultimately could be forced to stop offering some or all of its CBD products, which would materially, negatively affect the Company’s business and shareholders’ investments. The FDA can also subject individuals to criminal penalties, including fines and imprisonment, for violating certain provisions of the FDCA related to CBD products. In addition, notwithstanding the intense pressure on FDA to fast-track the CBD approval process, it is likely that the approval process for use of CBD or other cannabinoids in foods, cosmetics or supplements will take years and possible that it could never occur at all.

Due to the controversy over the cannabis plant within the United States, we face challenges getting our products into stores and into the hands of the end user.

The Company intends to release products that contain CBD derived from hemp that are legal within the U.S. However, it is possible we may face scrutiny and run into issues getting our products into stores due to hesitation by stores to carry any product at all affiliated with the cannabis plant, as well as federal, state and local regulations that may restrict our ability to sell cannabinoid products.

The Company’s production of Delta-8 THC and Delta-10 THC could subject it to enforcement action by certain federal and state regulatory agencies.

Delta-8 THC and delta-10 THC are cannabis compounds that can cause effects similar to delta-9 THC, the main compound in cannabis that causes psychoactive effects. Delta-8 THC and delta-10 THC can be extracted from either hemp or marijuana, but all of the Company’s delta-8 products are made with hemp containing no more than 0.3% THC. Because of the 2018 Farm Bill, hemp can be legally grown and used for extractions all over the United States. Notwithstanding the foregoing, the legality of hemp-derived delta-8 THC and delta-10 THC is in a gray area and varies from state-to-state, with some states allowing, some not addressing specifically, and others banning due to similarity to delta-9 THC. Although the federal legality of delta-8 THC and delta-10 THC is still unclear, the FDA has recently issued Warning Letters to five companies for selling products labeled as containing delta-8 tetrahydrocannabinol, noting that delta-8 THC has psychoactive and intoxicating effects and may be dangerous to consumers. The Warning Letters were primarily targeted at companies marketing the compound as unapproved treatments for various medical conditions or for other therapeutic uses, without adequate directions for use, or the addition of delta-8 THC in foods. Should the Company become subject to enforcement action by federal or state agencies, it could be forced to spend significant sums defending against such enforcement and ultimately could be forced to stop offering some or all of its delta-8 THC and/or delta-10 THC products and/or be subject to other civil or criminal sanctions, which would materially, negatively affect the Company’s business and shareholders’ investments.

1517

The novel coronavirus disease of 2019 (“COVID-19”) has had, and continues to have, broad impacts on multiple sectors of the global economy, making it difficult to predict the extent of its impact on our business.

On January 30, 2020, the World Health Organization (“WHO”) announced a global health emergency because of a new strain of coronavirus originating in Wuhan, China (the “COVID-19 outbreak”) and the risks to the international community as the virus spreads globally beyond its point of origin. In March 2020, the WHO classified the COVID-19 outbreak as a pandemic, based on the rapid increase in exposure globally.

The full impact of the COVID-19 outbreak continues to evolve as of the date of this Report. As such, it is uncertain as to the full magnitude that the pandemic will have on our financial condition, liquidity, and future results of operations. Management is actively monitoring the impact of the global situation on our financial condition, liquidity, operations, suppliers, industry, and workforce. Given the daily evolution of the COVID-19 outbreak and the global responses to curb its spread, we are not able to estimate the effects of the COVID-19 outbreak on our results of operations, financial condition, or liquidity for the foreseeable future. We have experienced negative impacts from COVID in the form of reduced sales, delayed operations, inability to effectuate certain business plans, supply chain issues and the like.

Our acquisitions may expose us to unknown liabilities.

Because we have acquired, and expect generally to acquire, all (or a majority of) the outstanding securities of certain of our acquisition targets, our investment in those companies are or will be subject to all of their liabilities other than their respective debts which we paid or will pay at the time of the acquisitions. If there are unknown liabilities or other obligations, our business could be materially affected. We may also experience issues relating to internal controls over financial reporting that could affect our ability to comply with the Sarbanes-Oxley Act, or that could affect our ability to comply with other applicable laws.

If we fail to comply with government laws and regulations it could have a materially adverse effect on our business.

Our industry is subject to extensive federal, state and local laws and regulations that are extremely complex and for which, in many instances, the industry does not have the benefit of significant regulatory or judicial interpretation. We exercise care in structuring our operations to comply in all material respects with applicable laws to the extent possible. We will also take such laws into account when planning future operations and acquisitions. The laws, rules and regulations described above are complex and subject to interpretation. In the event of a determination that we are in violation of such laws, rules or regulations, or if further changes in the regulatory framework occur, any such determination or changes could have a material adverse effect on our business. There can be no assurance however that we will not be found in noncompliance in any particular situation.

Any failure to comply with all applicable federal and state anti-kickback laws may result in fines and other liabilities, which may adversely affect the Company’s results of operations and reputation.

The federal anti-kickback statute (the “AKS”) applies to Medicare, Medicaid and other state and federal programs. AKS prohibits the solicitation, offer, payment or receipt of remuneration in return for referrals or the purchase, or in return for recommending or arranging for the referral or purchase, of goods, including drugs, covered by the federal health care programs. At present, the Company does not participate in any federal programs and its products are not reimbursed by Medicare, Medicaid or any other state or federal program. The AKS is a criminal statute with criminal penalties, as well as potential civil and administrative penalties. The AKS, however, provides several statutory exceptions and regulatory “safe harbors” for particular types of transactions. Many states have similar fraud and abuse laws and their own anti-kickback laws, some of which can apply to all payors, and not just governmental payors. While the Company believes that it is in material compliance with both federal and state AKS laws, the AKS laws present different levels of risks as to two of the Company’s lines of business: (1) sale of the Company’s medical foods, and (2) sale of the Company’s medical devices.

1618

At present, the Company’s products are not reimbursable under any federal program. If, however, that changes in the future and it were determined that the Company was not in compliance with the AKS, the Company could be subject to liability, and its operations could be curtailed, which could have a material adverse effect on the Company’s business, financial condition and results of operations. Moreover, if the activities of its customers or other entity with which the Company has a business relationship were found to constitute a violation of the AKS and the Company, as a result of the provision of products or services to such customer or entity, were found to have knowingly participated in such activities, the Company could be subject to sanctions or liability under such laws, including civil and/or criminal penalties, as well as exclusion from government health programs. As a result of exclusion from government health programs, neither products nor services could be provided to any beneficiaries of any federal healthcare program.

We may not maintain sufficient insurance coverage for the risks associated with our business operations.

Risks associated with our business and operations include, but are not limited to, claims for wrongful acts committed by our officers, directors, and other representatives, the loss of intellectual property rights, the loss of key personnel, risks posed by natural disasters and risks of lawsuits from customers who are injured from or dissatisfied with our products. Any of these risks may result in significant losses. We cannot provide any assurance that our insurance coverage is sufficient to cover any losses that we may sustain, or that we will be able to successfully claim our losses under our insurance policies on a timely basis or at all. If we incur any loss not covered by our insurance policies, or the compensated amount is significantly less than our actual loss or is not timely paid, our business, financial condition and results of operations could be materially and adversely affected.

Our ability to service our indebtedness will depend on our ability to generate cash in the future.

Our ability to make payments on our indebtedness will depend on our ability to generate cash in the future. Our ability to generate cash is subject to general economic and market conditions and financial, competitive, legislative, regulatory and other factors that are beyond our control. Our business may not generate sufficient cash to fund our working capital requirements, capital expenditure, debt service and other liquidity needs, which could result in our inability to comply with financial and other covenants contained in our debt agreements, our being unable to repay or pay interest on our indebtedness, and our inability to fund our other liquidity needs. If we are unable to service our debt obligations, fund our other liquidity needs and maintain compliance with our financial and other covenants, we could be forced to curtail our operations, our creditors could accelerate our indebtedness and exercise other remedies and we could be required to pursue one or more alternative strategies, such as selling assets or refinancing or restructuring our indebtedness. However, such alternatives may not be feasible or adequate.

Item 1B.

Unresolved Staff Comments

Not applicable.

Item 2.

Properties

The Company does not currently own any real property. We do, however, lease office space in Hicksville, New York ~~for~~on ~~$3,917~~a ~~per~~month to month, ~~out of~~basis ~~which~~following ~~all~~the ~~subsidiaries~~termination ~~other~~of our ~~than~~lese ~~PHP~~in ~~operate~~December 2023. ~~The~~We ~~Company’s~~have ~~wholly-owned~~reached ~~subsidiary,~~an ~~Pure~~agreement ~~Health~~in ~~Products,~~principle ~~operates~~with ~~its~~the ~~manufacturing~~landlord pursuant to which we would move into smaller space in the same facility inand ~~Lacey,~~our ~~Washington~~rent ~~with~~would ~~lease~~be ~~payments~~reduced ~~equal~~from $3,917 to $21,~~345~~562 per month. The Company has leases for ~~three~~two ~~(3)~~additional properties, as described below.

~~The Company~~CO ~~leases an approximately 14~~Botanicals,~~300~~ ~~square~~LLC ~~foot building and related parcel located at 14320 Longs Peak Court, Mead, CO 80504~~ (~~the~~ “~~LPC Property~~COB”) ~~for base rent equal to $13~~,~~764~~ a ~~for~~wholly ~~the~~owned ~~first~~subsidiary ~~year~~ of ~~the~~Can ~~lease~~B̅ Corp. ~~Following~~leases the ~~first~~real ~~year~~properties oflocated ~~the~~at ~~lease,~~17171 ~~on September~~County 1Road of21, ~~each~~Fort ~~year~~Morgan, ~~the~~CO ~~base~~80701 ~~rent for the LPC Property will be increased by the greater~~ (out of ~~(i)~~which ~~3%,~~PHP ~~or (ii~~operates) ~~the~~and ~~difference~~12555 ~~between the~~Energy ~~Consumer~~Road, ~~Price~~Fort ~~Index~~Morgan, ~~for~~CO ~~All~~80701 ~~Urban Consumers~~ (ascollectively, ~~published by~~ the ~~Bureau~~“Fort ofMorgan ~~Labor Statistics) (“CPI~~Properties”) ~~for~~on ~~August~~a ~~2021~~month-to-month ~~compared~~basis. toBase rent for the ~~CPI~~Fort ~~for~~Morgan ~~August~~Properties ofis ~~the~~$14,500 ~~applicable~~per ~~year~~month.

CO Botanicals, LLC (“COB”), a wholly-owned subsidiary of Can B̅ Corp. leases the real properties located at 17171 County Road 21, Fort Morgan, CO 80701 and 12555 Energy Road, Fort Morgan, CO 80701 (collectively, the “Fort Morgan Properties”) on a month-to-month basis. Base rent for the Fort Morgan Properties is $22,250 per month.19

Item 3.

Legal Proceedings

On April 28, 2021, the Company was served with a commercial legal action against the Company and certain officers by David Weissberg and Donna Marino, who are investors in the Company (collectively, the “Investors”). The complaint was filed in the Supreme Court of the State of New York, County of Nassau, Index No. 605191/2021. The complaint alleges four causes of action.

The first cause of action alleges that the Company breached Securities Purchase Agreements with the Investors by failing to assist the Investors in getting opinion letters to remove the restrictive legends from their shares, even though the Company made introductions and requests to the Company’s counsel, provided supporting documents for the Investor’s shares, and ultimately the opinion letters could not be rendered because the Investors failed to submit required documentation to counsel.

The second cause of action is similar to the first but related to alleged misrepresentations regarding removing the restrictive legends from shares that were issued for services rather than purchased.

The third cause of action alleges that the Company mislead the Investors to invest $500,000. The final cause of action alleges that officers of the Company made misrepresentations regarding the value of the Company’s stock, which caused David Weissberg to owe more in taxes than he was expecting.

We have consulted with attorneys and believe the Investors’ claims are meritless, factually inaccurate, and frivolous. We intend to vigorously defend ourselves against the aforementioned legal action and will likely bring counterclaims against the Investors.

Approximately November 24, 2021, a vendor of the Company filed amended suit against the Company in Florida, Case No. 2021 CA 001797, for monies allegedly owed and civil theft relating to such monies and related products and fraud in the inducement. We do not believe we owe such vendor any amount. The court has entered a default judgement against the Company for our failure to timely answer the complaint, which default has since been overturned. Subsequently the case has been set for interrogatories and document production which activities are being fulfilled.

On or about August 11, 2022, a Complaint was filed by Evexia Plus, LLC against Can B Corp. in a product payment trade dispute. Case Number 63-CV-2022-900692.00 in the Circuit Court of Tuscaloosa County, AL. On 1-26-2023 the court ordered a Summary Judgement in the amount of $336,924. The parties are trying to work out a payment schedule tied to production to satisfy the judgement.

On December 1, 2023,the Company, received a notice from Arena Special Opportunities Partners I, LP, Arena Special Opportunities Fund, LP and Arena Investors, LP (collectively, the “Arena Entities” or “Arena”) advising that by virtue of defaults in the performance of the obligations of the Company and its subsidiaries to the Arena Entities, the Arena Entities intended to conduct a public auction of certain assets of the Company and its subsidiaries under Article 9 of the Uniform Commercial Code.

The Arena Entities collectively hold approximately $3,838,770 aggregate principal amount of Convertible Notes (the “Arena Notes”) issued by the Company. The Arena Entities previously notified the Company and its subsidiaries that they were in default of certain obligations under the Forbearance Agreement dated February 27, 2023 among the Company, its subsidiaries and the Arena Entities pursuant to which the Arena Entities agreed to forbear from exercising remedies under the Arena Notes until December 31, 2024 provided that no defaults occurred under the Arena Notes or the Forbearance Agreement. The alleged defaults include a failure to deliver account control agreements, failure to enter into a servicing agreement, failure to timely make certain payments and the unauthorized use and misuse of receivable assigned to the Arena Entities.

On February 27, 2024, the Supreme Court, County of New York (the “Court”), denied a motion made by the Company seeking a temporary restraining order and preliminary injunction to halt the proposed sale. As a result of the decision, the Arena Entities proceeded with its proposed auction of the Company’s hemp division assets and the auction took place on March 14, 2024. Approximately $300,000 of proceeds were generated by the sale.

On April 7, 2024, Arena filed a complaint in the Court against the Company, it subsidiaries and certain officers of the Company and its subsidiaries alleging tortious interference with the auction and seeking a declaratory judgment that the Company is in breach of the Arena Notes and the Forbearance Agreement and that Arena has the right to auction certain equipment held at a Company facility that is not owned by the Company or any of its subsidiaries. The Company believes that Arena’s claims are without merit and intends to vigorously defend Arena’s claims.

Other than above, we are not aware of any pending or threatened legal proceedings in which we are involved.

Item 4.

Mine Safety Disclosures

Not applicable.

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market Information

Our common stock is listed for quotation on OTC Market’s OTCQB® Venture Market under the symbol “CANB.” Our common stock began trading in April 2011. Trading in our common stock has historically lacked consistent volume, and the market price has been volatile.

Record Holders

As of April 1012, ~~2023~~2024, there were 549,~~396~~344,~~682~~230 shares of common stock issued and outstanding and held by approximately 250 shareholders of record.

Dividends

The Company paid $0 in in-kind dividends on its Series B Preferred Stock by the issuance of common stock to the Series B holders in 2020 and 2019. Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The Series B Preferred Stock have no voting rights. There are no currently outstanding shares of Series B Preferred Stock*.

We do not anticipate paying any cash dividends in the foreseeable future. Except for its Series B Preferred Stock, of which there are none issued and outstanding*, the payment of dividends is within the discretion of our Board of Directors and will depend on our earnings, capital requirements, financial condition, and other relevant factors. There are no restrictions that currently limit our ability to pay dividends on our common stock other than those generally imposed by applicable state law.

* It has come to our attention that the Company’s transfer agent still shows 227,590 Series B Preferred shares as being held by RedDiamond Partners LLC (“RedDiamond”) due to an administrative oversight. Nonetheless, such shares were retired in exchange for 97,608 shares of common stock and rights to acquire an additional 35,667 shares of common stock issued to RedDiamond pursuant to an Exchange Agreement dated August 13, 2019.

Securities Authorized for Issuance under Equity Compensation Plans

On July 28, 2020, the Company adopted an Incentive Stock Option Plan (“ISO”). The purpose of this Can B Corp. 2020 ISO (the “Plan”) is to attract, retain, and motivate employees, officers, directors, consultants, agents, advisors and independent contractors of the Company and its Related Companies by providing them the opportunity to acquire a proprietary interest in the Company and to align their interests and efforts to the long-term interests of the Company’s stockholders. The Plan is administered by the Compensation Committee or, in the Board’s sole discretion, the Board. The Compensation Committee shall be composed of two or more directors, each of whom is a “non-employee director” within the meaning of Rule 16b-3(b)(3) promulgated under the Exchange Act, or any successor definition adopted by the Securities and Exchange Commission. As used in this Plan, the term “Compensation Committee” shall be construed as if followed by the words “(if any);” and nothing in this Plan requires the Board to have a Compensation Committee. Except for the terms and conditions explicitly set forth in the Plan and to the extent permitted by applicable law, the Committee shall have full power and exclusive authority, subject to such orders or resolutions not inconsistent with the provisions of the Plan as may from time to time be adopted by the Board or a Committee composed of members of the Board, to (i) select the Eligible Persons to whom Awards may from time to time be granted under the Plan; (ii) determine the type or types of Award to be granted to each Participant under the Plan; (iii) determine the number of shares of Preferred Stock and/or Common Stock (collectively, “Stock”) to be covered by each Award granted under the Plan; (iv) determine the terms and conditions of any Award granted under the Plan; (v) approve the forms of notice or agreement for use under the Plan; (vi) determine whether, to what extent and under what circumstances Awards may be settled in cash, shares of Preferred Stock and/or Common Stock or other property or canceled or suspended; (vii) determine whether, to what extent and under what circumstances cash, shares of Stock, other property and other amounts payable with respect to an Award shall be deferred either automatically or at the election of the Participant; (viii) interpret and administer the Plan and any instrument evidencing an Award, notice or agreement executed or entered into under the Plan; (ix) establish such rules and regulations as it shall deem appropriate for the proper administration of the Plan; (x) delegate ministerial duties to such of the Company’s employees as it so determines; and (xi) make any other determination and take any other action that the Committee deems necessary or desirable for administration of the Plan. Subject to adjustment from time to time, a maximum of two thousand (2,000) shares of Class C Preferred Stock and, effective as of February 8, 2024, one hundred ten million (10110,000,000) shares of Common Stock ~~shall~~are be available for issuance under the Plan. Shares issued under the Plan shall be drawn from authorized and unissued shares or shares now held or subsequently acquired by the Company as treasury shares. The Committee shall also, without limitation, have the authority to grant Awards as an alternative to or as the form of payment for grants or rights earned or due under other compensation plans or arrangements of the Company. Subject to earlier termination in accordance with the terms of the Plan and the instrument evidencing the Option, the maximum term of an Option shall be ten years from the Grant Date. An Award may be granted to any employee, officer or director of the Company or a Related Company whom the Committee from time to time selects. An Award may also be granted to any consultant, agent, advisor or independent contractor for bona fide services rendered to the Company or any Related Company that (a) are not in connection with the offer and sale of the Company’s securities in a capital-raising transaction and (b) do not directly or indirectly promote or maintain a market for the Company’s securities.

1921

Equity Compensation Plan Information

Plan Category

Number of Securities to be Issued Upon Excise of Outstanding Options, Warrants and Rights

Weighted-Average Exercise Price of Outstanding Options, Warrants and Rights

Number of Securities Remaining Available for Future Issuances Under Equity Compensation Plans*

Equity compensation plans approved by security holders

112,~~187~~223,~~199~~321

0.36

5847,~~812.801~~776,679

Equity compensation plans not approved by security holders

Total

112,~~187~~223,~~199~~321

0.36

5847,~~812~~776,~~801~~679

Represents 2,000 Series C Preferred Shares on an as-converted basis and 8,812,801 shares of common stock available under the Plan.

Recent Sales of Unregistered Securities

On ~~February~~ 24October 27, ~~2022~~2023, the Company ~~converted~~completed 15the ~~Shares~~sale of a convertible promissory note in the principal amount of ~~Series~~$156,250 Ato ~~Preferred~~an ~~Stock~~accredited investor. The purchase price of the note was $156,250, representing a 20% original issue discount. The note is non-interest bearing, except in the case of the event of a default, in which case interest will accrue from the date of the default at a rate equal to 33the lower of 18% per annum or the maximum rate permitted by law. The note becomes due on October 27,~~345~~ ~~shares~~2024. The holder may elect to convert the principal amount of the note and default interest, if any, subject to adjustment at a price equal to 90% of the lowest daily volume weighted average price of the common stock during the fifteen trading days preceding the conversion date. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

~~From January~~During 1,the ~~2022~~three ~~through~~months ended December 31, ~~2022~~2023, the Company issued an3,300,000 ~~aggregate~~shares of ~~51,282~~common ~~shares~~stock ofupon ~~Common~~the ~~Stock~~conversion ~~under~~of aoutstanding ~~Reg~~notes ~~A-1~~The ~~registration~~Company ~~and~~relied anupon ~~additional~~the ~~1,270,616~~exemption ~~shares~~provided by Section 3(a)(9) of ~~common~~the ~~stock~~Securities toAct ~~various~~of ~~consultants~~1933 ~~for~~in ~~service~~connection with these issuances.

~~From January~~During 1,the ~~2022~~three ~~through~~months ended December 31, ~~2022~~2023, the Company issued an1,233,025 ~~aggregate~~shares of ~~204,209~~common ~~shares~~stock ofas ~~Common~~payment ~~Stock~~for ~~under~~consulting ~~various~~and ~~asset~~advisory ~~acquisition~~service. The Company ~~agreements~~relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with these transactions.

~~From January~~In 1December 2023, ~~2022~~the ~~through~~Company ~~December~~issues 311,364,154 ~~2022~~shares of ~~the~~common stock in settlement of obligations under a purchase agreement. The Company ~~issued~~relied anupon the ~~aggregate~~exemption ofprovided ~~10,150~~by ~~shares~~Section 4(a)(2) of ~~Common~~the ~~Stock~~Securities ~~under~~Act ~~various~~of ~~note~~1933 ~~and~~in ~~related interest~~connection ~~conversion~~with ~~agreements~~this transaction.

~~From January~~In ~~1, 2022 through~~ December 312023, ~~2022~~ the Company ~~issued~~962,087 anshares ~~aggregate~~of common stock in settlement of 18$134,~~227~~683 ~~shares~~ of ~~Common~~indebtedness. ~~Stock~~The ~~resulting~~Company ~~from~~relied upon the ~~exercise~~exemption provided by Section 4(a)(2) of ~~warrants~~the Securities Act of 1933 in connection with this transaction.

~~With respect~~In toDecember ~~the transactions noted above~~2023, ~~each of~~ the ~~recipients of securities of the~~ Company ~~was~~issued ~~an accredited investor~~464,409 ~~or is considered~~shares ~~by the Company to be a “sophisticated person”, inasmuch as each~~ of ~~them~~common ~~has~~stock ~~such knowledge and experience~~ in ~~financial~~satisfaction ~~and business matters that they are capable~~ of ~~evaluating~~payments ~~the~~due ~~merits~~under ~~and~~a ~~risks of receiving securities of the Company~~note. ~~No solicitation was made and no underwriting discounts were given or paid in connection with these transactions.~~ The Company ~~believes~~relied ~~that~~upon the ~~issuance of~~exemption ~~its~~provided ~~securities~~by ~~as described above was exempt from registration with the Securities and Exchange Commission pursuant to~~ Section 4(a)(2) ~~and/or~~ ~~Regulation D~~ of the Securities Act of 1933 in connection with this transaction.

20In September 2023 the Company issued a convertible note in the principal amount of $10,000 for a purchase price of $15,000. The note has term of six months, bears interest at a rate of twelve percent per annum and is convertible into common stock at a price of $.0772 per share. In connection with this transaction, the Company issued the purchaser 100,000 shares of common stock. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

In December 2023 the Company issued a convertible note in the principal amount of $37,500 for a purchase price of $25,000. The note has term of six months, bears interest at a rate of twelve percent per annum and is convertible into common stock at a price of $.0772 per share. In connection with this transaction, the Company issued the purchaser 500,000 shares of common stock. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

In December 2023, the Company issued 9,167 shares of common stock in connection with the settlement of a litigation matter. The Company relied upon the exemption provided by Section 4(a)(2) of the Securities Act of 1933 in connection with this transaction.

Item 6.

Selected Financial Data

Not required for smaller reporting companies.

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operation

General

Can B̅ Corp. was originally formed as a Florida corporation on October 11, 2005, under the name of WrapMail, Inc. Effective January 5, 2015, we acquired 100% ownership of Prosperity Systems, Inc., which the Company is in the process of dissolving. Effective December 28, 2018, we acquired 100% ownership of Pure Health Products. In November 2018, we formed Duramed as a wholly- owned subsidiary. The Company is presently in the process of dissolving Prosperity.

The Company is in the business of promoting health and wellness through its development, manufacture and sale of products containing cannabinoids derived from hemp biomass and the licensing of durable medical devises. Can B̅’s products include oils, creams, moisturizers, isolate, gel caps, spa products, and concentrates and lifestyle products. Can B̅ develops its own line of proprietary products as well seeks synergistic value through acquisitions in the hemp industry. Can B̅ aims to be the premier provider of the highest quality hemp derived products on the market through sourcing the best raw material and offering a variety of products we believe will improve people’s lives in a variety of areas.

On March 14, 2024, an auction of the assets of our hemp division was conducted under Article 9 of the Uniform Commercial Code following allegations by Arena that we were in breach of our obligations under certain notes and a forbearance agreement. See “Item 3. Legal Proceedings.”

Following the auction, we have continued our hemp operations on a reduced scale using equipment provided by third parties and the services of third-party processors. Historically, revenues from our hemp division supported, in part, our durable medical equipment business conducted through Duramed. Due to reduced support from the hemp division, Duramed is operating with reduced staff which has adversely impacted revenues. While we plan to continue our hemp and durable medical equipment operations for the near term, our primary focus will be on protecting and commercializing the cannabis patents recently acquired by Nascent.

Results of Operations

	Year Ended
	Year Ended December 31,
	December 31,
	2023			2022			$ Change			% Change
	2022			2021			$ Change			% Change
Revenues
Product sales	$	51,~~524~~336,~~036~~117		$	45,~~156~~524,~~281~~036		$	1(4,~~367~~187,~~755~~919	)		32-75.98	%
Service revenue		1819,~~161,483~~627			~~447~~1,~~548~~161,483			~~713~~(341,~~935~~856	)		~~159~~-29.54	%
Total revenues		62,~~685~~155,~~519~~744			46,~~603~~685,~~829~~519			2(4,~~081~~529,~~690~~775	)		45-67.28	%
Cost of revenues		41,~~071~~797,~~144~~047			14,~~611~~071,~~730~~144			(2,~~459~~274,~~414~~097	)		~~152~~-55.69	%
Gross profit		2358,~~614,375~~698			2,~~992~~614,~~099~~375			(~~377~~2,~~724~~255,677	)		-1286.63	%
Operating expenses		167,~~782~~845,~~522~~140			1316,~~258~~782,~~106~~522			3(8,~~524~~937,~~416~~382	)		2653.63	%
Loss from operations		(147,~~168~~486,~~147~~442	)		(1014,~~266~~168,~~007~~147	)		(36,~~902~~681,~~140~~705	)		38-47.02	%
Other (expense) income:
Other income		-			2,991			(2,991	)		-100.0	%
Change in fair value of warrant liability		201,277			154,010			(16,762	)		-7.7	%
Change in fair value of warrant liability		154,010			-			154,010			NA
Interest expense		(2,510,811	)		(902,130	)		(1,851,417	)		280.8	%
Gain on debt extinguishment		-			196,889			(196,889	)		-100.0	%
Other expense		68,108			(7,115	)		72,928			-1513	%
Interest expense		(902,130	)		(2,102,193	)		1,200,063			-57.1	%
Other expense		(2,241,426	)		(755,235	)		1,795,251			402.4	%
Other expense		(7,115	)		-			(7,115	)		NA
Loss before provision for income taxes		(9,727,868	)		(14,923,382	)		4,886,454			-33.4	%
Other expense		(755,235	)		(1,902,313	)		1,147,078			-60.3	%
Provision for income taxes		9,596			793			9,596			NA
Loss before provision for income taxes		(14,923,382	)		(12,168,320	)		(2,755,062	)		22.6	%
Net loss	$	(9,737,464	)	$	(14,924,175	)	$	4,876,858			-33.4	%
Provision for income taxes		793			1,075			(282	)		-26.2	%
Net loss	$	(14,924,175	)	$	(12,169,395	)	$	(2,754,780	)		22.6	%

Year Ended December 31, ~~2022~~2023 compared with Year Ended December 31, ~~2021~~2022:

Revenues ~~increased~~ ~~$2,081,690~~decreased ~~from~~ $4,~~603~~529,~~829 in 2021 to $6,685,519 in 2022~~775. The ~~increase~~decrease largely due to anthe ~~increase~~normalization inof ~~the~~sales ~~Company’s~~activity ~~Duramed division~~with of2022 ~~approximately~~positively ~~$1,785,000~~impacted inby ~~fiscal~~the ~~2022~~wind ~~compared~~down toof ~~fiscal~~restrictions ~~2021~~related ~~due~~ to ~~increased~~the ~~surgical~~Covid-19 ~~procedures~~Pandemic surrounding ~~and~~elective ~~healthcare~~surgeries, ~~services which~~enabling ~~enabled~~an increase in the ~~Company~~usage toof ~~continue~~the toCompany’s ~~grow~~Duramed ~~within~~product ~~the~~lines and ultrasound device ~~sales~~ associated with patient recovery.

Compensation expenses ~~increased~~decreased $~~2,201,970 from $~~4,~~997~~275,~~155~~357 ~~in 2021 to $7,199,125~~ primarily related to ana ~~increase~~decrease in non-cash stock -based compensation expense.

Consulting and professional fees ~~increased~~decreased $~~1,447,262 from $~~3,~~968~~591,~~744~~ 054 in ~~2021~~2023. toThe ~~$5,416,006~~decrease inrelates ~~2022.~~to ~~The~~one ~~2022~~time ~~expense~~ amount ~~includes~~including legal, accounting, and other consulting fees and services incurred during the year ending December 31, 2022. ~~The increase was~~ related to an increase in legal fees and increase in consulting fees related to expansion of our durable medical device offerings as well as additional consulting fees related to formulation and development consulting related to hemp product development and other product enhancements. which did not recur in 2023

~~Depreciation of~~Other ~~property~~operating ~~and~~expenses ~~equipment~~decreased ~~increased~~ $~~914~~1,~~405 from $593~~070,~~656~~971 which inis ~~2021~~mainly due to ~~$1,408,061~~decrease in ~~2022~~rent ~~related~~expense tofrom ~~the~~closing ~~acquisition~~certain offacilities ~~property~~ and ~~equipment~~other ~~via~~cost ~~asset~~saving ~~purchases~~initiatives.

~~Other operating expenses increased $1,721,365 from 2021 to 2022 which is mainly due to bad debt expense of $313,228 and a loss on disposal of assets of $929,417.~~23

Net loss increased $2,754,780 from $12,169,395 in 2021 to $14,924,175 in 2022. The loss is related to additional incurred costs to jump start the Company’s operations within Miami and Tennessee during the first quarter of 2022 and a decrease in the Company’s gross margin due to unforeseen integration issues within the Company’s operations in Miami and Tennessee.

Liquidity and Capital Resources

As of December 31, ~~2022~~2023, the Company had cash and cash equivalents of $7334,~~194~~006 and negative working capital of $35,~~281~~747,~~494~~103. Cash and cash equivalents decreased $~~375,807 from $449,001 at December~~ 31,519 ~~2021~~compared to ~~$73,194 at~~ December 31, 2022. For the year ended December 31, ~~2022~~2023, $31,~~571~~349,~~617~~938 was provided by financing activities, and $31,~~947~~311,~~424~~838 was used in operating activities.

~~In March~~The ~~2023, the~~ Company ~~completed~~currently ~~the~~has ~~sale~~no ~~of a promissory note (the “Note”) in the principal amount of $1~~agreements,~~823,529~~ ~~and a~~arrangements, ~~warrant~~or ~~(the~~understandings ~~“Warrant”)~~with toany ~~purchase~~person ~~1,307,190 shares of Common Stock~~ to anobtain ~~investor~~funds ~~(the~~through ~~“Investor”)~~bank ~~pursuant to a Securities Purchase Agreement dated as of February 27~~loans, ~~2023.~~lines ~~The purchase price~~ of ~~the~~credit Note was $1,550,000, representing a 15% original issue discount. The Note is non-interest bearing, except in the case of the event of a default, in which case interest will accrue from the date of the default at a rate equal to the lower of 18% per annum or ~~the~~any ~~maximum~~other ~~rate permitted by law~~sources.

The Note is payable in nine (9) monthly installments of $232,500 each, consisting of a $227,941 principal reduction payment and a $4,559 redemption fee, commencing on April 27, 2023. The Company’s obligations under the note are secured by a security interest in the Company’s deposit accounts and the deposit accounts of the Company’s subsidiaries. In addition, each the Company’s subsidiaries has agreed that if an event of default occurs under the Note, the subsidiary will pay to the Investor an amount equal to 10% of revenues received during the prior month from the sale of goods or services or collections of accounts receivable.

The Company may elect to pay all or a portion of a monthly installment due under the Note by converting such amount into shares of the Company’s common stock at a price of $4.00 per share, subject to adjustment in accordance with the terms of the Note. If the Company does not pay an installment when due it is deemed an election by the Company to convert the installment payment into common stock at a price equal to the lower of $4.00 per share or 90% of the lowest daily volume weighted average price of the common stock during the five trading days preceding the conversion date. The Investor may elect at any time to convert amounts payable under the Note into shares of the Company’s common stock at a conversion price of $4.00 per share, subject to adjustment in accordance with the terms of the Note.

Contemporaneous with the sale of the Note and Warrant to the Investor, Arena Special Opportunities Partners I, L.P. and Arena Special Opportunities Fund, L.P. (collectively, “Arena”), who hold promissory notes with an unpaid principal balance of approximately $3,877,000 which became due on April 30, 2022 (the “Arena Notes”), entered into a Forbearance Agreement with the Company pursuant to which they agreed to forbear from exercising remedies under the Arena Notes until December 31, 2024 provided that the Company does not default on its obligations under the Forbearance Agreement.

The Forbearance Agreement requires the Company and/or Company’s subsidiaries, Duramed, Inc. and Duramed MI, LLC (together the “Duramed Subsidiaries”) to remit to Arena on a monthly basis certain accounts receivable collected by the Company and/or the Duramed Subsidiaries until the total amount collected is $5,700,000. The Company and the Duramed Subsidiaries have assigned their rights to these receivables to Arena.

If Arena fully exercises warrants to purchase shares of the Company’s common stock that were previously issued to it, and the aggregate market value of the shares acquired is less than $1,500,000, the Company must pay to Arena an amount equal to such difference.

As a condition to the closing of the sale of the Note and Warrant to the Investor, certain terms of certain promissory notes previously issued by the Company were amended, including the following:

● the maturity date of a promissory note in the principal amount of $62,500 was extended from June 6, 2023 to September 1, 2023; provided, however, that the holder can require full payment if the Company completes an offering of its common stock that results in an uplisting of its common stock to a national securities exchange; ● in consideration of the Company repaying an aggregate of $200,000 under notes issued in March 2022, the holders of the notes agreed to extend the maturity dates of the notes until September 1, 2023 and reduce the percentage of the cash proceeds received by the Company from the issuance of equity or debt that the holders of the notes can require the Company to apply to the repayment of the notes from 50% to 33%; ● in consideration of an increase in the aggregate principal amount by $10,000 and an increase in the interest rate to 18% per annum, the holder of notes in the aggregate principal amount of $150,000 agreed to waive his right to require the Company to repay a $50,000 note upon the Company’s receipt of $1,500,000 of financing and extend maturity dates from November 18,2021 and January 22, 2023 to September 1, 2023; ● in consideration of the Company’s agreement to provide a product credit for future orders of $50,000, the holder of a promissory note in the principal amount of $150,000 agreed to extend the maturity date from August 10,2022 to September 1, 2023; ● the maturity date of a promissory note in the principal amount of $1,250,000 was extended from August 12, 2022 until the earlier of September 1, 2023 or the date that the Company completes an offering resulting in an uplisting of its common stock to the Nasdaq Capital Market; ● in consideration of the repayment of a total of $232,500 under the notes, the holders of promissory notes in the aggregate principal amount of $435,000 issued in October and November 2022 that bore interest at 18% per annum and were past due agreed to exchange the notes for new notes that mature on September 1, 2023 and bear interest at 15% per annum; and ● in consideration of an increase in the aggregate principal amount to $937,000, the holder of notes in the aggregate principal amount of $852,000 having maturity dates between August 24, 2022 and April 12, 2023 agreed to exchange the notes for a single note that matures on September 1, 2023.

The Company currently has no agreements, arrangements or understandings with any person to obtain funds through bank loans, lines of credit or any other sources.

We currently have no commitments with any person for any capital expenditures.

We have no off-balance sheet arrangements. It is anticipated that Green Grow will again begin operations later in 2022 as Pure Health Products revenue increases and the need for additional isolate is present. Today, the available oversupply of isolate makes it cheaper to buy quality product at the market than to grow, harvest, and extract from scratch. Duramed, Inc. is beginning to show improvements in office utilization of its ultrasound device as more surgery centers are reopening.

23As of December 31, 2023 the Company had $8.9 million aggregate principal amount of notes that are past due. The Company plans to seek additional extensions of these notes or refinance the indebtedness. No assurance can be given that the Company will be successful in obtaining extensions or refinancing the indebtedness.

Item 7A.

Quantitative and Qualitative Disclosure About Market Risk

Not applicable.

Item 8.

Financial Statements and Supplementary Data

Our Consolidated Financial Statements and Notes thereto, for the fiscal years ended December 31, ~~2021~~2022 and ~~2020~~2021 and the report of BF Borgers CPA PC, our independent registered public accounting firm, are set forth on pages F-1 through F-25 of this Annual Report.

Item 9

Changes in and Disagreements With Accountants on Accounting and Financial Disclosure

N/A

Item 9A.

Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Disclosure controls and procedures are designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act is recorded, processed, summarized , and reported, within the time period specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in the reports filed under the Exchange Act is accumulated and communicated to management, including the Chief Executive Officer (CEO), as appropriate, to allow timely decisions regarding required disclosure. Based on the evaluation, the CEO has concluded that our disclosure controls and procedures are ineffective to ensure that information disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms. This determination was based on the small size of our accounting staff and the lack of segregation of duties.

To address the material weaknesses, we performed additional analysis and other post-closing procedures in an effort to ensure our financial statements included in this annual report have been prepared in accordance with generally accepted accounting principles. Accordingly, management believes that the financial statements included in this report fairly present in all material respects our financial condition, results of operations and cash flows for the periods presented.

Management Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. Our internal control system was designed to provide reasonable assurance to our management and board of directors regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Any internal control system, no matter how well designed, has inherent limitations and may not prevent or detect misstatements. Accordingly, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Management, with the participation of our Chief Executive Officer, has evaluated the effectiveness of our internal control over financial reporting as of December 31, ~~2022~~2023 based on criteria established in Internal Control—Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this evaluation, because of the Company’s limited resources and limited number of employees, and the absence of an audit committee, management concluded that, as of December 31, ~~2022~~2023, our internal control over financial reporting is not effective in providing reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with U.S. generally accepted accounting principle, which creates a material weakness. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the Company’s annual or interim financial statements will not be prevented or detected on a timely basis. A material weakness means there is a risk that our financial reports or other filings may contain an error or inaccuracy or not submitted timely.

There was a material weakness in the Company’s internal control over financial reporting due to the fact that the Company did not have an adequate process established to ensure appropriate levels of review of accounting and financial reporting matters, which resulted in our closing process not identifying all required adjustments and disclosures in a timely fashion. We expect that the Company will need to hire accounting personnel with the requisite knowledge to improve the levels of review of accounting and financial reporting matters. The Company may experience delays in doing so and any such additional employees would require time and training to learn the Company’s business and operating processes and procedures. For the near-term future, until such personnel are in place, this will continue to constitute a material weakness in the Company’s internal control over financial reporting that could result in material misstatements in the Company’s financial statements not being prevented or detected.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Securities and Exchange Act of 1934) during the year ended December 31, ~~2022~~2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Item 9B.

Other Information

None.

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections

Not Applicable.

Item 10.

Directors, Executive Officers and Corporate Governance

Our board of directors is to be elected annually by our shareholders. The board of directors elects our executive officers annually. Our directors and executive officers as of March 31, 2024 ~~2023~~ are as follows:

Name	Age	Position
Marco Alfonsi	6263	CEO, Director and Chairman since June 15, 2017
Stanley L. Teeple	7475	CFO, Secretary and Director since October 1, 2018
Frederick Alger Boyer, Jr.	5455	Independent Director appointed October 9, 2019
Ronald A. Silver	87	Independent Director appointed October 9, 2019
James F. Murphy	76	Independent Director appointed October 9, 2019
James F. Murphy	75	Independent Director appointed October 9, 2019
Pasquale Ferro	61	President of Pure Health Products

Marco Alfonsi, CEO and Chairman Director has been a financial service professional for the past 20 years. Mr. Alfonsi was appointed director and CEO of the Company in or around January 2015. Immediately prior to that, he spent eight years serving as the CEO of Prosperity Systems, Inc.

Throughout his career, Mr. Alfonsi was directly and indirectly involved in raising over $100 million dollars for small and medium sized business. Prior to his involvement in the financial services industry, Mr. Alfonsi has owned, operated, financed and sold several businesses. Mr. Alfonsi successfully started and managed two companies (ExecuteDirect.com, and Bakers Express of New York, Inc.), and held senior management positions with a number of financial institutions, including: Global American Investments, Clark Street Capital and Basic Investors.

Stanley L. Teeple –Mr. Teeple, CFO, Secretary, Director, was engaged from 2017-2018 with Solis Tek, Inc. (OTCQB:SLTK) a California based publicly traded corporation as Senior Vice President, Corporate Secretary , and Chief Compliance Officer. Solis Tek, Inc. a NV Corporation, is a developer of lighting and nutrient products, and most recently in cultivation and processing for the cannabis industry. Previously, from 2015-2016 Mr. Teeple was Chief Financial Officer and Secretary for Zonzia Media, Inc. (OTC:ZONX), a provider of streaming video and content to cable subscribers and hotel networks throughout the eastern US. From 2008 to 2014 Mr. Teeple was Chief Financial Officer and Secretary of Indigo-Energy, Inc. (OTC:IDGG) a publicly traded company in the oil and gas exploration business. Over the prior three plus decades Mr. Teeple through his turnaround consulting business, Stan Teeple, Inc., has held numerous senior management positions in several public and private companies across a broad spectrum of industries. Additionally, he has operated and worked for various court appointed trustees and principals as CEO, COO, and CFO in the entertainment, pharmaceuticals, food, travel, and tech industries. He operated his consulting business on a project-to-project basis and holds various other directorships. His businesses operational strengths include knowing how to manage and maximize the resources and preserve the integrity of a company from start-up through to maturity and corporate compliance in a regulatory environment.

Frederick Alger Boyer, Jr. Independent Director, is President & CEO of Advance Care Medical, Inc. - Mr. Boyer has over 25 years of Wall Street experience having worked on both the investment side as well as the banking side of the business Most recently he served as Head of Equities for the New York based investment bank H.C. Wainwright & Co. where he had overseen efforts in capital markets, sales, and trading. Prior to that he worked and or supervised teams at Rodman & Renshaw, Oppenheimer, Piper Jaffray, and Credit Suisse in New York, San Francisco, and Minneapolis. In his various roles he has advised hundreds of companies in their financing efforts both publicly and privately. Mr. Boyer has numerous securities licenses and is a graduate of the University of California at Berkeley.

Ronald A. Silver, Independent Director, was first elected to the Florida House of Representatives In 1978 and continued his tenure in that body until 1992. While in the Florida House, Silver served in major positions including Majority Whip (1984-1986) and Majority Leader (1986-1988). He also chaired various committees including the Select Committee on Juvenile Justice, Criminal Justice, Ethics and Elections and the subcommittee of Appropriations on General Government. He was then elected to the Florida Senate in 1992 and subsequently re-elected, serving as the Majority (Democratic) leader for the 1994 session. During his last term in the Senate he was designated by both the House and Senate as the Dean of the Legislature recognizing his standing as the longest serving member. His career as a lawmaker has yielded a vast and extensive knowledge of public policy issues and the legislative process, allowing him to be an advocate and servant for his diverse community. Throughout his tenure in the House and Senate, Mr. Silver has been known to tackle tough issues, transcend partisanship and build strong coalitions and in addition served on the Judiciary committee, which heard all condominium issues. As Senator, he served on a variety of committees, and was chairman of both the Appropriations Subcommittee on Health and Human Services and Criminal Justice. His career in the Senate has earned praise from his colleagues, in both the legislature and other branches of government throughout the nation. In 1993 Mr. Silver was elected Chairman of the Southern Legislative Conference (17 Southern States) of the Council of State Governments. Most recently, a new prescription drug plan of Medicare-eligible senior citizens in the State of Florida has been named “Silver Saver” in his honor. Since his retirement from the Senate in 2002, Mr. Silver also functions as President of his own consulting firm (Ron Silver & Associates) and maintains his law practice in Miami Beach, Florida. Mr. Silver is married with two children and three grandchildren.

James F. Murphy, Independent Director, brings more than 40 years of investigative and consulting experience as the Founder and President of Sutton Associates. From 1980 to 1984, Mr. Murphy was an Assistant Special Agent in Charge with the Federal Bureau of Investigation, responsible for a territory encompassing more than seven million people. His investigative specialties included organized crime, white-collar crime, labor racketeering and political corruption. From 1976 to 1980, Mr. Murphy was assigned to the Office of Planning and Evaluation at FBI headquarters, Washington, D.C. In this capacity, he evaluated and recommended changes in the FBI’s administrative and investigative programs. Since entering the private sector in 1984, Mr. Murphy has advanced the industry by developing systematic and professional protocols for performing due diligence, as well as other investigative services.

Pasquale Ferro (“Pat” to his friends and co-workers), President of Pure Health Products LLC, built Pure Health Products from the ground up inside a vacant warehouse including all mechanical, electrical, environmental, regulatory, and lab-quality specifications. Right out of school Pat began a career in real estate development both on the retail and commercial side of the business. Pat formed a company that would take new or distressed buildings (or anything in-between) and rehab and repair the facilities so they were commercially viable and move-in ready. During the course of this career Pat was often in charge of multiple work crews, union and non-union, for work in demolition, construction, plumbing, electrical, grounds crew and other professionally skilled tradesmen required to complete a building project.

Pat had his first foray into the manufacturing process in 2015 when he started Pure Health Products, LLC, which he developed into a regional research laboratory, new product development resource, and full-on production facility capable of producing capsules, tinctures, drops, salves, tablets and other products for the supplement and custom label community. Later in 2015, Pat connected with Marco Alfonsi, CEO of the Company, and became the production facility for all of the Company’s CBD based products. In late 2018, Pat sold Pure Health Products to the Company and became the President of that wholly-owned facility which he operates and manages today under a long term employment services agreement.

Board Committees

We have established an audit committee, compensation committee, or nominating committee. With one of the independent Directors sitting as chair of each committee. Mr. ~~Ron~~Ronald ~~Silver~~Siver isserved as Chairman of the Nominating Committee, until his resignation from the Board in July 2023 and the position is currently vacant. Mr. James Murphy is Chairman of the Audit Committee, and Mr. Alger Boyer is Chairman of the Compensation Committee.

Family Relationships

There are no familial relationships between any of our officers and directors.

Director or Officer Involvement in Certain Legal Proceedings

Our current directors and executive officers have not been involved in any legal proceedings as described in Item 401(f) of Regulation S-K in the past ten years.

Director Independence

The Company is not currently listed on any national securities exchange that has a requirement that the board of directors be independent. However, in anticipation of a possible exchange up listing, and in an effort toward better Board oversight, the company has engaged three independent Directors making the independent outside directors a majority on the Board of Directors.

Code of Ethics

We have adopted a Code of Ethics that applies to all of our employees and officers, and the members of our Board of Directors. This Code of Ethics is posted on the Company’s website www.canbiola.com and applies to all executive officers including CEO, CFO and COO.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Exchange Act requires our directors and executive officers, and persons who own more than 10% of a registered class of our equity securities, to file reports of ownership and changes in ownership with the SEC. Officers, directors and greater than 10% shareholders are required by SEC regulation to furnish the Company with copies of all Section 16(a) forms they file. Based on our review of the reports filed by Reporting Persons, we believe that, during the year ended December 31, ~~2022~~2023, the following Reporting Persons did not meet all applicable Section 16(a) filing requirements: (i) Stanley Teeple, ~~(ii) Phil Scala~~ and (~~iii~~ii) Marco Alfonsi. Otherwise, we believe that the Reporting Persons met such filing requirements.

Item 11.

Executive Compensation

The table below summarizes all compensation awarded to, earned by, or paid to our executive officers and directors for all services rendered in all capacities to us during the fiscal years ended December 31, ~~2022~~2023 and ~~2021~~2022.

Name and principal position	Year		Salary		Bonus		Stock awards		Option awards (54)		Non-equity incentive plan comp.		Non-qualified deferred comp. earnings		All other comp.		Total
Marco Alfonsi (1)		~~2022~~2023	$	2510,~~962~~000	$	0	$	~~500,100~~0	$	~~100~~108,~~000~~333	$	0	$	0	$	0	$	~~626~~118,~~062~~333
		2021	$	107,142	$	0	$	2,512,500	$	100,000	$	0	$	0	$	0	$	2,719,642
		2022	$	25,962	$	0	$	500,100	$	100,000	$	0	$	0	$	0	$	626,062
Stanley L. Teeple (2)		~~2022~~2023	$	2510,~~962~~000	$	0	$	~~500,100~~0	$	~~100~~108,~~000~~333	$	0	$	0	$	0	$	~~626~~118,~~062~~333
		2021	$	90,000	$	0	$	2,512,500	$	100,000	$	0	$	0	$	0	$	2,702,500
		2022	$	25,962	$	0	$	500,100	$	100,000	$	0	$	0	$	0	$	626,062
Pasquale Ferro (3)		2022	$	25,962	$	0	$	500,100	$	100,000	$	0	$	0	$	0	$	626,062
		2021	$	98,654	$	0	$	2,512,500	$	100,000	$	0	$	0	$	0	$	2,711,154
Phil Scala (4)		2022	$	15,000	$	0	$	61,6740	$	100,000	$	0	$	0	$	0	$	176,674
		2021	$	52,000	$	0	$	0	$	0	$	0	$	0	$	0	$	52,000

(1) ~~Pursuant~~ ~~to an employment agreement entered on or around May 14, 2015, Marco Alfonsi was entitled to receive compensation of $6,000 per month through September 31, 2017 when the contract expired.~~ On or around October 3, 2017, the Company entered into a new employment agreement with Mr. Alfonsi whereby he was entitled to receive $10,000 per month for a period of three years. Mr. Alfonsi also received one share of Series A Preferred Stock upon his execution of the new agreement. In addition, on or around October 4, 2017, the Company authorized the issuance of an additional two shares of Series A Preferred Stock to Mr. Alfonsi in consideration for cancellation of approximately $120,000 of deferred income owed to Mr. Alfonsi. The Company entered into a new employment agreement dated October 21, 2018 Mr. Alfonsi, pursuant to which Mr. Alfonsi agreed to continue to serve as the Company’s Chief Executive Officer (“CEO”) and accept appointment as Chairman of the Board of Directors (“Chairman”) for an initial term of four (4) years. He is entitled to receive $15,000 per month and other compensation under the new agreement. On December 28, 2020, Marco Alfonsi signed a three year Employment Agreement. Under that agreement, he iswas i) entitled to receive a i) base salary of fifteen thousand dollars ($15,000.00) per month, ii) iswas eligible to receive cash and or stock bonuses, iii) ~~shall~~was entitled to receive a stock bonus in accordance with the Company’s Incentive Stock Option Plan (“ISOP”) in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) issued 200 shares of the Company’s Series C Preferred ~~stock~~Stock, and v) granted usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Actual salary compensation was ~~paid~~$25,962 during 2022 and $10,000 for 2023. In February 2024 the ~~1st~~Company ~~quarter~~and Mr. Alfonsi entered into a new three year employment agreement containing terms substantially similar to the prior agreement except that the base salary was increased to $20,000 per month and the agreement provides that Mr. Alfonsi will be entitled to quarterly distributions of ~~2022~~two ~~only~~percent (2%) of the total revenues received by the Company from Nascent during and after the term of the agreement.

(2) ~~Pursuant~~ to an employment agreement entered on or around October 15, 2018, Mr. Teeple serves as the Company’s Chief Financial Officer and Secretary for a term of 4 years. The Agreement also provided for compensation to Mr. Teeple of $15,000 cash per month and the issuance of 1 share of Series A Preferred Stock upon execution of the Agreement. The fair value of the Series A preferred share is $578,000 and has a conversion vesting (but not voting) period of four years. An additional three shares of Series A Preferred Stock were issued in April 2019 per a new employment Agreement. The fair value of the Series A Preferred share issued in April 2019 is $992,250 and has a conversion (but not voting) vesting period of three years. In 2020 and 2019, the amortized portion of Series A preferred shares is $469,301 and $372,667, respectively. On December 28, 2020, Stanley Teeple ~~signed~~entered into a ~~new~~ three-year ~~Employment~~employment ~~Agreement~~agreement with the Company. Under that agreement, he iswas i) entitled to receive ~~a i)~~ base salary of fifteen thousand dollars ($15,000.00) per month, ii) is eligible to receive cash and or stock bonuses, iii) ~~shall~~entitled to receive a stock bonus in accordance with the Company’s ISOP in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) issued 200 shares of the Company’s Series C Preferred ~~stock~~Stock, and v) granted usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Actual salary compensation was ~~paid~~$25,962 during 2022 and $10,000 for 2023. In February 2024 the ~~1st~~Company and Mr. Teeple entered into a new three year employment agreement containing terms substantially similar to the prior agreement ~~quarter~~except that the base salary was increased to $18,500 per month and the agreement provides that Mr. Teeple Alfonsi will be entitled to quarterly distributions of ~~2022~~two ~~only~~percent (2%) of the total revenues received by the Company from Nascent during and after the term of the agreement.

As of December 31, 2023, there were Incentive Stock Option Awards issued to Marco Alfonsi and Stanley Teeple in the amount of $100,000 each. The Options were issued on December 29, 2020 under the ISO Plan, at a strike price of $.361 per share for 277,008 shares for each of the 4 persons named.

(5) The amounts reported in this column represent the grant date fair value of option awards granted during the years ended December 31, 2023 and 2022 in accordance with FASB ASC 718. The assumptions used in the calculation of these awards are discussed in Note 11 to the Consolidated Financial Statements included in this Report.

(3) On December 28, 2018, the Company executed an Executive Service Agreement (“Ferro Agreement”) with Pasquale Ferro. The Ferro Agreement provides that Mr. Ferro serves as the President of Pure Health Products, LLC for a term of 4 years. The Ferro Agreement also provides for compensation to Mr. Ferro of $15,000 cash per month and the issuance of 5 shares of Series A Preferred Stock upon execution of the Ferro Agreement. The fair value of the Series A preferred shares is $2,109,700 and has a conversion (but not voting) vesting period of four years. In 2019, the amortized portion of Series A preferred stock is $527,425. On December 28, 2020, Pasquale Ferro signed a three year Employment Agreement. Under that agreement, he is to receive a i) base salary of fifteen thousand dollars ($15,000.00) per month, ii) is eligible to receive cash and or stock bonuses, iii) shall receive a stock bonus in accordance with the Company’s ISOP in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) 200 shares of the Company’s Series C Preferred stock, and v) usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Actual salary compensation was paid for the 1st quarter of 2022 only.

(4) On October 11, 2019, the Company executed an Executive Service Agreement (“Scala Agreement”) with Phil Scala. The Scala Agreement provided that Mr. Scala served as the Interim Chief Operating Officer for a term of 90 days. The Scala Agreement also provided for compensation to Mr. Scala of $2,500 cash per month. On January 1, 2020, Scala and the Company extended the engagement until March 31, 2020. On December 28, 2020, Phil Scala signed a three-year Employment Agreement. Under that agreement, he was to receive a i) base salary of fifty-two thousand dollars per year, ii) was eligible to receive cash and or stock bonuses, iii) a stock bonus in accordance with the Company’s ISOP in an amount of one-hundred thousand dollars ($100,000), iv) 20 shares of the Company’s Series C Preferred stock, and v) usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Actual salary compensation was paid for the 1st quarter of 2022 only. Mr. Scala resigned his position as an officer of the Company in March 2023.

As of December 31, 2022, there were Incentive Stock Option Awards issued to Marco Alfonsi, Pasquale Ferro, Stanley Teeple, and Phil Scala in the amount of $100,000 each. The Options were issued on December 29, 2020 under the ISO Plan, at a strike price of $.361 per share for 277,008 shares for each of the 4 persons named.

(5) The amounts reported in this column represent the grant date fair value of option awards granted during the years ended December 31, 2022 and 2021 in accordance with FASB ASC 718. The assumptions used in the calculation of these awards are discussed in Note 11 to the Consolidated Financial Statements included in this Report.

The table below summarizes all compensation awarded to, earned by, or paid to our non-interested directors for all services rendered in all capacities to us during the previous two fiscal years, as of December 31, 2022.

Non-Interested Director Summary Compensation Table
Name and principal position	Year	Fees Earned or Paid in Cash		Stock awards (1)		Option awards (2)		Non-equity incentive plan comp.		Non-qualified deferred comp. earnings		All other com.		Total
Frederick A. Boyer	~~2022~~2023	$	0	$	~~100,020~~0	$	0	$	0	$	0	$	0	$	~~100,020~~0
Director	~~2021~~2022	$	0	$	0100,020	$	0	$	0	$	0	$	0	$	0100,020
Ronald Silver	~~2022~~2023	$	0	$	~~100,020~~0	$	0	$	0	$	0	$	0	$	~~100,020~~0
Director	2021	$	0	$	0	$	0	$	0	$	0	$	0	$	0
Director (3)	2022	$	0	$	100,020	$	0	$	0	$	0	$	0	$	100,020
James F. Murphy	~~2022~~2023	$	0	$	~~100,020~~	$	0	$	0	$	0	$	0	$	~~100,020~~0
Director	~~2021~~2022	$	0	$	0100,020	$	0	$	0	$	0	$	0	$	0100,020

	1)	Each of the 3 non-interested independent directors was issued 20 Preferred C shares in 2022.
	2)	As of December 31, 2022, Directors Boyer, Silver and Murphy each owned 10,000 options to exercise and purchase stock at $.30 at any time until 2023.

	1)	Each of the 3 non-interested independent directors was issued 20 Preferred C shares in 2022.
	2)	As of December 31, 2023, Directors Boyer, Silver and Murphy each owned 10,000 options to exercise and purchase stock at $.30 at any time until 2023.
	3)	Mr. Silver resigned his position as Director in July 2023.

No director has received cash compensation for their directorship. We do have a compensation committee and compensation for our directors and officers is determined by our board of directors.

We reimburse Non-Employee Directors for actual out-of-pocket costs incurred to attend board meetings. No additional compensation is paid for attendance in person or by telephone at board meetings.

The table below summarizes all outstanding equity awards for officers, as of December 31, 2022.

Outstanding Equity Awards at Fiscal Year-End
Name and principal position	Grant Date		~~Grant Type~~	~~Number~~Grant ~~of Securities Underlying Unexercised Options Exercisable~~Type		Number of Securities Underlying Unexercised Options ~~Unexercisable~~Exercisable		~~Option~~Number ~~Exercise~~of ~~Price~~Securities Underlying Unexercised Options Unexercisable		Option ~~Expiration~~Exercise ~~Date~~Price		Option Expiration Date
Stanley Teeple – CFO	~~10/21/2018~~	10/21/2018	~~Stock Options~~		~~667~~Stock Options		0667	$	~~4.50~~0	~~10/20/2023~~$	4.50		10/20/2023
Johnny Mack PhD – Ex COO	9/9/2019		Stock Options		1,778		0	$	4.50	9/8/2024
Marco Alfonsi – CEO		8/28/2022			Stock Options		100,000		0	$	3.00		8/27/2027
Frederick A. Boyer – Director	10/15/2019		Stock Options		667		0	$	4.50	10/14/2024
Stanley Teeple – CFO		8/28/2022			Stock Options		100,000		0	$	3.00		8/27/2027
Ronald Silver – Director	10/15/2019		Stock Options		667		0	$	4.50	10/14/2024
James F. Murphy – Director	10/15/2019		Stock Options		667		0	$	4.50	10/14/2024
Ronald Silver – Director	12/9/2020		Stock Options		833		0	$	7.50	12/9/2025
Stanley Teeple – CFO	12/29/2020		Stock Options		18,467		0	$	5.42	12/29/2025
Pasquale Ferro – President	12/29/2020		Stock Options		18,467		0	$	5.42	12/29/2025
Phil Scala – COO	12/29/2020		Stock Options		18,467		0	$	5.42	12/29/2025
Marco Alfonsi – CEO	12/29/2020		Stock Options		18,467		0	$	5.42	12/29/2025
Stanley Teeple – CFO	7/15/2021		Stock Options		19,608		0	$	6.60	7/15/2026
Pasquale Ferro – President	7/15/2021		Stock Options		19,608		0	$	6.60	7/15/2026
Marco Alfonsi – CEO	7/15/2021		Stock Options		19,608		0	$	6.60	7/15/2026
Marco Alfonsi – CEO	4/26/2021		Stock Options		3,401		0	$	7.50	4/26/2026
Marco Alfonsi – CEO	1/6/2022		Stock Options		19,753		0	$	7.35	1/5/2027
Pasquale Ferro – President	1/6/2022		Stock Options		19,753		0	$	7.35	1/5/2027
Phil Scala – COO	1/6/2022		Stock Options		19,753		0	$	7.35	1/5/2027
Stanley Teeple – CFO	1/6/2022		Stock Options		19,753		0	$	7.35	1/5/2027
Marco Alfonsi – CEO	8/28/2022		Stock Options		100,000		0	$	3.00	8/27/2027
Pasquale Ferro – President	8/28/2022		Stock Options		100,000		0	$	3.00	8/27/2027
Phil Scala – COO	8/28/2022		Stock Options		50,000		0	$	3.00	8/27/2027
Stanley Teeple – CFO	8/28/2022		Stock Options		100,000		0	$	3.00	8/27/2027

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth the ownership, as of April 1012, 2023, of our common stock, Series C Preferred Stock and Series D Preferred Stock by (i) each person known by us to be the beneficial own of more than five (5%) percent of the applicable class; (ii) each of the Company’s executive officers and directors; and (iii) the Company’s directors and executive officers as a group. To the best of our knowledge, the persons named have sole voting and investment power with respect to such shares, except as otherwise noted. There are not any pending or anticipated arrangements that may cause a change in control. The information presented below regarding beneficial ownership of our voting securities has been presented in accordance with the rules of the Securities and Exchange Commission and is not necessarily indicative of ownership for any other purpose. Under these rules, a person is deemed to be a “beneficial owner” of a security if that person has or shares the power to vote or direct the voting of the security or the power to dispose or direct the disposition of the security. A person is deemed to own beneficially any security as to which such person has the right to acquire sole or shared voting or investment power within 60 days through the conversion or exercise of any convertible security, warrant, option or other right. More than one person may be deemed to be a beneficial owner of the same securities.

Shares Beneficially Owned(1) As of April 12, 2023
Name and Address of Beneficial Owner(2):	Common Stock			Percent of Class(3)			Series C Preferred Stock		Percent of Class(4)			Series D Preferred Stock		Percent of Class(5)			Percent of Total Voting Power
Marco Alfonsi, CEO and Director		3,620,805	(6)		6.90	%		300		27.3	%		1,250		31.3	%		7.89	%

Stanley L. Teeple, CFO and Director		3,620,632	(7)		6.88	%		300		27.3	%		1,250		31.3	%		7.87	%

Frederick A. Boyer, Director		1,008,668	(8)		2.00	%		–		–			–		–			1.84	%

James F. Murphey, Director		1,208,668	(9)		2.39	%		–		–			–		-			2.20	%

All directors and executive officers as a group (4 persons)		9,470,773			16.59	%		600		10.4	%		2,500		62.5	%		18.35	%

Arena Special Opportunities Fund, L.P		5,421,840	(11)		9.9	%		–		–			–		–			9.19	%

Walleye Opportunities Master Fund LTD		5,421,840	(12)		9.9	%												9.19	%

ClearThink Capital Partners		5,421,840	(13)		9.9	%		–		–			–		–			9.46	%

(1)	Shares of common stock subject to stock options, warrants or convertible securities currently exercisable or convertible, or exercisable or convertible within 60 days of April 12, 2023 are deemed to be outstanding for computing the percentage ownership of the person holding such options, warrants or convertible securities and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage ownership of any other person.
(2)	Except as otherwise indicated, the address of each beneficial owner is c/o Can B Corp., 960 South Broadway, Suite 120, Hempstead, New York 11801.
(3)	Based on 49,344,230 shares of common stock issued and outstanding as of April 12, 2023.
(4)	Based on 1,100 shares of Series C Preferred Stock issued and outstanding as of April 12, 2023. Shares of Series C Preferred Stock entitle their holders to vote on an as converted basis (1,667 shares of common stock per share of Series C Preferred Stock).
(5)	Based on 4,000 shares of Series D Preferred Stock issued and outstanding as of April 12, 2023. Holders of Series D Preferred Stock are entitled to 667 votes per share.
(6)	Includes 2,774,965 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon conversion of 300 shares of Series C Preferred Stock. Does not include 42,343 shares of common stock held by adult members of Mr. Alfonsi’s family.
(7)	Includes 2,778,526 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon conversion of 300 shares of Series C Preferred Stock.
(8)	Includes 1,000,667 shares of common stock issuable upon the exercise of options.
(9)	Includes 1,200,667 shares of common stock issuable upon the exercise of options.
(10)	Includes 2,778,526 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon conversion of 300 shares of Series C Preferred Stock.
(11)	Includes shares beneficially owned by the shareholder’s affiliates, Arena Investors, LP and Arena Special Opportunities Partners I, LP, and 4,650,146 shares issuable upon conversion of convertible securities and exercise of warrants that contain a 9.99% beneficial ownership limitation. The address of this shareholder is 405 Lexington Avenue, 59^th Floor, New York, New York 10174.
(12)	Includes 4,826,358 shares of common stock issuable upon conversion of convertible notes and exercise of warrants that contain a 9.99% beneficial ownership limitation. The address of this shareholder is 2800 Niagara Lane North, Plymouth Minnesota 55447.
(13)	Includes 3,488,815 shares of common stock issuable upon conversion of convertible notes that contain a 9.99% beneficial ownership limitation

Shares Beneficially Owned(1) As of April 10, 2023

Name and Address of Beneficial Owner(2):	Common Stock			Percent of Class(3)			Series C Preferred Stock		Percent of Class(4)			Series D Preferred Stock		Percent of Class(5)			Percent of Total Voting Power
Marco Alfonsi, CEO and Director		1,000,512	(6)		16.6	%		300		27.3	%		1,250		31.3	%		18.3	%
Stanley L. Teeple, CFO and Director		981,946	(7)		16.3	%		300		27.3	%		1,250		31.3	%		18.1	%
Frederick A. Boyer, Director		8,668	(8)		0.16	%		–		–			–		–			0.09	%
Ronald Silver, Director		9,280	(9)		0.17	%		–		–			–		–			0.09	%
James F. Murphey, Director		8,668	(10)		0.16	%		–		–			–		-			0.09	%
All directors and executive officers as a group (5 persons)		2,009,074			30.1	%		600		10.4	%		2,500		62.5	%		36.7	%
Pasquale Ferro		990,884	(11)		16.4	%		300		27.3	%		1,250		31.3	%		16.8	%
Arena Special Opportunities Fund, L.P		592,976	(12)		9.9	%		–		–			–		–			5.7	%
Walleye Opportunities Master Fund LTD		592,976	(13)		9.9	%												5.7	%

(1)	Shares of common stock subject to stock options, warrants or convertible securities currently exercisable or convertible, or exercisable or convertible within 60 days of April 10, 2023 are deemed to be outstanding for computing the percentage ownership of the person holding such options, warrants or convertible securities and the percentage ownership of any group of which the holder is a member, but are not deemed outstanding for computing the percentage ownership of any other person.
(2)	Except as otherwise indicated, the address of each beneficial owner is c/o Can B Corp., 960 South Broadway, Suite 120, Hempstead, New York 11801.
(3)	Based on 5,396,682 shares of common stock issued and outstanding as of April 10, 2023.
(4)	Based on 1,100 shares of Series C Preferred Stock issued and outstanding as of April 10, 2023. Shares of Series C Preferred Stock entitle their holders to vote on an as converted basis (1,667 shares of common stock per share of Series C Preferred Stock).
(5)	Based on 4,000 shares of Series D Preferred Stock issued and outstanding as of April 10, 2023. Holders of Series D Preferred Stock are entitled to 667 votes per share.
(6)	Includes 142,672 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon the exercise of 300 shares of Series C Preferred Stock. Does not include 42,343 shares of common stock held by adult members of Mr. Alfonsi’s family.
(7)	Includes 139,361 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon the exercise of 300 shares of Series C Preferred Stock.
(8)	Includes 667 shares of common stock issuable upon the exercise of options.
(9)	Includes 1,500 shares of common stock issuable upon the exercise of options.
(10)	Includes 667 shares of common stock issuable upon the exercise of options.
(11)	Includes 139,361 shares of common stock issuable upon the exercise of options and 500,100 shares of common stock issuable upon exercise of 300 shares of Series C Preferred Stock.
(12)	Includes shares beneficially owned by the shareholder’s affiliates, Arena Investors, LP and Arena Special Opportunities Partners I, LP, and 542,391 shares issuable upon conversion of convertible securities and exercise of warrants that contain a 9.99% beneficial ownership limitation. The address of this shareholder is 405 Lexington Avenue, 59th Floor, New York, New York 10174.
(13)	Includes 492,976 shares of common stock issuable upon conversion of convertible notes and exercise of warrants that contain a 9.99% beneficial ownership limitation. The address of this shareholder is 2800 Niagara Lane North, Plymouth Minnesota 55447.

Item 13.

Certain Relationships and Related Party Transactions, and Director Independence

Can B̅ Corp.’s Corporate Governance Guidelines establish standards for evaluating Director independence and requires that a majority of Directors be independent. The Board determines the independence of each Director under Nasdaq governance standards. Those standards identify the types of relationships that, if material, could impair independence. The Board determined that, under the Nasdaq listing standards, the following non-employee Directors are independent: Frederick A. Boyer, ~~Ronald Silver~~ and James F. Murphy. Our non-independent directors are Marco Alfonsi and Stanley L. Teeple.

Except as described herein (or within the section entitled Executive Compensation of this report), none of the following parties (each a “Related Party”) has, in our fiscal years ended 2022 and 2021, had any material interest, direct or indirect, in any transaction with us or in any presently proposed transaction that has or will materially affect us:

	●	any of our directors or officers;
	●	any person who beneficially owns, directly or indirectly, shares carrying more than 10% of the voting rights attached to our outstanding shares of common stock; or
	●	any member of the immediate family (including spouse, parents, children, siblings and in- laws) of any of the above persons.

LI Accounting Associates, LLC (“LIA”), an entity controlled by a relative of the Managing Member PHP, is a vendor of Can B̅ Corp. As of December 31, ~~2022~~2023, the Company had accounts payable due to LIA of $~~5,000~~_____. For the twelve months ended December 31, ~~2022~~2023, the Company had expenses to LIA of $~~17,100~~______.

~~Pasquale Ferro,~~At ~~President~~December of31, ~~Pure Health Products LLC~~2023, ~~manages~~ the ~~R&D and manufacturing of the~~ Company ~~products~~has ~~sold~~amounts ~~via other subsidiary~~due ~~companies.~~to ~~Mr. Ferro is also~~ a ~~substantial~~director ~~shareholder~~ of the Company ~~but~~of ~~receives~~approximately no$____ ~~direct~~which ~~compensation~~are ~~from~~expected ~~Can~~to B,be ~~Corp.~~repaid ~~other than outlined~~ in ~~his~~the ~~Employment~~next ~~Agreement~~twelve months.

At December 31, 2022, the Company has amounts due to a director of the Company of approximately $295,245 which are expected to be repaid in the next twelve months.

Item 14.

Principal Accounting Fees and Services

The following table sets forth fees billed to us by BF Borgers CPA PC, our independent registered public accounting firm during the fiscal years ended December 31, ~~2022~~2023 and December 31, 2022 ~~2021~~ for: (i) services rendered for the audit of our annual financial statements and the review of our quarterly financial statements; (ii) services by our independent registered public accounting firms that are reasonably related to the performance of the audit or review of our financial statements and that are not reported as audit fees; (iii) services rendered in connection with tax compliance, tax advice and tax planning; and (iv) all other fees for services rendered.

	December 31, 2022		December 31, 2021
	December 31, 2023		December 31, 2022
Audit Fees	$	197,300	$	~~103~~197,~~312~~300
Audited Related Fees	$	0	$	0
Tax Fees	$	0	$	0
All Other Fees	$	0	$	0

3231

PART IV

Item 15.

Exhibits, Financial Statement Schedules.

Exhibits Schedule

The following exhibits are filed with this Annual Report:

Exhibit		Description
2.1		Share Purchase Agreement with Prosperity Systems, Inc., dated January 5, 2015(2)
2.2		Membership Purchase Agreement with Pure Health Products(6)
2.3		Green Grow Stock Purchase Agreement(4)
2.4		Green Grow Modification Agreement(1)
3.1		Articles of Incorporation, as amended(1)
3.2		Bylaws(2)
4.1		Articles of Amendment designating Series A Preferred Stock rights, as amended(9)
4.2		Articles of Amendment designating Series B Preferred Stock rights(1)
4.3		Articles of Amendment designating Series C Preferred Stock rights(7)
4.4		Articles of Amendment designating Series D Preferred Stock rights(10)
10.1		Employment Agreement with Marco Alfonsi dated December 29, 2020(10)
10.2		Employment Agreement with Stanley L. Teeple dated December 29, 2020(10)
10.3		Employment Agreement with Pasquale Ferro dated December 29, 2020(10)
10.4		Employment Agreement with Phil Scala dated December 29, 2020(10)
10.5		Commission Agreement with Andrew Holtmeyer(10)
10.6		Employment Agreement with Bradley Lebsock(10)
10.7		Memorandum of Understanding with Sam International and ZetrOZ Systems LLC(3)
10.8		Can B̅ Corp. 2020 Incentive Stock Option Plan(8)
10.9		Arena Securities Purchase Agreement(10)
10.10		ASOF Original Issue Discount Senior Secured Convertible Promissory Note(10)
10.11		ASOF Warrant to Purchase Common Stock(10)
10.12		ASOP Original Issue Discount Senior Secured Convertible Promissory Note(10)
10.14		ASOP Warrant to Purchase Common Stock(10)
10.15		Arena Security Agreement(10)
10.16		Arena Intellectual Property Security Agreement(10)
10.17		Arena Registration Rights Agreement(10)
10.18		Arena Holding Escrow Agreement(10)
10.19		Arena Guaranty Agreement from Company Subsidiaries(10)
10.20		Amendment to 2020 ASOF Promissory Note(11)
10.21		Amendment to 2020 ASOP Promissory Note(11)
10.22		2021 Arena Securities Purchase Agreement(11)
10.23		2021 ASOF Original Issue Discount Senior Secured Convertible Promissory Note(11)
10.24		2021 ASOF Warrant to Purchase Common Stock(11)
10.25		2021 ASOP Original Issue Discount Senior Secured Convertible Promissory Note(11)
10.26		2021 ASOP Warrant to Purchase Common Stock(11)
10.27		2021 Arena Registration Rights Agreement(11)
10.28		2021 Addendum to Arena Security Agreement(11)

10.29		2021 Addendum to Arena Intellectual Property Security Agreement(11)
10.30		2021 Addendum to Arena Guaranty Agreement from Company Subsidiaries(11)
10.31		Asset Acquisition Agreement with Imbibe(10)
10.32		Equipment Acquisition Agreement with TWS(12)
10.33		Promissory Note to TWS(12)
10.34		Asset Purchase Agreement with MCB(12)
10.35		Commercial Lease with Makers Developments LLC(13)
10.36		Single-Tenant NNN Lease Agreement with CS2 Real Estate Holdings, LLC(13)
10.37		Commercial Lease with Red Road Business Park(13)
10.38		Asset Acquisition Agreement with various Sellers (Botanical Biotech)(10)
10.39		PrimeX Distribution Agreement(15)
10.40		American Development Partners development agreement(15)
10.41		Mast Hill Securities Purchase and Related Agreements(14)
10.42		Blue Lake Partners Securities Purchase and Related Agreements(14)
10.43		Fourth Man Securities Purchase and Related Agreements(16)
10.44		Extension and Amendment to Arena Transactional Documents(16)
10.45		Amended Placement Agent Agreement(18)
10.46		Alumni Capital Securities Purchase and Related Documents(19)
10.47		Arena Exchange Agreement(20)
10.48		Agreement with Forever Bradst(21)
10.49		Promissory Note Modification Agreement with TWS Pharma LLC(22)
10.50		Walleye Securities Purchase Agreement(22)
10.51		Walleye Promissory Note(22)
10.52		Walleye Revenue Pledge and Security Agreement(22)
10.53		Walleye Common Stock Purchase Warrant(22)
10.54		Amendment to Walleye Common Stock Purchase Agreement(22)
10.55		Walleye Registration Rights Agreement(22)
10.56		Intercreditor Agreement among Can B Corp., Walleye and Arena(22)
10.57		Arena Forbearance Agreement(22)
10.58		Amendment No. 2 to Blue Lake Partners Promissory Note and Amendment to Securities Purchase Agreement, Consent and Waiver Agreement(22)
10.59		Amendment No. 2 to Mast Hill Fund Promissory Note, Amendment to Securities Purchase Agreement, Consent and Waiver Agreement(22)
10.60		Amendment No. 2 to Fourth Man Promissory Note, Amendment to Securities Purchase Agreement, Consent and Waiver Agreement(22)
10.61		Walleye May 2023 Promissory Note(23)
10.62		Securities Purchase Agreement dated as of October 26, 2023 between Can B Corp. and Walleye Opportunities Master Fund Ltd.(24)
10.63		Promissory Note dated October 27, 2023 issued by Can B Corp. to Walleye Opportunities Master Fund Ltd.(24)
10.64		Consolidated Note dated October 27, 2023 issued by Can B Corp. to Walleye Opportunities Master Fund Ltd.(24)
10.65		Distribution and Assignment Agreement dated as of October 27, 2023 among Can B Corp, Nascent Pharma, LLC and Walleye Opportunities Master Fund Ltd.(24)
10.66		Registration Rights Agreement dated as of October 27, 2023 between Can B Corp and Walleye Opportunities Master Fund Ltd.(24)
10.67		Employment Agreement with Marco Alfonsi dated February 8, 2024
10.68		Employment Agreement with Stanley Teeple dated February 8, 2024
10.69		Amendment Modification to Convertible Promissory Note dated August 7, 2023 between Can B Corp. and ClearThink Capital Partners, LLC
10.70		Promissory Note dated September 22, 2023 issued by Can B Corp. to ClearThink Capital Partners, LLC
10.71		Promissory Note dated December 20, 2023 issued by Can B Corp. to ClearThink Capital Partners, LLC
10.72		Promissory Note dated February 29, 2024 issued by Can B Corp. to ClearThink Capital Partners, LLC
14.1		Code of Ethics(1)
21.1		List of Subsidiaries(10)
31.1		Chief Executive Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Chief Financial Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Chief Executive Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

10.6		Employment Agreement with Bradley Lebsock(10)
101.INS		Inline XBRL Instance Document
10.7		Memorandum of Understanding with Sam International and ZetrOZ Systems LLC(3)
101.SCH		Inline XBRL Taxonomy Extension Schema
10.8		Can B̅ Corp. 2020 Incentive Stock Option Plan(8)
101.CAL		Inline XBRL Taxonomy Extension Calculation
10.9		Arena Securities Purchase Agreement(10)
101.DEF		Inline XBRL Taxonomy Extension Definition
10.10		ASOF Original Issue Discount Senior Secured Convertible Promissory Note(10)
101.LAB		Inline XBRL Taxonomy Extension Labels
10.11		ASOF Warrant to Purchase Common Stock(10)
101.PRE		Inline XBRL Taxonomy Extension Presentation
10.12		ASOP Original Issue Discount Senior Secured Convertible Promissory Note(10)
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)
10.14		ASOP Warrant to Purchase Common Stock(10)
10.15		Arena Security Agreement(10)
10.16		Arena Intellectual Property Security Agreement(10)
10.17		Arena Registration Rights Agreement(10)
10.18		Arena Holding Escrow Agreement(10)
10.19		Arena Guaranty Agreement from Company Subsidiaries(10)
10.20		Amendment to 2020 ASOF Promissory Note(11)
10.21		Amendment to 2020 ASOP Promissory Note(11)
10.22		2021 Arena Securities Purchase Agreement(11)
10.23		2021 ASOF Original Issue Discount Senior Secured Convertible Promissory Note(11)
10.24		2021 ASOF Warrant to Purchase Common Stock(11)
10.25		2021 ASOP Original Issue Discount Senior Secured Convertible Promissory Note(11)
10.26		2021 ASOP Warrant to Purchase Common Stock(11)
10.27		2021 Arena Registration Rights Agreement(11)
10.28		2021 Addendum to Arena Security Agreement(11)
10.29		2021 Addendum to Arena Intellectual Property Security Agreement(11)
10.30		2021 Addendum to Arena Guaranty Agreement from Company Subsidiaries(11)
10.31		Asset Acquisition Agreement with Imbibe(10)
10.32		Equipment Acquisition Agreement with TWS(12)
10.33		Promissory Note to TWS(12)
10.34		Asset Purchase Agreement with MCB(12)
10.35		Commercial Lease with Makers Developments LLC(13)
10.36		Single-Tenant NNN Lease Agreement with CS2 Real Estate Holdings, LLC(13)
10.37		Commercial Lease with Red Road Business Park(13)

(1)	Filed with the Annual Report on Form 10-K filed with the SEC on April 2, 2020 and incorporated herein by reference.
(2)	Filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated herein by reference.
(3)	Filed with the Current Report on Form 8-K filed with the SEC on January 30, 2019 and incorporated herein by reference.
(4)	Filed with the Current Report on Form 8-K filed with the SEC on December 6, 2019 and incorporated herein by reference.
(5)	Filed with the Current Report on Form 8-K filed with the SEC on February 18, 2020 and incorporated herein by reference.
(6)	Filed with the Current Report on Form 8-K filed with the SEC on January 15, 2019 and incorporated herein by reference.
(7)	Filed with the Form 1-A/A, Part II, filed with the SEC on July 17, 2020 and incorporated herein by reference.
(8)	Filed with the Form 1-A POS, Part II, filed with the SEC on September 11, 2020 and incorporated herein by reference.
(9)	Filed with the Current Report on Form 8-K filed with the SEC on November 23, 2020 and incorporated herein by reference.
(10)	Filed with the Annual Report on Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference.
(11)	Filed with the Quarterly Report on Form 10-Q filed with the SEC on May 21, 2021 and incorporated herein by reference.
(12)	Filed with the Current Report on Form 8-K filed with the SEC on August 17, 2021 and incorporated herein by reference.
(13)	Filed with the Current Report on Form 8-K filed with the SEC on September 1, 2021 and incorporated herein by reference.
(14)	Filed with the Current Report on Form 8-K filed with the SEC on March 31, 2022 and incorporated herein by reference.
(15)	Filed with the Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference.
(16)	Filed with the Current Report on Form 8-K filed with the SEC on April 29, 2022 and incorporated herein by reference.
(17)	Filed with Form S-1/A filed with the SEC on February 14, 2022 and incorporated herein by reference.
(18)	Filed with Form S-1/A filed with the SEC on May 25, 2022 and incorporated herein by reference.
(19)	Filed with the Current Report on Form 8-K filed with the SEC on June 15, 2022 and incorporated herein by reference.
(20)	Filed with Form S-1/A filed with the SEC on May 25, 2022 and incorporated herein by reference.
(21)	Filed with the Current Report on Form 8-K filed with the SEC on July 25, 2022 and incorporated herein by reference.
(22)	Filed with the Annual Report on Form 10-K filed with the SEC on April 17, 2023 and incorporated herein by reference.
(23)	Filed with the Quarterly Report on Form 10-Q filed with the SEC on May 22, 2023 and incorporated herein by reference.
(24)	Filed with the Current Report on Form 8-K filed with the SEC on November 3, 2023 and incorporated herein by reference.

10.38		Asset Acquisition Agreement with various Sellers (Botanical Biotech)(10)
10.39		PrimeX Distribution Agreement
10.40		American Development Partners development agreement
10.41		Mast Hill Securities Purchase and Related Agreements(14)
10.42		Blue Lake Partners Securities Purchase and Related Agreements(14)
10.43		Fourth Man Securities Purchase and Related Agreements(16)
10.44		Extension and Amendment to Arena Transactional Documents(16)
10.45		Amended Placement Agent Agreement(18)
10.46		Alumni Capital Securities Purchase and Related Documents(19)
10.47		Arena Exchange Agreement(20)
10.48		Agreement with Forever Bradst(21)
10.49		Promissory Note Modification Agreement with TWS Pharma LLC
10.50		Walleye Securities Purchase Agreement
10.51		Walleye Promissory Note
10.52		Walleye Revenue Pledge and Security Agreement
10.53		Walleye Common Stock Purchase Warrant
10.54		Amendment to Walleye Common Stock Purchase Agreement
10.55		Walleye Registration Rights Agreement
10.56		Intercreditor Agreement among Can B Corp., Walleye and Arena
10.57		Arena Forbearance Agreement
10.58		Amendment No. 2 to Blue Lake Partners Promissory Note and Amendment to Securities Purchase Agreement, Consent and Waiver Agreement
10.59		Amendment No. 2 to Mast Hill Fund Promissory Note, Amendment to Securities Purchase Agreement, Consent and Waiver Agreement
10.60		Amendment No. 2 to Fourth Man Promissory Note, Amendment to Securities Purchase Agreement, Consent and Waiver Agreement
14.1		Code of Ethics(1)
21.1		List of Subsidiaries(10)
31.1		Chief Executive Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
31.2		Chief Financial Officer certification under Section 302 of the Sarbanes-Oxley Act of 2002
32.1		Chief Executive Officer certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS		Inline XBRL Instance Document
101.SCH		Inline XBRL Taxonomy Extension Schema
101.CAL		Inline XBRL Taxonomy Extension Calculation
101.DEF		Inline XBRL Taxonomy Extension Definition
101.LAB		Inline XBRL Taxonomy Extension Labels
101.PRE		Inline XBRL Taxonomy Extension Presentation
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

(1)	Filed with the Annual Report on Form 10-K filed with the SEC on April 2, 2020 and incorporated herein by reference.
(2)	Filed with the Form S-1 Registration Statement filed with the SEC on December 2, 2015 and incorporated herein by reference.
(3)	Filed with the Current Report on Form 8-K filed with the SEC on January 30, 2019 and incorporated herein by reference.
(4)	Filed with the Current Report on Form 8-K filed with the SEC on December 6, 2019 and incorporated herein by reference.
(5)	Filed with the Current Report on Form 8-K filed with the SEC on February 18, 2020 and incorporated herein by reference.
(6)	Filed with the Current Report on Form 8-K filed with the SEC on January 15, 2019 and incorporated herein by reference.
(7)	Filed with the Form 1-A/A, Part II, filed with the SEC on July 17, 2020 and incorporated herein by reference.
(8)	Filed with the Form 1-A POS, Part II, filed with the SEC on September 11, 2020 and incorporated herein by reference.
(9)	Filed with the Current Report on Form 8-K filed with the SEC on November 23, 2020 and incorporated herein by reference.
(10)	Filed with the Annual Report on Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference.
(11)	Filed with the Quarterly Report on Form 10-Q filed with the SEC on May 21, 2021 and incorporated herein by reference.
(12)	Filed with the Current Report on Form 8-K filed with the SEC on August 17, 2021 and incorporated herein by reference.
(13)	Filed with the Current Report on Form 8-K filed with the SEC on September 1, 2021 and incorporated herein by reference.
(14)	Filed with the Current Report on Form 8-K filed with the SEC on March 31, 2022 and incorporated herein by reference.
(15)	Filed with the Form 10-K filed with the SEC on April 15, 2022 and incorporated herein by reference.
(16)	Filed with the Current Report on Form 8-K filed with the SEC on April 29, 2022 and incorporated herein by reference.
(17)	Filed with Form S-1/A filed with the SEC on February 14, 2022 and incorporated herein by reference.
(18)	Filed with Form S-1/A filed with the SEC on May 25, 2022 and incorporated herein by reference.
(19)	Filed with the Current Report on Form 8-K filed with the SEC on June 15, 2022 and incorporated herein by reference.
(20)	Filed with Form S-1/A filed with the SEC on May 25, 2022 and incorporated herein by reference.
(21)	Filed with the Current Report on Form 8-K filed with the SEC on July 25, 2022 and incorporated herein by reference.

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Can B̅ Corp.
Date: April 17, 2023	By:	/s/ Marco Alfonsi
Date: April 15, 2024	By:	/s/ Marco Alfonsi
	Name:	Marco Alfonsi
	Title:	Chief Executive Officer
		(Principal Executive Officer and Principal Accounting Officer)
Date: April 17, 2023	By:	/s/ Stanley L. Teeple
Date: April 15, 2024	By:	/s/ Stanley L. Teeple
	Name:	Stanley L. Teeple
	Title:	Chief Financial Officer

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature	Title	Date
/s/ Marco Alfonsi	Chief Executive Officer, Director and Chairman	April 1715, ~~2023~~2024
Marco Alfonsi	(Principal Executive Officer)
/s/ Stanley L. Teeple	Secretary, CFO and Director	April 1715, ~~2023~~2024
Stanley L. Teeple	(Principal Financial and Accounting Officer)
/s/ Frederick Alger Boyer Jr.	Independent Director	April 1715, ~~2023~~2024
Frederick Alger Boyer Jr.
/s/ Ron Silver	Independent Director	April 17, 2023
/s/ James Murphy	Independent Director	April 15, 2024
Ron Silver
/s/ James Murphy	Independent Director	April 17, 2023
James Murphy

3635

Can B Corp. and Subsidiaries
Index to Financial Statements

Consolidated Financial Statements

Report of Independent Registered Public Accounting Firm	F-2

Consolidated Balance Sheets	F-3

Consolidated Statements of Operations	F-4

Consolidated Statements of Stockholders’ Equity	F-5

Consolidated Statements of Cash Flows	F-6

Notes to Consolidated Financial Statements.	F-7

F-1

Report of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Can B Corp.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of Can B Corp. as of December 31, ~~2022~~2023 and ~~2021~~2022, the related statements of operations, stockholders'’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the "“financial statements"”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, ~~2022~~2023 and ~~2021~~2022, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

Substantial Doubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company’s significant operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company'’s management. Our responsibility is to express an opinion on the Company'’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("“PCAOB"”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matter

Critical audit matters are matters arising from the current-period audit of the financial statements that were communicated or required to be communicated to the audit committee and that (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments.

We determined that there are no critical audit matters.

/S/ BF Borgers CPA PC (PCAOB ID 5041)

We have served as the Company’s auditor since 2021

Lakewood, CO

April 17 15, ~~2023~~2024

F-2

Can B̅ Corp. and Subsidiaries

Consolidated Balance Sheets

	December 31,			December 31,
	December 31, 2023			December 31, 2022
	2022			2021
Assets
Current assets:
Cash and cash equivalents	$	7334,~~194~~006		$	~~449~~73,~~001~~194
Accounts receivable, less allowance for doubtful accounts of $985,028 and $547,241 at December 31, 2022 and 2021, respectively		6,586,210			3,646,677
Accounts receivable, less allowance for doubtful accounts of $2,818,395 and $985,028 at December 31, 2023 and 2022, respectively		3,723,344			6,586,210
Inventory		21,~~024~~619,~~053~~542			2,~~553~~024,~~438~~053
Prepaid expenses and other current assets		214,~~024~~138			421,~~523~~024
Total current assets		85,~~704~~381,~~481~~029			68,~~653~~704,~~639~~481
Other assets:
Deposits		~~165~~235,~~787~~418			165,787
Intangible assets, net		~~107~~95,144			~~369~~107,~~015~~144
Property and equipment, net		54,~~432~~106,~~357~~283			75,~~052~~432,~~926~~357
Right of use assets, net		1295,~~136,883~~151			21,~~220~~136,~~134~~883
Other noncurrent assets		13,139			13,139
Total other assets		64,~~855~~745,~~310~~135			96,~~821~~855,~~001~~310
Total assets	$	1510,~~559~~126,~~791~~164		$	1615,~~474~~559,~~640~~791
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	31,~~140~~945,~~408~~243		$	13,~~163~~140,~~284~~408
Accrued expenses		~~181,700~~-			2181,~~407,528~~700
Due to related party		~~295~~357,243			~~218~~295,~~273~~243
Notes and loans payable, net		78,~~951~~569,~~196~~489			47,~~865~~951,~~749~~196
Warrant liabilities		~~203~~1,~~043~~766			-203,043
Operating lease liability - current		~~652~~254,~~172~~391			~~808~~652,~~223~~172
Total current liabilities		1211,~~423~~128,~~762~~132			912,~~463~~423,~~057~~762
Long-term liabilities:
Operating lease liability - noncurrent		~~438,104~~-			1438,~~392,068~~104
Total long-term liabilities		~~438,104~~-			1438,~~392,068~~104
Total liabilities	$	1211,~~861~~128,~~866~~132		$	1012,~~855~~861,~~125~~866
Commitments and contingencies (Note 14)		-			-
Stockholders’ equity:
Preferred stock, authorized 5,000,000 shares:
Series A Preferred stock, no par value: 20 shares authorized, 5 shares and 20 shares issued and outstanding at December 31, 2022 and 2021, respectively		5,320,000			28,440,000
Series A Preferred stock, no par value: 20 shares authorized, 5 shares and 20 shares issued and outstanding at December 31, 2023 and 2022, respectively		5,320,000			5,320,000
Series B Preferred stock, $0.001 par value: 500,000 shares authorized, 0 issued and outstanding		-			-
Series C Preferred stock, $0.001 par value: 2,000 shares authorized, 1,100 and 23 issued and outstanding at December 31, 2022 and 2021, respectfully		2,900,039			207,000
Series C Preferred stock, $0.001 par value: 2,000 shares authorized, 1,100 and 23 issued and outstanding at December 31, 2023 and 2022, respectfully		2,900,039			2,900,039
Series D Preferred stock, $0.001 par value: 4,000 shares authorized, 4,000 and 1,950 issued and outstanding at December 31, 2022 and 2021, respectfully		4			2
Series D Preferred stock, $0.001 par value: 4,000 shares authorized, 4,000 and 1,950 issued and outstanding at December 31, 2023 and 2022, respectfully		4			4
Preferred stock, value
Common stock, no par value; 1,500,000,000 shares authorized, 4,422,584 and 2,834,755 issued and outstanding at December 31, 2022 and 2021, respectively		79,614,986			49,676,847
Common stock, no par value; 1,500,000,000 shares authorized, 4,422,584 and 2,834,755 issued and outstanding at December 31, 2023 and 2022, respectively		83,263,105			79,614,986
Common stock issuable, no par value; 36,248 and 0 shares at December 31, 2022 and 2021, respectively		119,586			-
Common stock issuable, no par value; 36,248 and 0 shares at December 31, 2023 and 2022, respectively		119,586			119,586
Treasury stock		(572,678	)		(572,678	)
Additional paid-in capital		810,~~006~~396,~~822~~274			58,~~635~~006,~~003~~822
Accumulated deficit		(92102,~~690~~428,~~834~~298	)		(7792,~~766~~690,~~659~~834	)
Total stockholders’ equity		2(1,~~697~~001,~~925~~968	)		52,~~619~~697,~~515~~925
Total liabilities and stockholders’ equity	$	1510,~~559~~126,~~791~~164		$	1615,~~474~~559,~~640~~791

See notes to consolidated financial statements

F-3

Can B̅ Corp. and Subsidiaries

Consolidated Statement of Operations

	2022			2021
	2023			2022
	Year Ended
	Year Ended December 31,
	December 31,
	2023			2022
	2022			2021
Revenues
Product sales	$	51,~~524~~336,~~036~~117		$	45,~~156~~524,~~281~~036
Service revenue		1819,~~161,483~~627			~~447~~1,~~548~~161,483
Total revenues		62,~~685~~155,~~519~~744			46,~~603~~685,~~829~~519
Cost of revenues		41,~~071~~797,~~144~~047			14,~~611~~071,~~730~~144
Gross profit		2358,~~614,375~~698			2,~~992~~614,~~099~~375
Operating Expenses
Compensation		72,~~199~~923,~~215~~858			47,~~997~~199,~~155~~215
Consulting and professional fees		51,~~416~~824,~~006~~952			35,~~968~~416,~~744~~006
Rent and utilities		926,696			675,310
Other operating expenses		3,096,330			4,167,301
Other operating expenses		3,240,605			3,616,897
Total operating expenses		7,845,140			16,782,522
Total operating expenses		16,782,522			13,258,106
Loss from operations		(7,486,442	)		(14,168,147	)
Loss from operations		(14,168,147	)		(10,266,007	)
Other (expense) income:
Other income		-			2,991
Change in fair value of warrant liability		201,277			154,010
Change in fair value of warrant liability		154,010			-
Interest expense		(2,510,811	)		(902,130	)
Gain on debt extinguishment		-			196,889
Other income/(expense)		68,108			(7,115
Interest expense		(902,130	)		(2,102,193	)
Other expense		(2,241,426	)		(755,235	)
Other expense		(7,115	)		-
Loss before provision for income taxes		(9,727,868	)		(14,923,382	)
Other expense		(755,235	)		(1,902,313	)
Provision for income taxes		9,596			793
Loss before provision for income taxes		(14,923,382	)		(12,168,320	)
Net loss	$	(9,737,464	)	$	(14,924,175	)
Provision for income taxes		793			1,075
Loss per share - basic and diluted	$	(0.77	)	$	(4.18	)
Net loss	$	(14,924,175	)	$	(12,169,395	)
Weighted average shares outstanding - basic and diluted		12,590,147			3,570,087
Loss per share - basic and diluted	$	(4.18	)	$	(9.06	)
Weighted average shares outstanding - basic and diluted		3,570,087			1,343,219

See notes to consolidated financial statements

F-4

Can B̅ Corp. and Subsidiaries

Consolidated Statements of Stockholders’ Equity

Years ended December 31, ~~2022~~2023 and ~~2021~~2022

	Shares			Amount			Shares		Amount		Shares			Amount			Shares		Amount		Shares		Amount		Issuable		Shares		Amount			Capital		Deficit			Total
	Series A						Series B				Series C						Series D								Common							Additional
	Series A Preferred Stock						Series B Preferred Stock				Series C Preferred Stock						Series D Preferred Stock				Common Stock				Common Stock		Treasury Stock					Additional Paid-in		Accumulated
	Preferred Stock						Preferred Stock				Preferred Stock						Preferred Stock				Common Stock				Stock		Treasury Stock					Paid-in		Accumulated
	Shares			Amount			Shares		Amount		Shares			Amount			Shares		Amount		Shares		Amount		Issuable		Shares		Amount			Capital		Deficit			Total
Balance, December 31, 2020		20		$	28,440,000			-	$	-		623		$	5,607,000			-	$	-		369,639	$	30,874,270	$	-		36,248	$	(572,678	)	$	2,724,689	$	(65,597,264	)	$	1,476,017
Issuance of preferred stock		-			-			-		-		-			-			1,950		2		-		-		-		-		-			-		-			2
Conversion of Series C Preferred stock to common stock		-			-			-		-		(600	)		(5,400,000	)		-		-		1,000,000		5,400,000		-		-		-			-		-			-
Sale of common stock		-			-			-		-		-			-			-		-		814,336		6,555,453		-		-		-			-		-			6,555,453
Issuance of common stock in lieu of note repayments		-			-			-		-		-			-			-		-		77,017		537,748		-		-		-			-		-			537,748
Issuance of common stock for services rendered		-			-			-		-		-			-			-		-		157,115		2,657,048		-		-		-			-		-			2,657,048
Issuance of common stock for asset acquisitions		-			-			-		-		-			-			-		-		381,791		3,453,014		-		-		-			-		-			3,453,014
Issuance of common stock warrants and commitment shares in connection with convertible promissory note		-			-			-		-		-			-			-		-		-		-		-		-		-			515,276		-			515,276
Issuance of common stock in lieu of interest payments		-			-			-		-		-			-			-		-		34,857		199,314		-		-		-			-		-			199,314
Stock-based compensation		-			-			-		-		-			-			-		-		-		-		-		-		-			2,395,038		-			2,395,038
Net loss		-			-			-		-		-			-			-		-		-		-		-		-		-			-		(12,169,395	)		(12,169,395	)
Balance, December 31, 2021		20		$	28,440,000			0	$	-		23		$	207,000			1,950	$	2		2,834,755	$	49,676,847	$	-		36,248	$	(572,678	)	$	5,635,003	$	(77,766,659	)	$	5,619,515
Balance		20		$	28,440,000			0	$	-		23		$	207,000			1,950	$	2		2,834,755	$	49,676,847	$	-		36,248	$	(572,678	)	$	5,635,003	$	(77,766,659	)	$	5,619,515
Conversion of Series A Preferred stock to Common stock		(15	)		(23,120,000	)		-		-		-			-			-		-		33,345		23,120,000		-		-		-			-		-			-
Issuance of preferred stock		-			-			-		-		-			-			2,050		2		-		-		-		-		-			-		-			2
Sale of common stock		-			-			-		-		-			-			-		-		51,282		500,000		-		-		-			-		-			500,000
Issuance of common stock in lieu of note interest repayments		-			-			-		-		-			-			-		-		10,150		73,078		-		-		-			-		-			73,078
Issuance of common stock for services rendered		-			-			-		-		-			-			-		-		1,270,616		4,370,256		119,586		-		-			-		-			4,489,842
Issuance of common stock for equipment		-			-			-		-		-			-			-		-		13,704		98,666		-		-		-			-		-			98,666
Issuance of common stock for asset acquisition		-			-			-		-		-			-			-		-		190,505		1,767,498		-		-		-			-		-			1,767,498
Issuance of common stock resulting from the exercise of warrants		-			-			-		-		-			-			-		-		18,227		8,641		-		-		-			-		-			8,641
Stock-based compensation		-			-			-		-		1,077			2,693,039			-		-		-		-		-		-		-			2,371,819		-			5,064,858
Net loss		-			-			-		-		-			-			-		-		-		-		-		-		-			-		(14,924,175	)		(14,924,175	)
Balance, December 31, 2022		5		$	5,320,000			0	$	-		1,100		$	2,900,039			4,000	$	4		4,422,584	$	79,614,986	$	119,586		36,248	$	(572,678	)	$	8,006,822	$	(92,690,834	)	$	2,697,925
Balance		5		$	5,320,000			0	$	-		1,100		$	2,900,039			4,000	$	4		4,422,584	$	79,614,986	$	119,586		36,248	$	(572,678	)	$	8,006,822	$	(92,690,834	)	$	2,697,925
Balance, value		5		$	5,320,000			0	$	-		1,100		$	2,900,039			4,000	$	4		4,422,584	$	79,614,986	$	119,586		36,248	$	(572,678	)	$	8,006,822	$	(92,690,834	)	$	2,697,925
Issuance of common stock for services rendered		-			-			-		-		-			-			-		-		3,965,385		1,046,194		-		-		-			-		-			1,046,194
Issuance of common stock for purchase of equipment		-			-			-		-		-			-			-		-		125,000		46,875		-		-		-			-		-			46,875
Warrants issued in connection with the issuance of convertible note		-			-			-		-		-			-			-		-		-		-		-		-		-			937,787		-			937,787
Issuance of common stock for for wages and salaries		-			-			-		-		-			-			-		-		6,940,118		589,216		-		-		-			-		-			589,216
Issuance of common stock for purchase of inventory		-			-			-		-		-			-			-		-		675,000		175,500		-		-		-			-		-			175,500
Issuance of common stock in lieu of interest payments		-			-			-		-		-			-			-		-		3,224,474		328,932		-		-		-			-		-			328,932
Issuance of common stock or legal settlement		-			-			-		-		-			-			-		-		1,419,156		185,499		-		-		-			-		-			185,499
Issuance of common stock in lieu of note repayments		-			-			-		-		-			-			-		-		11,981,479		1,275,903		-		-		-			-		-			1,275,903
Stock-based compensation		-			-			-		-		-			-			-		-		-		-		-		-		-			1,451665		-			1,451,665
Net loss		-			-			-		-		-			-			-		-		-		-		-		-		-			-		(9,737,464	)		(9,737,464	)
Balance, December 31, 2023		5		$	5,320,000			-	$	-		1,100		$	2,900,039			4,000	$	4		32,753,196	$	83,263,105	$	119,586		36,248	$	(572,678	)	$	10,396,274	$	(102,428,298	)	$	(1,001,968	)
Balance, value		5		$	5,320,000			-	$	-		1,100		$	2,900,039			4,000	$	4		32,753,196	$	83,263,105	$	119,586		36,248	$	(572,678	)	$	10,396,274	$	(102,428,298	)	$	(1,001,968)

See notes to consolidated financial statements

F-5

Can B̅ Corp. and Subsidiaries

Consolidated Statements of Cash Flows

	2022			~~2021~~2022
	Year Ended
	Year Ended December 31,
	December 31,
	2022			2022
	2022			2021
Operating activities:
Net loss	$	(149,~~924~~737,~~175~~464	)	$	(1214,~~169~~924,~~395~~175	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		51,~~064~~451,~~860~~665			25,~~395~~064,~~038~~860
Depreciation		1,408,061			493,656
Common stock in lieu of cash payroll		589,216			-
Amortization of intangible assets		26,906			48,689
Depreciation		1,387,949			1,408,061
Amortization of original-issue-discounts		444,920			1,640,242
Amortization of intangible assets		12,000			26,906
Bad debt expense		751,025			61,393
Amortization of original-issue-discounts		1,417,583			444,920
Impairment of intangible assets		252,462			-
Bad debt expense		1,833,367			751,025
Loss on sale of property and equipment		309,000			-
Impairment of intangible assets		-			252,462
Change in fair value of warrant liability		(154,010	)		-
Loss on sale of property and equipment		-			309,000
Gain on debt extinguishment		-			(196,889	)
Cancellation of debt		(110,000	)		-
Stock-based interest expense		73,078			199,314
Change in fair value of warrant liability		(201,277	)		(154,010	)
Stock-based consulting expense		4,489,842			2,657,048
Stock-based interest expense		328,932			73,078
Stock-based consulting expense		1,046,194			4,489,842
Changes in operating assets and liabilities:
Accounts receivable		(31,~~690~~029,~~558~~499	)		(13,~~705~~690,~~006~~558	)
Inventory		~~529~~580,~~385~~011			(2529,~~208,484~~385	)
Prepaid expenses		~~(14~~16,~~327~~887	)		8(14,~~476~~327
Deposits		-			(144,500	)
Operating lease right-of-use asset		5,847			(26,764	)
Other noncurrent assets		-			7,176
Accounts payable		(954,904	)		1,988,699
Operating lease right-of-use asset		(26,764	)		(20,667	)
Accrued expenses		-			(475,828	)
Accounts payable		1,988,699			1,009,644
Net cash used in operating activities		(1,304,495	)		(3,947,424	)
Accrued expenses		(475,828	)		457,033
Net cash used in operating activities		(3,947,424	)		(7,467,232	)
Investing activities:
Purchase of property and equipment		-(15,000	)		~~(538,763~~-	)
Purchase of intangible assets		-			(177,530	)
Deposits paid		(69,631	)		-
Net cash used in investing activities		-(84,631	)		~~(716,293~~-	)
Financing activities:
Net proceeds received from notes and loans payable		32,~~449~~405,~~853~~000			13,~~625~~449,~~000~~853
Proceeds from issuance of Series D Preferred Stock		-			2-
Proceeds from sale of common stock		~~500,000~~-			6500,~~555,453~~000
Repayments of notes and loans payable		(~~377~~939,~~500~~062	)		(~~224~~377,~~000~~500	)
Deferred financing costs		(77178,~~706~~000	)		-(77,706
Amounts received from related parties, net		7662,~~970~~000			~~218~~76,~~273~~970
Net cash provided by financing activities		31,~~571~~349,~~617~~938			83,~~174~~571,~~728~~617
Decrease in cash and cash equivalents		(~~375~~39,~~807~~188	)		(8375,~~797~~807	)
Cash and cash equivalents, beginning of period		~~449~~73,~~001~~194			~~457~~449,~~798~~001
Cash and cash equivalents, end of period	$	7334,~~194~~006		$	~~449~~73,~~001~~194
Supplemental Cash Flow Information:
Income taxes paid	$	~~1,075~~-		$	1,075
Interest paid	$	~~83,147~~-		$	483,~~000~~147
Non-cash Investing and Financing Activities:
Issuance of common stock in lieu of repayment of notes payable	$	-1,275,903		$	~~537,748~~-
Issuance of common stock in asset acquisitions	$	1175,~~767,498~~500		$	31,~~453~~767,~~014~~498
Assets acquired through common stock payable				$	1,750,000
Issuance of common stock for property and equipment	$	46,875		$	-
Assets acquired through issuance of promissory note		-		$	~~1,250,000~~-
Debt discount associated with warrant liability	$	~~357~~273,~~049~~529		$	-357,049
Issuance of common stock resulting from the exercise of warrants	$	~~8,641~~-		$	-8,641
Issuance of common stock warrants and commitment shares in connection with convertible promissory note	$	-937,787		$	~~515,276~~-

See notes to consolidated financial statements

F-6

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Note 1 – Organization and Description of Business

Can B̅ Corp. was originally incorporated as WrapMail, Inc. (“WRAP”) in Florida on October 11, 2005. On May 15, 2017, WRAP changed its name to Canbiola, Inc. On January 16, 2020 Canbiola, Inc. changed its name to Can B̅ Corp. (the “Company”, “we”, “us”, “our”, “CANB”, “Can B̅” or “Registrant”).

The Company acquired 100% of the membership interests in Pure Health Products, LLC, a New York limited liability company (“PHP” or “Pure Health Products”) effective December 28, 2018. The Company runs it manufacturing operations through PHP and holds and sells several of its brands through PHP as well. The Company’s durable equipment products, such as sam® units with and without CBD infused pads, are marketed and sold through its wholly-owned subsidiaries, Duramed Inc. (incorporated on November 29, 2018) and Duramed MI LLC (fka DuramedNJ, LLC) (incorporated on May 29, 2019) (collectively, “Duramed”). Duramed began operating on or about February 1, 2019. Most of the Company’s consumer products include hemp derived cannabidiol (“CBD”); however, the Company has just recently begun extracting cannabinol (“CBN”) and cannabigerol (“CBG”) for wholesale to third-parties looking to incorporate such compounds into their products through its wholly owned subsidiaries, Botanical Biotech, LLC (incorporated March 10, 2021), TN Botanicals, LLC and CO Botanicals LLC (both incorporated in August 2021). These three subsidiaries have also begun synthesizing Delta-8 and Delta-10 from hemp. Delta-8 and Delta-10 can produce similar, though less potent, effects as delta-9 (commonly referred to as THC); however, the legality of hemp derived Delta-8 and Delta-10 are in a gray area and considered a potential loophole at this point due to the 2018 hemp bill. The Company’s other subsidiaries did not have operations during the year ended December 31, 2022.

Note 2 – Going Concern

The consolidated financial statements have been prepared on a “going concern” basis, which contemplates the realization of ~~assets~~ assets and liquidation of liabilities in a normal course of business. As of December 31, ~~2022~~2023, the Company had cash and cash equivalents of $7334,~~194~~ 006 and negative working capital of $35,~~281~~747,~~494~~103. For the years ended December 31, ~~2022~~2023 and ~~2021~~2022, the Company had incurred losses of $149,~~924~~737,~~175~~ 464 and $1214,~~169~~924,~~395~~175, respectively. These factors raise substantial doubt as to the Company’s ability to continue as a going concern.

After careful consideration and analysis of the economics, supply chain, processing logistics, and management of manpower the Company decided to consolidate operations in its CO operations in Mead and Ft. Morgan. The ~~company~~Company ~~remains~~has ~~fully~~very ~~vertically~~limited ~~integrated~~processing inability ~~legal~~via ~~hemp~~3rd ~~operations~~party ~~and~~vendors ~~sales~~to ~~with~~process ~~processing~~its ofowned ~~hemp~~ biomass ~~and crude hemp oil~~ into ~~distillate,~~ isolate~~, and ultimately into isomers~~. The Company moved all of its help processing equipment previously located in its Miami, FL operation under Botanical Biotech, LLC to its main hemp processing center in CO. The Company also terminated its lease with the Miami landlord. The Company moved all of the hemp processing equipment previously located in its McMinnville, TN operation under TN Botanicals, LLC to its main hemp processing center in CO.

As a result of ~~these~~the ~~equipment~~consolidation ~~moves,~~of the ~~Colorado~~Florida ~~operation~~and ~~will,~~Tennessee ~~once~~operations ~~fully~~into ~~operational,~~Fort ~~improve operating efficiencies~~Morgan, ~~increase~~Colorado ~~management oversight,~~ and ~~be able to increase throughput by double verse~~ the ~~prior~~subsequent ~~three~~Article ~~independent~~9 ~~operating facilities. Senior management of~~auction ~~the~~sale ~~Company will be on-site in CO during this consolidation period to ensure maximum efficiencies and continue operations during this rebuilding period. Immediate impact~~ of the ~~consolidation~~primary ishemp ~~elimination~~division ~~of duplicate lines~~assets, ~~better~~the ~~coordination~~Colorado ofoperation ~~customer~~has ~~orders,~~limited ~~reduction in~~ability ~~transportation~~to ~~charges,~~process ~~and~~any ~~manpower~~materials ~~efficiencies~~other ~~with~~than ~~larger~~through ~~batch~~third party ~~sizes and reduced personnel~~operations.

The consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

Note 3 – Basis of Presentation and Summary of Significant Accounting Policies

Basis of presentation

The accompanying consolidated financial statements are presented in conformity with accounting principles generally accepted in the United States of America (“GAAP”).

On February 8, 2022, the Company effected a 1-for-15 reverse stock split of the Company’s common stock, or the 2021 Reverse Stock Split. As a result of the 2021 Reverse Stock Split, every 15 shares of the Company’s pre-2021 Reverse Stock Split common stock were combined and reclassified into one share of the Company’s common stock.

Principles of Consolidation

The consolidated financial statements contained herein include the accounts of Can B Corp. and its wholly owned subsidiaries. All significant intercompany balances and transactions have been eliminated.

F-7

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Covid-19

Commencing in December 2019, the novel strain of coronavirus (“COVID-19”) began spreading throughout the world, including the first outbreak in the US in February 2020. On March 11, 2020, the World Health Organization declared COVID-19 a global pandemic and recommended containment and mitigation measures worldwide. COVID-19 has disrupted and continues to significantly disrupt local, regional, and global economies and businesses. The

COVID-19 outbreak is disrupting supply chains and affecting production and sales across a range of industries. The extent of the impact of COVID-19 on the Company’s operational and financial performance will depend on certain developments, including the duration and spread of the outbreak, impact on the Company’s customers, employees and vendors, all of which are uncertain and cannot be predicted. At this point, the extent to which COVID-19 may impact the Company’s financial condition and/or results of operations is uncertain.

In response to COVID-19, the Company put into place certain restrictions, requirements and guidelines to protect the health of its employees and clients, including requiring that certain conditions be met before employees return to the Company’s offices. Also, to protect the health and safety of its employees, the Company’s daily execution has evolved into a largely virtual model. The Company plans to continue to monitor the current environment and may take further actions that may be required by federal, state or local authorities or that it determines to be in the interests of its employees, customers, and partners.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of sales (or revenues) and expenses during the reporting period.

Making estimates requires management to exercise significant judgment. It is at least reasonably possible that estimates made as of the date of the financial statements could change in the near term due to one or more future events. Accordingly, the actual results could differ significantly from those estimates. Significant accounting estimates reflected in the Company’s consolidated financial statements include, but are not limited to, revenue recognition, allowance for doubtful accounts, recognition and measurement of income tax assets, valuation of share-based compensation, and the valuation of net assets acquired.

Asset Acquisitions

When applicable, the Company accounts for the acquisition of a business in accordance with the accounting standards codification (“ASC”) guidance for business combinations, whereby the total purchase consideration transferred is allocated to the assets acquired and liabilities assumed, including amounts attributable to non-controlling interests, when applicable, based on their respective estimated fair values as of the date of acquisition. Goodwill represents the excess of purchase consideration transferred over the estimated fair value of the identifiable net assets acquired in a business combination.

Assigning estimated fair values to the net assets acquired requires the use of significant estimates, judgments, inputs, and assumptions regarding the fair value of the assets acquired and liabilities assumed. Estimated fair values of assets acquired and liabilities assumed are generally based on available historical information, independent valuations or appraisals, future expectations, and assumptions determined to be reasonable but are inherently uncertain with respect to future events, including economic conditions, competition, the useful life of the acquired assets, and other factors. The company may refine the estimated fair values of assets acquired and liabilities assumed, if necessary, over a period not to exceed one year from the date of acquisition by taking into consideration new information that, if known at the date of acquisition, would have affected the estimated fair values ascribed to the assets acquired and liabilities assumed. The judgments made in determining the estimated fair value assigned to assets acquired and liabilities assumed, as well as the estimated useful life and depreciation or amortization method of each asset, can materially impact the net earnings of the periods subsequent to the acquisition through depreciation and amortization, and in certain instances through impairment charges, if the asset becomes impaired in the future. During the measurement period, any purchase price allocation changes that impact the carrying value of goodwill affects any measurement of goodwill impairment taken during the measurement period, if applicable. If necessary, purchase price allocation revisions that occur outside of the measurement period are recorded within cost of sales or selling, general and administrative expense within the Consolidated Statements of Earnings depending on the nature of the adjustment.

F-8

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

When an acquisition does not meet the definition of a business combination because either: (i) substantially all of the fair value of the gross assets acquired is concentrated in a single identifiable asset, or group of similar identified assets, or (ii) the acquired entity does not have an input and a substantive process that together significantly contribute to the ability to create outputs, the company accounts for the acquisition as an asset acquisition. In an asset acquisition, goodwill is not recognized, but rather, any excess purchase consideration over the fair value of the net assets acquired is allocated on a relative fair value basis to the identifiable net assets as of the acquisition date and any direct acquisition-related transaction costs are capitalized as part of the purchase consideration.

Revenue Recognition

The Company recognizes revenue in accordance with the Financial Accounting Standards Board (“FASB”) ASC 606, Revenue from Contracts with Customers, which requires that five basic steps be followed to recognize revenue: (1) a legally enforceable contract that meets criterial standards as to composition and substance is identified; (2) performance obligations relating to provision of goods or services to the customer are identified; (3) the transaction price, with consideration given to any variable, noncash, or other relevant consideration, is determined; (4) the transaction price is allocated to the performance obligations; and (5) revenue is recognized when control of goods or services is transferred to the customer with consideration given, whether that control happens over time or not. Determination of criteria (3) and (4) are based on our management’s judgments regarding the fixed nature of the selling prices of the products and services delivered and the collectability of those amounts.

Private Label Customers are wholesale distributors of the Company’s product, under their own wholesale private label brand. The products are made to Company specifications and shipped directly to the wholesaler. The pricing is predicated upon a volume discount negotiated at the time of the placement of the orders. Product is produced and labeled in the Washington manufacturing facility and shipped directly to the Private Label customer who re-distributes to their retail and other customers. The products are fully paid when shipped.

Revenue from product sales is recognized when an order has been obtained, the price is fixed and determinable, the product is shipped, title has transferred, and collectability is reasonably assured.

The Company’s Duramed Division provides a sam® Pro 2.0 medical device to patients through a doctor program whereby the physician evaluates the patients’ needs for medical necessity, and if determined that the device use would be beneficial, writes a prescription for the patient who signs a rental form, for a 35-day cycle for the unit, that is submitted to Duramed who bills the appropriate insurance company. The insurance company pays the invoice, or a negotiated amount via arbitration, and that revenue is reported as revenue when invoiced to the insurance carrier. The collected amount is reconciled with the invoice amount on a daily basis.

Service revenue consists of hemp processing services provided by the Company to other hemp related entities. Services revenues are recorded when services are rendered.

Freight billed to customers is included within sales on the consolidated statement of operations. The related freight charged to the Company is included within cost of revenues. Sales tax collected from customers is remitted to governmental authorities on a net basis.

Cost of Revenues

The cost of revenues is the total cost incurred to obtain a sale, the cost of the goods sold, and costs related to the processing of hem for outside parties. The Company’s policy is to recognize it in the same manner as, and in conjunction with, revenue recognition. Cost of revenues primarily consist of the costs directly attributable to revenue recognized and includes expenses related to the production, packaging and labeling of our CBD products and durable medical goods.

F-9

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Cash, cash equivalents and restricted cash

The Company considers all short-term investments with an original maturity of three months or less when purchased to be cash equivalents.

Accounts receivables, net

Trade receivables arise from granting credit to customers in the normal course of business, are unsecured and are presented net of an allowance for doubtful accounts. The allowance is based on a number of factors, including the length of time the receivable is past due, the Company’s previous loss history, the customer’s current ability to pay, and the general condition of the economy and industry as a whole. Depending on the customer, payment is due between 30 and 60 days after the customer receives an invoice. Certain receivables related to durable medical devices can have collection periods of 18 to 24 months due to the inherent nature of no-fault insurance claims. The Company has taken this into consideration when assessing receivables related to durable medical devices. Other accounts that are more than 45 days past due are individually analyzed for collectability. When all collection efforts have been exhausted, the accounts are written off. Historically, the Company has not suffered significant losses with respect to its trade receivables.

Inventories

Inventories, which consist of purchased components for resale, are valued at the lower of average cost (which approximates the first-in, first-out method) and net realizable value. The Company reduces the carrying value of inventory for those items that are potentially excess, obsolete or slow-moving based on changes in customer demand, technology developments or other economic factors.

Long-lived assets

Property and equipment are recorded at cost and presented net of accumulated depreciation. Major additions and betterments are capitalized while maintenance and repairs, which do not improve or extend the life of the respective assets, are expensed. Property and equipment are depreciated on the straight-line basis over their estimated useful lives.

Definite-lived intangible assets arising from asset acquisitions include intellectual property, patents, trademarks, and certain hemp processing registrations. Definite-lived intangible assets are amortized over the estimated period during which the asset is expected to contribute directly or indirectly to future cash flows.

The Company reviews its long-lived assets for impairment whenever events or circumstances exist that indicate the carrying amount of an asset or asset group may not be recoverable. The recoverability of long-lived assets is measured by a comparison of the carrying amount of the asset or asset group to the future undiscounted cash flows expected to

be generated by that asset group. If the asset or asset group is considered to be impaired, an impairment loss would be recorded to adjust the carrying amounts to the estimated fair value. No such impairment was recorded during the periods covered by this report.

F-10

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Leases

The Company determines if an arrangement is or contains a lease at contract inception. In arrangements that involve an identified asset, there is also judgment in evaluating if we have the right to direct the use of that asset.

The Company does not have any finance leases. Operating leases are recorded in our consolidated balance sheets. Right-of-use (“ROU”) assets and lease liabilities are measured at the lease commencement date based on the present value of the remaining lease payments over the lease term, determined using the discount rate for the lease at the commencement date. Because the rate implicit in our leases is not readily determinable, we use our incremental borrowing rate as the discount rate, which approximates the interest rate at which we could borrow on a collateralized basis with similar terms and payments and in similar economic environments. As of December 31, ~~2022~~2024, our ~~leases had remaining lease terms of up to 3 years~~Hicksville, ~~some~~NY ofoffice ~~which included options to extend the~~ lease ~~for~~was upterminated toand 14we ~~years~~are ~~and~~renting ~~options~~ month-to-month ~~terminate~~until ~~the~~a new lease ~~within~~is ~~1 year~~signed. ~~Optional~~The ~~periods~~Colorado ~~to extend the lease~~operations, presently ~~including~~in bytwo ~~not~~Fort ~~exercising~~Morgan, aColorado ~~termination option~~facilities, are ~~included in~~being ~~the~~rented ~~lease~~on ~~term~~a ~~when~~month itto ismonth ~~reasonably~~basis ~~certain~~for ~~that~~approximately ~~the~~$14,500 ~~option~~per ~~will be exercised~~month. Operating lease expense is recognized on a straight-line basis over the lease term. We account for lease and non-lease components, principally common area maintenance for our facilities leases, as a single lease component.

In accordance with accounting requirements, leases with an initial term of 12 months or less are recorded on the balance sheet, with lease expense for these leases recognized on a straight-line basis over the lease term.

Income taxes

Income taxes are accounted for under the asset and liability method pursuant to ASC Topic 740, Income Taxes (ASC 740), whereby deferred tax assets and liabilities are recognized for the expected future consequences attributable to the differences between the financial statement carrying amounts and the tax basis of assets and liabilities. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in the period of the change. Further, deferred tax assets are recognized for the expected realization of available net operating loss and tax credit carryforwards. A valuation allowance is recorded on gross deferred tax assets when it is “more likely than not” that such asset will not be realized. When evaluating the realizability of deferred tax assets, all evidence, both positive and negative, is evaluated. Items considered in this analysis include the ability to carry back losses, the reversal of temporary differences, tax planning strategies, and expectations of future earnings. The Company reviews its deferred tax assets on a quarterly basis to determine if a valuation allowance is required based upon these factors. Changes in the Company’s assessment of the need for a valuation allowance could give rise to a change in such allowance, potentially resulting in additional expense or benefit in the period of change.

The Company’s income tax provision or benefit includes U.S. federal, state and local income taxes and is based on pre-tax income or loss. In determining the annual effective income tax rate, the Company analyzed various factors, including its annual earnings and taxing jurisdictions in which the earnings were generated, the impact of state and local income taxes, and its ability to use tax credits and net operating loss carryforwards.

F-11

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Under ASC 740, the amount of tax benefit to be recognized is the amount of benefit that is “more likely than not” to be sustained upon examination. The Company analyzes its tax filing positions in all of the U.S. federal, state, local,

and foreign tax jurisdictions where it is required to file income tax returns, as well as for all open tax years in these jurisdictions. If, based on this analysis, the Company determines that uncertainties in tax positions exist, a liability is established in the consolidated financial statements. The Company recognizes accrued interest and penalties related to unrecognized tax positions in the provision for income taxes.

The Company’s income tax returns are subject to examination by federal and state authorities in accordance with prescribed statutes.

Stock-based compensation

The Company accounts for stock-based compensation in accordance with ASC 718, Compensation—Stock Compensation (“ASC 718”), by recognizing compensation expense based upon the estimated fair value of the awards on the date of grant. The Company determines the estimated grant-date fair value of restricted shares using the closing price on the date of the grant and the grant-date fair value of stock options using the Black-Scholes-Merton model. In order to calculate the fair value of the options, certain assumptions are made regarding the components of the model, including risk-free interest rate, volatility, expected dividend yield and expected option life. Changes to the assumptions could cause significant adjustments to the valuation. The Company recognizes compensation costs ratably over the period of service using the straight-line method.

Due to the limited trading history of the Company’s common stock, estimated volatility was based on a peer group of public companies and took into consideration the increased short-term volatility in historical data due to COVID-19.

Net loss per common share

Pursuant to ASC Topic 260, Earnings Per Share, basic net loss per common share is computed by dividing net loss by the weighted average number of common shares outstanding during the reporting periods, including vested but undelivered stock options.

Diluted net loss per share is based on the weighted average number of shares outstanding during the periods plus the effect, if any, of the potential exercise or conversion of securities, such as warrants and restricted stock units that would cause the issuance of additional shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders during the periods listed in the consolidated statements of operations, the weighted average number of shares are the same for both basic and diluted net loss per share due to the fact that when a net loss exists, dilutive shares are not included in the calculation as the impact is anti-dilutive. An anti-dilutive impact is an increase in earnings per share or a decrease in net loss per share that would result from the conversion, exercise, or issuance of certain contingent securities.

Concentration of business and credit risk

Financial instruments, which potentially subject the Company to concentrations of credit risk, consist primarily of cash and cash equivalents and accounts receivable. Cash held by the Company, in financial institutions, may exceed the federally insured limit of $250,000 at certain times. ~~At December 31, 2021, cash balances held with a financial institution exceeded the federally insured limit.~~ There were no cash and cash equivalents which exceeded federally insured limits as of December 31, 2023 or 2022.

No customer accounted for more than 10% of sales or accounts receivable in each of the periods presented in the accompanying consolidated financial statements.

Fair value of financial instruments

Fair value is the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact, and it considers assumptions that market participants would use when pricing the asset or liability.

F-12

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

ASC Topic 820, Fair Value Measurements and Disclosures provides a fair value hierarchy, which prioritizes the inputs to valuation techniques used to measure fair value into three broad levels. The level in the hierarchy within which the fair value measurement in its entirety falls is based upon the lowest level of input that is significant to the fair value measurement as follows:

	●	Level 1 — inputs are based upon unadjusted quoted prices for identical assets or liabilities traded in active markets.
	●	Level 2 — inputs are based upon quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	●	Level 3 — inputs are generally unobservable and typically reflect management’s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models, and similar techniques.

Assets measured at fair value on a non-recurring basis include goodwill, and tangible and intangible assets. Such assets are reviewed annually for impairment indicators. If a triggering event has occurred, the assets are re-measured when the estimated fair value of the corresponding asset group is less than the carrying value. The fair value measurements, in such instances, are based on significant unobservable inputs (Level 3).

The carrying amounts of the Company’s financial instruments, which include accounts receivables, accounts payable and accrued expenses and debt at floating interest rates, approximate their fair values, principally due to their short-term nature, maturities or nature of interest rates.

Advertising and vendor considerations

Advertising costs are expensed as incurred.

Reclassifications

Certain prior period amounts have been reclassified to conform to the current period presentation.

Segment reporting

The Company operates as a single operating segment. The Chief Executive Officer, who is the chief operating decision maker, manages the Company as a single profit center in order to promote collaboration, provide comprehensive service offerings across the entire customer base, and provide incentives to employees based on the success of the organization as a whole. Although certain information regarding selected products or services is discussed for purposes of promoting an understanding of the Company’s business, the chief operating decision maker manages the Company and allocates resources at the consolidated level.

Recently Adopted Accounting Pronouncements

The Financial Accounting Standards Board (“FASB”) issued the following accounting pronouncement which became effective for the Company in 2021, and which did not have a material impact on its condensed consolidated financial statements:

F-13

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

In May 2021, the FASB issued ASU No. 2021-04, Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU No. 2021-04”), which provides guidance for a modification or an exchange of a freestanding equity-classified written call option that is not within the scope of another Topic. Under ASU 2021-04, an entity is required to treat a modification of the terms or conditions or an exchange of a freestanding equity-classified written call option, that remains equity classified, as an exchange of the original instrument for a new instrument. ASU 2021-04 also provides guidance on the measurement of the effect of a modification or exchange and requires entities to recognize the effect of any such modification or exchange on the basis of the substance of the transaction.

ASU No. 2021-04 was effective for fiscal years beginning after December 15, 2021, including interim periods within those fiscal years. Entities were required to apply the amendments prospectively to modifications or exchanges that occurred on or after the effective date. ASU No. 2021-04 was effective for the Company on January 1, 2022. The adoption did not materially impact the Company’s financial condition or results as the Company’s treatment of such modifications were already consistent with the guidance in ASU 2021-04.

Recently issued accounting standards

The Company does not believe other recently issued but not yet effective accounting standards, if currently adopted, would have a material effect on the Company’s consolidated balance sheets, statements of changes in equity, statements of operations and statements of cash flows.

Note 4 – Fair Value Measurements

The carrying value and fair value of the Company’s financial instruments are as follows:

~~SCHEDULE~~Schedule OFof ~~CARRYING~~Carrying ~~VALUE~~Value ~~AND~~and ~~FAIR~~Fair ~~VALUE~~Value

December 31, 2022

Level 1

Level 2

Level 3

Total

December 31, 2023

Level 1

Level 2

Level 3

Total

Liabilities

Warrant liabilities

—

~~203~~1,~~043~~766

As of December 31, 2021	Level 1		Level 2		Level 3		Total
As of December 31, 2022	Level 1		Level 2		Level 3		Total
Liabilities
Warrant liabilities	$	—	$	—	$	—203,043	$	—203,043

The fair value of the warrants outstanding was estimated using the Black-Scholes model. The application of the Black-Scholes model requires the use of a number of inputs and significant assumptions including volatility. The following reflects the inputs and assumptions used:

~~SCHEDULE~~Schedule OFof ~~FAIR~~Fair ~~VALUE~~Value ~~ASSUMPTIONS~~Assumptions

As of	December 31, ~~2022~~2023			December 31, ~~2021~~2022
Stock price	$	10.3007		$	~~N/A~~1.30
Exercise price	$	6.0440		$	~~N/A~~6.04
Remaining term (in years)		03.465			~~N/A~~0.46
Volatility		~~159~~171.008	%		~~N/A~~159	%
Risk-free rate		3.9984	%		~~N/A~~3.99	%
Expected dividend yield		—	%		—
Warrant measurement input		-			-

The warrant liabilities will be remeasured at each reporting period with changes in fair value recorded in other income (expense), net on the consolidated statements of operations. The change in fair value of the warrant liabilities was as follows:

~~SCHEDULE OF~~Schedule ~~CHANGE~~of INChange ~~FAIR~~in ~~VALUE~~Fair OFValue ~~THE~~of ~~WARRANT~~the Warrant ~~LIABILITIES~~Liabilities

Warrant liabilities
Estimated fair value at December 31, 2021	$	-
Issuance of warrant liabilities		357,053
Change in fair value		(154,010	)
Estimated fair value at December 31, 2022	$	203,043
Issuance of warrant liabilities		-
Change in fair value		(201,277	)
Estimated fair value at December 31, 2023	$	1,766

F-14

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~ 2022

Note 5 – ~~Asset Acquisitions~~Inventories

Botanical Biotech Asset Acquisition

On March 11, 2021, Company entered into an Asset Acquisition Agreement, which was fully executed on March 17, 2021, with multiple sellers (each, a “Seller” and, collectively, the “Sellers”), pursuant to which the Sellers agreed to sell certain assets to Company, and to transfer such assets to Botanical Biotech, LLC, a newly-formed, wholly-owned subsidiary of the Company (“Transferee” or “BB”). The assets purchased (“BB Assets”) include certain materials and manufacturing equipment, marketing or promotional designs, brochures, advertisements, concepts, literature, books, media rights, rights against any other person or entity in respect of any of the foregoing and all other promotional properties, in each case primarily used, developed or acquired by the Sellers for use in connection with the ownership and operation of the BB Assets. In exchange for the BB Assets the Company will pay the Seller a maximum of $355,057, payable half in the form of cash or cash equivalent and half in the form of restricted shares of common stock of the Company (the “Shares”) at a price per Share equal to the average closing price of the common stock of the Company during the ten (10) consecutive trading days immediately preceding the closing. The Company has agreed to indemnify the Sellers for certain breaches of covenants, representations and warranties and for claims relating to the BB Assets following closing.

In conjunction with the BB asset acquisition, the Company entered into consulting agreements with two sellers to coordinate the new start-up. All consideration was related to the acquisition of equipment and supplies. No liabilities were acquired.

The Company and BB entered into an employment agreement with Lebsock dated March 11, 2021 (the “Lebsock Agreement”) pursuant to which Lebsock will serve as the President of BB for a term of three (3) years. The term of the Lebsock Agreement will automatically renew for an additional 3-year term unless other terminated by either party.

Lebsock will receive a base salary equal to $120,000 per year, subject to an annual increase of not less than 3% on each anniversary of the Lebsock Agreement during the term. The Company also agreed to issue a stock bonus to Lebsock in accordance with the Company’s Incentive Stock Option Plan (“ISOP”) in an amount of $100,000, and to pay Lebsock a defined percentage of the EBITDA for BB each calendar quarter (“Profit Split”) according to a mutually agreed performance target (“Target”). EBITDA is defined as the earnings before interest, depreciation, taxes, depreciation, and amortization and will be paid as reported by the Company’s accountant and as reviewed by the Company’s auditor. It will be accumulative on a quarter-to-quarter basis, meaning if one quarter has a negative EBITDA, it would be offset against the following quarter’s positive EBITDA distribution. Lebsock has the option to accept the Profit Split in either direct cash payment or Shares, or any combination, at Lebsock’s option. Shares would be valued at the prior 10-day closing price and issued under SEC Rule 144 restriction.

Effective March 16, 2021, BB entered into a Consulting Agreement (the “Schlosser Agreement”) with Schlosser pursuant to which Schlosser has agreed to provide consulting services to BB for a period of 3 months in exchange for compensation equal to $10,000 per month. Schlosser will also be entitled to reimbursement for certain work-related expenses. Pursuant to the Schlosser Agreement, Schlosser also agreed to assign to BB all inventions developed by Schlosser in connection with his services to BB. The Schlosser Agreement also contains certain non-compete and confidentiality provisions. Per the Acquisition Agreement, Schlosser was to receive an employment agreement similar to the Lebsock Agreement; however, BB and Schlosser elected to enter into the Schlosser Agreement instead.

F-15

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, 2022 and 2021

CO Botanicals Asset Acquisition

On August 12, 2021, The Company and CO Botanicals LLC (“COB”), a newly-formed, wholly-owned subsidiary of the Company entered into an Equipment Acquisition Agreement (the “TWS Agreement”) with TWS Pharma, LLC,

(“TWS Pharma”) and L7 TWS Pharma, LLC (“L7 TWS” and, collectively with TWS Pharma, “TWS”). Pursuant to the TWS Agreement, COB agreed to purchase certain equipment and other assets from TWS (the “TWS Assets”) for a total purchase price equal to $5,316,774, with $1,250,000 payable via a 12-month promissory note issued by the Company to TWS Pharma with 6% simple interest and monthly payments of $100,000 due per month (the “TWS Note”), and $4,066,774 payable in shares of the Company’s common stock valued at $0.62 per share (the “TWS Shares”); provided, however, that $1,750,000 of the TWS Shares will be withheld in escrow for a period of ninety (90) days from the closing date, which will be deducted from the purchase price should the Company discover any defects or misrepresentations. The first $500,000 of payments of the TWS Note will be secured by 1,000,000 shares of the Company’s common stock to be held in escrow. During the year ending December 31, 2022, the $1,750,000 of shares held in escrow were released and issued.

TN Botanicals Asset Acquisition

On August 13, 2021 the Company and TN Botanicals LLC (“TNB”), a newly-formed, wholly-owned subsidiary of the Company, entered into an Asset Purchase Agreement (the “MCB Agreement”) with Music City Botanicals, LLC, pursuant to which TNB agreed to purchase certain equipment, other assets, and intellectual property from MCB (the “MCB Assets”) for a total purchase price equal to $1,394,324, with $498,259 payable in cash and $896,065 payable in shares of the Company’s common stock valued at $0.62 per share (the “MCB Shares”).

Imbibe Health Solutions Asset Acquisition

On February 22, 2021, Can B̅ Corp. (the “Company”) entered into a material definitive agreement (“Acquisition Agreement”) with Imbibe Health Solutions, LLC, a Delaware limited liability company (“Imbibe”), pursuant to which Imbibe agreed to sell certain of its assets to the Company. The assets to be purchased (“Assets”) include the intellectual property rights and other intangible assets relating to its branded products containing CBD. In exchange for the Assets, the Company has agreed to pay Imbibe $102,501 in the form of shares of common stock of the Company (with standard restricted legend, the “Shares”) at a price per share equal to the average price of the common stock of the Company during the ten (10) consecutive trading days immediately preceding the closing. The transaction finalized and $102,502 worth of shares were issued on November 7, 2021 and the remaining balance of $17,498 of shares were issued during the year ended December 31, 2022.

Note 6 – Inventories

Inventories consist of hemp biomass that is received in bulk. The CBD biomass is initially processed by extraction into winterized crude oil. The winterized crude oil is then processed into distillate and then into CBD isolate. These three processes are continuous as raw materials are converted from biomass to isolate in back-to-back operations so work in process is just a matter of hours in the processing cycle from biomass to CBD isolate. The isolate is then sold at wholesale or further processed into isomers. Inventories consistent of the following:

Schedule of Inventories

	December 31,		December 31,
	December 31, 2023		December 31, 2022
	2022		2021
Raw materials	$	1,196,112	$	829,844
Raw materials	$	829,844	$	818,042
Finished goods		423,430		1,194,209
Finished goods		1,194,209		1,735,396
Total	$	1,619,542	$	2,024,053
Total	$	2,024,053	$	2,553,438

F-1615

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Note 76 – Property and Equipment

Property and equipment consist of:

Schedule of Property and Equipment

	December 31,			December 31,
	December 31, 2023			December 31, 2022
	2022			2021
Furniture and fixtures	$	21,724		$	21,724
Furniture and fixtures	$	21,724		$	21,727
Office equipment		12,378			12,378
Manufacturing equipment		6,~~766~~828,~~208~~083			76,~~018~~766,~~522~~208
Medical equipment		776,396			776,396
Leasehold improvements		26,902			26,902
Total		7,~~603~~665,~~608~~483			7,~~855~~603,~~922~~608
Accumulated depreciation		(23,~~171~~559,~~251~~200	)		(~~802~~2,~~996~~171,251	)
Net	$	54,~~432~~106,~~357~~283		$	75,~~052~~432,~~926~~357

Depreciation expense related to property and equipment was $1,~~408~~387,~~061~~949 and $~~493~~1,~~656~~408,061 for the years ending December 31, ~~2022~~2023 and ~~2021~~2022, respectively.

Note 87 –Intangible Assets

Intangible assets consist of:

Schedule of Intangible Assets

	December 31,			December 31,
	December 31, 2023			December 31, 2022
	2022			2021
Technology, IP and patents	$	119,998		$	119,998
Technology, IP and patents	$	119,998		$	418,003
Total		119,998			119,998
Total		119,998			418,003
Accumulated amortization		(24,854	)		(12,854	)
Accumulated amortization		(12,854	)		(48,998	)
Intangible assets, net	$	95,144		$	107,144
Intangible assets, net	$	107,144		$	369,015

Amortization expense, related to technology, IP, and patents was $2612,~~906~~000 and $4826,~~689~~906 for the years ended December 31, ~~2022~~2023 and ~~2021~~2022, respectively.

Amortization expense for each of the next five years ending and thereafter is estimated to be as follows:

Years ending December 31,
2023	$	12,000
2024	$	12,000
2024		12,000
2025		12,000
2026		12,000
2027		12,000
Thereafter		47,144
2028		12,000
Total	$	107,144
Thereafter		35,144
Total	$	95,144

F-1716

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Note 98 – Notes and Loans Payable

Convertible Promissory Notes

In December 2020, the Company entered into a convertible promissory note (“ASOP Note I”) with Arena Special Opportunities Partners I, LP (“ASOP”). The original principal ~~balance~~amount of the note iswas $2,675,239 and itthe isproceeds are to be utilized for working capital purposes. The note ~~matures~~matured on January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOP convertible promissory note was issued with 228,419 common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to 228,419 shares of the Company’s common stock at an exercise price of $6.75 per share. The common stock purchase warrants issued to ASOP are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOP Note I. The principal balance ~~outstanding~~ outstanding at December 31, ~~2022~~2023 was $2,400,997.

In December 2020, the Company entered into a convertible promissory note (“ASOF Note I”) with Arena Special Opportunities Fund, LP (“ASOF”). The principal balance of the note is $102,539 and it is to be utilized for working capital purposes. The note matures on January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOF convertible promissory note was issued with 8,755 common stock warrants. The common ~~stock~~ stock purchase warrants entitle the holder to purchase an aggregate of up to 8,755 shares of the Company’s common stock at an ~~exercise~~ exercise price of $6.75 per share. The common stock purchase warrants issued to ASOF are considered derivatives, but satisfied the criteria ~~for~~ for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOF Note I. The principal balance outstanding at December 31, ~~2022~~2023 was $87,773.

In May 2021, the Company entered into a convertible promissory note (“ASOP Note II”) with Arena Special Opportunities Partners I, LP. The principal balance of the note is $1,193,135 and it is to be utilized for working capital purposes. The note matures on January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOP convertible promissory note was issued with 101,978 common stock warrants. The common stock purchase warrants ~~entitle~~ entitle the holder to purchase an aggregate of up to 101,978 shares of the Company’s common stock at an exercise price of $6.75 per share. The common stock purchase warrants issued to ASOP are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOP Note II. The principal balance outstanding at December 31, ~~2022~~2023 was $1,073,250.

In May 2021, the Company entered into a convertible promissory note (“ASOF Note II”) with Arena Special Opportunities Fund, LP. The principal balance of the note is $306,865 and it is to be utilized for working capital purposes. The note matures on January 31, 2022 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the ASOP convertible promissory note was issued with 26,228 common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to 26,228 shares of the Company’s common stock at an exercise price of $6.75 per share. The common stock purchase warrants issued to ASOF are considered derivatives, but satisfied the criteria for classification as equity instruments, and were bifurcated from the host contract - convertible promissory note and recorded in equity at their relative fair values with a corresponding debt discount recorded to ASOF Note II. The principal balance outstanding at December 31, ~~2022~~2023 was $276,750.

The maturity dates for the above notes were extended to April 30, 2022 on April 14, 2022 in exchange for the Company’s promise to pay the holders $300,000. The holders agreed to allow the Company to extend the notes for two additional 30-day periods for $100,000 per extension. The holders also waived certain defaults under the notes. The Company ~~has~~subsequently ~~since~~ elected to extend the maturity date to ~~May~~ May 31, 2022 for the promise to pay an additional $100,000. ~~The~~As discussed below under “Forbearance and Amendment of Outstanding Notes,” ASOP and ASOF have agreed to forbear from exercising remedies under the notes until December 31, 2023 provided that the Company isdoes ~~currently~~not default on its obligations under the Forbearance Agreement. In September 2023, Arena notified the Company that it was in ~~discussions~~default ~~regarding~~of certain obligations under the ~~further~~Forbearance ~~extension~~Agreement but did not declare an acceleration of the ~~notes~~ indebtedness.

F-17

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, 2023 and 2022

On January 1, 2022, the Company entered into a convertible promissory note (“Empire Note”) with Empire Properties, LLC (“Empire”). The principal balance of the note is $52,319 and it is to be utilized for working capital purposes. The note matured on December 31, 2022 or due on demand subsequently to any major funding received by the Company in excess of $5,000,000 and all principal, accrued and unpaid interest is due at maturity at a rate of 8% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. The principal balance outstanding at December 31, 2023 was $52,319.

In March 2022, the Company entered into a convertible promissory note (“BL Note”) with Blue Lake Partners, LLC (“BL”). The original principal amount of the note was $250,000 and the proceeds are to be utilized for working capital purposes. The note had an original maturity date of March 22, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the BL Note was issued with 39,062 common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to 39,062 shares of the Company’s common stock at an initial exercise price of $6.40 per share (subject to adjustment upon the occurrence of certain events, including the issuance of lower priced securities). The common stock purchase warrants issued to BL are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the BL Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Effective February 27, 2023, in consideration of the Company repaying an aggregate of $66,667 under the BL Note, BL agreed to extend the maturity date of the BL Note until September 1, 2023 and reduce the percentage of the cash proceeds received by the Company from the issuance of equity or debt that BL can require the Company to apply to the repayment of the BL Note from 50% to 33%. The principal balance outstanding at December 31, 2023 was $102,623 and the BL Note is past due.

In March 2022, the Company entered into a convertible promissory note (“MH Note”) with Mast Hill Fund, LP (“MH”). The original principal amount of the note was $350,000 and the proceeds are to be utilized for working capital purposes. The note had an original maturity date of March 22, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the MH Note was issued with 39,062 common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to 39,062 shares of the Company’s common stock at an initial exercise price of $6.40 per share (subject to adjustment upon the occurrence of certain events, including the issuance of lower priced securities). The common stock purchase warrants issued to MH are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the MH Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Effective February 27, 2023, in consideration of the Company repaying an aggregate of $93,333 under the MH Note, MH agreed to extend the maturity date of the MH Note until September 1, 2023 and reduce the percentage of the cash proceeds received by the Company from the issuance of equity or debt that MH can require the Company to apply to the repayment of the MH Note from 50% to 33%. . The principal balance outstanding at December 31, 2023 was $256,667 and the MH Note is past due.

In April 2022, the Company entered into a convertible promissory note (“FM Note”) with Fourth Man, LLC (“FM”). The original principal amount of the note was $150,000 and the proceeds are to be utilized for working capital purposes. The note had an original maturity date of April 22, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered derivatives and therefore have been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the FM Note was issued with 23,437 common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to 23,437 shares of the Company’s common stock at an initial exercise price of $6.40 per share (subject to adjustment upon the occurrence of certain events, including the issuance of lower priced securities). The common stock purchase warrants issued to FM are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the FM Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. Effective February 27, 2023, in consideration of the Company repaying an aggregate of $40,000 under the FM Note, FM agreed to extend the maturity date of the FM Note until September 1, 2023 and reduce the percentage of the cash proceeds received by the Company from the issuance of equity or debt that FM can require the Company to apply to the repayment of the FM Note from 50% to 33%. On June 30^th, 2023 the Company entered into a Settlement and Mutual Release Agreement to extinguish the $110,000 principal outstanding on the FM Note. As of December 31, 2023 the FM Note had been satisfied in full.

F-18

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

OnIn ~~January~~June 1, 2022, the Company entered into a convertible promissory note (“~~Empire~~Alumni Note”) with ~~Empire~~Alumni ~~Properties~~Capital, ~~LLC~~LP (“~~Empire~~Alumni”). The original principal ~~balance~~amount of the note iswas $5262,~~319~~500 and itthe isproceeds are to be utilized for working capital purposes. The note ~~matured on December 31,~~had ~~2022~~an ororiginal ~~due~~maturity ondate ~~demand~~of ~~subsequently~~June to6, ~~any~~2023 ~~major~~which ~~funding~~was ~~received~~extended byuntil ~~the~~September ~~Company~~1, in2023 ~~excess~~effective ofFebruary $527,~~000,000~~ ~~and~~2023. ~~all~~All principal, accrued ~~and~~ and unpaid interest is due at maturity at a rate of 812% per annum. The ~~conversion~~holder can require the full payment of the note if the Company completes an offering of its common stock that results in an uplisting of its common stock to a national securities exchange. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered aderivatives ~~derivative~~ and therefore ~~has~~ have been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the Alumni Note was issued with 9,766 common stock warrants. The ~~principal~~common ~~balance~~stock ~~outstanding~~purchase atwarrants ~~December~~entitle 31the holder to purchase an aggregate of up to 9,766 ~~2022~~shares ~~was~~of the Company’s common stock at an exercise price of $~~52,319~~6.40 per share. The common stock purchase warrants issued to Alumni are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the Alumni Note with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date.

~~In February 2022, the Company entered into a convertible promissory note (“Tysadco Note”) with Tysadco Partners, LLC (“Tysadco”).~~ The ~~principal balance of the note is $450,000 and it is to be utilized for working capital purposes. The note matured on July 25, 2022~~ ~~and all~~ principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of the convertible promissory note and not bifurcated. The principal balance outstanding at December 31, ~~2022~~2023 was $~~450~~62,~~000~~500. ~~This note has been extended an additional 6 months by mutual consent for the additional consideration of issuance of twenty thousand shares of common stock.~~

In ~~March~~August 2022, the Company entered into a convertible promissory note (“~~BL Note~~WN”) with ~~Blue~~Walleye ~~Lake~~Opportunities ~~Partners,~~Master ~~LLC~~Fund Ltd. (“BLWOMF”). The original principal ~~balance~~amount of the note iswas $~~250~~385,000 and itthe isproceeds are to be utilized for working capital purposes. The note originally matured on ~~March~~August 2230, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in the convertible promissory note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered aderivatives ~~derivative~~ and therefore ~~has~~have been recorded in liabilities as part of the convertible promissory note and not bifurcated. In addition, the BLWN Note was issued with 3971,~~062~~296 common stock warrants. The common stock purchase warrants entitle the holder to purchase an aggregate of up to 3971,~~062~~296 shares of the Company’s common stock at an exercise price of $65.40 per share. The common stock purchase warrants issued to BLWOMF are considered derivatives and did not satisfy the criteria for classification as equity instruments and were bifurcated from the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the BLWN ~~Note~~ with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting date. The principal balance outstanding at December 31, ~~2022~~2023 was $~~250~~385,000.

In ~~March~~January ~~2022,~~2023 the Company entered into a convertible promissory note (“MHTysadco Note VI”) with ~~Mast~~Tysadco ~~Hill Fund~~Partners, LPLLC (“MHTysadco”). The original principal ~~balance~~amount of the note iswas $~~350~~100,000 and itthe isproceeds are to be utilized for working capital purposes. The note ~~matured~~had a onmaturity ~~March~~date 22of April 12, 2023 , and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. ~~The conversion options contained in the~~Effective ~~convertible~~January ~~promissory~~31, ~~note~~2023, ~~were~~Tysadco ~~evaluated~~agreed ~~for~~to ~~derivative~~exchange ~~accounting~~the ~~under~~Tysdaco ~~ASC~~Note ~~815,~~VI ~~Derivatives~~ and ~~Hedging,~~other ~~and~~notes ~~determined~~held ~~not~~by toTysdaco ~~be considered~~in athe ~~derivative~~aggregate ~~and~~principal ~~therefore~~amount ~~has~~of $752,000 ~~been~~having ~~recorded~~maturity indates ~~liabilities~~between asAugust ~~part~~24, of2022 ~~the convertible promissory note~~ and ~~not~~March ~~bifurcated. In addition~~19, ~~the~~2023 MHfor ~~Note~~a ~~was~~single ~~issued~~note ~~with~~that ~~39,062~~matured ~~common~~on ~~stock~~September ~~warrants~~1, 2023. ~~The~~Contemporaneous with ~~common~~this ~~stock~~exchange, ~~purchase~~Tysadco ~~warrants~~assigned ~~entitle~~ the ~~holder~~combined note to ~~purchase an~~ClearThink ~~aggregate~~Capital ~~of up to 39~~Partners,~~062~~ ~~shares~~LLC ofand the Company’s ~~common~~issued ~~stock~~130,000 atshares ~~an exercise price~~ of ~~$6.40 per share. The~~ common stock ~~purchase warrants issued~~ to MHClearThink ~~are~~Capital ~~considered~~Partners, ~~derivatives~~LLC. ~~and~~The ~~did~~conversion ~~not~~options ~~satisfy~~contained in the ~~criteria~~combined ~~for~~note ~~classification~~were asevaluated ~~equity~~for ~~instruments~~derivative ~~and were bifurcated~~accounting ~~from~~under ~~the~~ASC ~~host~~815, ~~contract~~Derivatives -and ~~convertible~~Hedging, ~~promissory note~~ and ~~recorded~~determined asnot ato ~~liability~~be atconsidered ~~fair~~derivatives ~~value~~and ~~with~~therefore ahave ~~corresponding~~been ~~debt discount~~ recorded to ~~the MH Note with subsequent changes~~ in ~~fair~~liabilities as ~~values~~part ~~recognized~~of in the ~~consolidated~~convertible ~~statement~~promissory ofnote ~~operations~~and atnot ~~each reporting date~~bifurcated. The principal balance ~~outstanding~~of the combined note at December 31, ~~2022~~2023 was $~~350~~1,~~000~~007,500 and the combined note is past due.

InOn ~~April~~March ~~2022~~2, 2023, the Company ~~entered~~completed ~~into~~the asale ~~convertible~~of a promissory note (~~“FM~~the “Note”) ~~with~~in ~~Fourth~~the ~~Man, LLC (“FM”). The~~ principal ~~balance~~amount of ~~the note is~~ $~~150~~1,~~000 and it is to be utilized for working capital purposes. The note matures on April 22~~823,529 ~~2023 and~~to ~~all~~WOMF ~~principal,~~pursuant ~~accrued~~to ~~and~~a ~~unpaid~~Securities ~~interest~~Purchase isAgreement ~~due~~dated atas ~~maturity at a rate~~ of ~~12%~~February ~~per~~27, ~~annum~~2023. The ~~conversion~~purchase ~~options~~price ~~contained~~of in the ~~convertible promissory~~Note ~~note~~was ~~were evaluated for derivative accounting under ASC 815~~$1, ~~Derivatives and Hedging~~550,000, ~~and determined not to be considered~~representing ~~derivatives~~a ~~and~~15% ~~therefore~~original ~~have~~issue ~~been recorded in liabilities as part of the convertible promissory note and not bifurcated~~discount. InThe ~~addition, the FM~~ Note ~~was~~is ~~issued~~non-interest ~~with 23~~bearing,~~437~~ ~~common~~except ~~stock~~in ~~warrants. The common stock purchase warrants entitle~~ the ~~holder~~case ~~to purchase an aggregate~~ of ~~up to 23,437 shares of~~ the ~~Company’s~~event ~~common stock at an exercise price~~ of ~~$6.40~~a ~~per~~default, ~~share.~~in ~~The~~which ~~common~~case ~~stock purchase warrants~~interest ~~issued~~will toaccrue FMfrom ~~are considered derivatives and did not satisfy~~ the ~~criteria~~date ~~for~~of ~~classification as equity instruments and were bifurcated from~~ the ~~host~~default ~~contract - convertible promissory note and recorded as a liability~~ at ~~fair value with~~ a ~~corresponding~~rate ~~debt~~equal ~~discount recorded~~ to the FMlower ~~Note~~of ~~with~~18% ~~subsequent~~per ~~changes~~annum inor ~~fair values recognized in~~ the ~~consolidated~~maximum ~~statement~~rate ofpermitted ~~operations~~by ~~at each reporting date~~law. ~~The principal balance outstanding at December 31, 2022 was $150,000.~~

The Note is payable in nine (9) monthly installments of $232,500 each, consisting of a $227,941 principal reduction payment and a $4,559 redemption fee, commencing on April 27, 2023. The Company’s obligations under the note are secured by a security interest in the Company’s deposit accounts and the deposit accounts of the Company’s subsidiaries. In addition, each the Company’s subsidiaries has agreed that if an event of default occurs under the Note, the subsidiary will pay to WOMF an amount equal to 10% of revenues received during the prior month from the sale of goods or services or collections of accounts receivable.

F-19

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

InThe ~~June~~Note ~~2022,~~requires the Company ~~entered~~to ~~into~~use areasonable ~~convertible~~commercial ~~promissory~~efforts ~~note~~to ~~(“Alumni~~complete ~~Note”)~~an ~~with~~offering ~~Alumni~~which ~~Capital,~~will LPresult ~~(“Alumni”). The~~in ~~principal~~an ~~balance~~uplisting of ~~the~~its ~~note~~common stock ~~is $62,500 and it is~~ to bea ~~utilized~~national ~~for~~securities ~~working~~exchange ~~capital~~within ~~purposes.~~a ~~The~~reasonable ~~note~~time ~~matured~~following onthe ~~June~~issuance ~~6, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate~~ of ~~12%~~the ~~per annum~~Note. The ~~conversion~~Note ~~options~~contains ~~contained~~certain ~~in the~~negative ~~convertible~~covenants, ~~promissory~~including ~~note~~a ~~were~~prohibition ~~evaluated~~on ~~for~~the ~~derivative~~incurrence ~~accounting~~of ~~under~~debt ~~ASC~~that ~~815,~~is ~~Derivatives~~senior ~~and~~or ~~Hedging,~~pari ~~and~~passu ~~determined not~~ to ~~be considered derivatives and therefore have been recorded in liabilities as part of~~ the ~~convertible~~indebtedness ~~promissory~~represented ~~note~~by ~~and not bifurcated.~~the ~~In addition~~Note, the ~~Alumni~~creation ~~Note~~of ~~was~~liens ~~issued~~on ~~with~~the 9Company’s assets,~~766~~ ~~common stock warrants. The common stock purchase warrants entitle~~ the ~~holder~~payment ~~to purchase an aggregate~~ of updividends toand ~~9,766~~other ~~shares~~distributions ofon the Company’s common stock, atthe anrepurchase ~~exercise price~~ of ~~$6.40~~the ~~per~~Company’s ~~share. The~~ common stock, ~~purchase warrants issued to Alumni are considered derivatives and did not satisfy~~ the ~~criteria~~sale ~~for~~of ~~classification~~a assignificant ~~equity~~portion ~~instruments~~of ~~and were bifurcated from~~ the ~~host~~Company’s ~~contract~~assets ~~- convertible promissory note~~ and ~~recorded as a liability at fair value with a corresponding debt discount recorded to~~ the ~~Alumni Note with subsequent changes in fair values recognized in the consolidated statement~~ repayment of ~~operations~~indebtedness atother ~~each~~than ~~reporting date.~~existing ~~The principal balance outstanding at December 31, 2022 was $62,500~~indebtedness.

InThe ~~June~~Company ~~2022,~~may ~~the~~elect ~~Company~~to ~~entered~~pay ~~into~~all or a ~~convertible~~portion ~~promissory~~of ~~note~~a ~~(“Tysadco~~monthly ~~Note~~installment ~~II”)~~due ~~with~~under ~~Tysadco~~the ~~Partners,~~Note ~~LLC.~~by ~~The~~converting ~~principal balance~~such amount into shares of the ~~note~~Company’s common isstock ~~$75,000~~at ~~and~~a itprice isof to$4.00 beper ~~utilized~~share, ~~for~~subject ~~working~~to ~~capital~~adjustment ~~purposes.~~in ~~The~~accordance ~~note~~with ~~matured~~the onterms ~~December~~of 7,the ~~2022~~Note. ~~and~~As ~~all~~of ~~principal~~September 30, 2023, ~~accrued~~the ~~and~~adjusted ~~unpaid~~conversion ~~interest~~price iswas ~~due~~$.0772. atIf ~~maturity~~the atCompany adoes ~~rate~~not ofpay ~~12%~~an ~~per~~installment ~~annum.~~when ~~The~~due ~~conversion~~it ~~options~~is ~~contained~~deemed inan ~~the~~election ~~convertible~~by ~~promissory~~the Company ~~note~~to ~~were~~convert ~~evaluated~~the ~~for~~installment ~~derivative~~payment ~~accounting~~into ~~under~~common ~~ASC~~stock ~~815,~~at ~~Derivatives~~a ~~and~~price ~~Hedging,~~equal ~~and~~to ~~determined~~the ~~not~~lower toof be$4.00 ~~considered~~per ~~derivatives and~~share ~~therefore~~or ~~have~~90% ~~been~~of ~~recorded~~the inlowest ~~liabilities~~daily asvolume weighted ~~part~~average price of the ~~convertible~~common ~~promissory~~stock ~~note~~during ~~and~~the ~~not~~five ~~bifurcated~~trading days preceding the conversion date. ~~The~~WOMF ~~Tysadco~~has ~~Note~~the IIright isto determine ~~convertible~~the ~~into~~timing ~~common~~of ~~stock~~any ofsuch ~~the~~conversion. ~~Company~~WOMF may elect at any time ~~prior~~ to convert amounts payable under the ~~maturity~~Note ~~date~~into shares of the Company’s common stock at a conversion price of $4.00 per share, subject to adjustment in accordance with the ~~lesser~~terms of $7the Note.50 ~~and~~The Company did ~~75%~~not ofpay the ~~lowest~~installments ~~daily~~due ~~volume~~under ~~weighted~~the ~~average~~Note ~~price~~on ~~(“VWAP”)~~April ~~over~~27, ~~the~~2023, ~~previous~~May ~~ten~~1, ~~trading~~2023, ~~days~~June ~~prior~~1, to2023, ~~conversion.~~July ~~The principal~~1, ~~balance~~2023, ~~outstanding~~August at1, ~~December~~2023 31and September 1, ~~2022~~2023 ~~was~~in ~~$75~~cash. As a result,~~000~~ these installment payments will be converted into common stock at such time as WOMF elects to effect the conversions.

InIf ~~August 2022,~~ the Company ~~entered~~receives ~~into~~cash aproceeds ~~convertible~~from ~~promissory~~any ~~note (“WN”) with Walleye Opportunities Master Fund Ltd. (“WOMF”). The principal balance of the note is $385~~source,~~000~~ ~~and~~including itpayments isfrom tocustomers beor ~~utilized~~from ~~for working capital purposes. The note matures on August 30, 2023 and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in~~ the ~~convertible~~ ~~promissory~~issuance ~~note were evaluated for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered derivatives and therefore have been recorded in liabilities as part~~ of ~~the~~equity ~~convertible~~or ~~promissory note and not bifurcated. In addition~~debt, ~~the~~WOMF ~~WN Note was issued with 71,296 common stock warrants. The common stock purchase warrants entitle the holder to purchase~~can anrequire ~~aggregate of up to 71,296 shares of~~ the Company’s ~~common~~to ~~stock~~apply at100% ~~an exercise price~~ of ~~$5.40~~such ~~per~~proceeds ~~share. The common stock purchase warrants issued~~ to ~~WOMF are considered derivatives and did not satisfy~~ the ~~criteria~~repayment ~~for~~of ~~classification as equity instruments and were bifurcated from~~ the host contract - convertible promissory note and recorded as a liability at fair value with a corresponding debt discount recorded to the WN with subsequent changes in fair values recognized in the consolidated statement of operations at each reporting dateNote. ~~The principal balance outstanding at December 31, 2022 was $385,000.~~

InIf ~~August 2022,~~ the Company ~~entered~~completes ~~into~~ a ~~convertible~~placement ~~promissory~~of ~~note~~securities, ~~(“Tysadco~~WOMF ~~Note~~will ~~III”)~~have ~~with Tysadco. The principal balance of~~ the ~~note~~right isto ~~$110,000~~accept ~~and~~such itnew issecurities toin belieu ~~utilized~~of ~~for~~the ~~working~~Note ~~capital~~and ~~purposes~~Warrant. For ~~The~~so ~~note~~long ~~matured~~as onthe ~~February~~Note ~~12,~~is ~~2023 and all principal~~outstanding, ~~accrued~~ ~~and~~if ~~unpaid~~the ~~interest~~Company isissues ~~due~~a atsecurity ~~maturity~~or atamends athe ~~rate~~terms of ~~12%~~a ~~per~~security ~~annum.~~issued ~~The~~before ~~conversion~~the ~~options~~issue ~~contained~~date of in the ~~convertible~~Note, ~~promissory note~~and ~~were~~WOMF ~~evaluated~~believes ~~for~~that ~~derivative~~terms ~~accounting~~of ~~under~~the ~~ASC~~new ~~815,~~or ~~Derivatives~~amended ~~and~~security ~~Hedging,~~are ~~and~~more ~~determined~~favorable ~~not~~ to bethe ~~considered~~holder athan ~~derivative~~the terms provided to ~~and~~WOMF, ~~therefore~~WOMF ~~has~~may ~~been~~require ~~recorded~~that insuch ~~liabilities~~terms asbecome part of ~~the~~WOMF’s ~~convertible~~transaction ~~promissory~~documents ~~note~~with ~~and~~the ~~not bifurcated~~Company. ~~The principal balance outstanding at December 31, 2022 was $110,000.~~

In ~~September 2022,~~ the ~~Company~~event ~~entered~~of ~~into~~ a ~~convertible~~default ~~promissory~~under ~~note~~the ~~(“Tysadco~~ Note, ~~IV”)~~the ~~with~~Company ~~Tysadco.~~shall ~~The~~be ~~principal~~required ~~balance of~~to ~~the~~pay ~~note~~WOMF isan ~~$65,000~~amount ~~and~~equal ~~it is~~ to bethe ~~utilized~~amount ~~for~~determined ~~working~~by ~~capital~~multiplying the ~~purposes.~~principal ~~The~~amount ~~note~~then ~~matured~~outstanding onplus ~~March~~default ~~19,~~interest ~~2023,~~by ~~and all principal~~135%, ~~accrued~~ ~~and~~plus ~~unpaid~~costs ~~interest~~of iscollection. ~~due~~WOMF atmay ~~maturity~~elect atto aaccept ~~rate~~payment of ~~12%~~any such ~~per~~amount ~~annum.~~in ~~The~~cash ~~conversion~~and/or ~~options~~shares ~~contained~~of in the ~~convertible~~Company’s ~~promissory note~~common ~~were~~stock, ~~evaluated~~valued for ~~derivative~~this ~~accounting~~purpose ~~under~~at ~~ASC~~the ~~815,~~lower ~~Derivatives~~of ~~and~~the ~~Hedging,~~conversion ~~and~~price ~~determined~~then in ~~not~~effect toor ~~be considered~~ a ~~derivative and~~60% ~~therefore~~discount ~~has~~to ~~been~~the ~~recorded~~lowest involume ~~liabilities~~weighted asaverage ~~part~~price of the ~~convertible~~common ~~promissory~~stock ~~note~~during ~~and~~the ~~not~~five ~~bifurcated.~~trading ~~The~~days ~~principal~~preceding ~~balance outstanding~~the atconversion ~~December 31, 2022 was $65,000~~date.

InWOMF ~~October~~has ~~2022,~~been ~~the~~granted ~~Company entered into~~ a ~~convertible~~right ~~promissory note (“Tysadco Note V”) with Tysadco. The principal balance~~ of ~~the~~first ~~note~~refusal ~~is $50,000 and it is~~ to beparticipate utilized for working capital purposes. The note matured on March 19, 2023, and all principal, accrued and unpaid interest is due at maturity at a rate of 12% per annum. The conversion options contained in ~~the~~future ~~convertible~~financing ~~promissory note~~transactions ~~were~~conducted ~~evaluated~~by ~~for derivative accounting under ASC 815, Derivatives and Hedging, and determined not to be considered a derivative and therefore has been recorded in liabilities as part of~~ the ~~convertible promissory note and not bifurcated~~Company. ~~The principal balance outstanding at December 31, 2022 was $50,000.~~

As additional consideration for the purchase of the Note, the Company issued WOMF a warrant (the “Warrant”) to purchase 1,307,190 shares of the Company’s common stock at an exercise price equal to 90% of the lowest volume weighted average price of the common stock during the five trading days preceding the date of exercise. The Warrant contains a cashless exercise provision and is exercisable at any time during the period beginning on August 27, 2023 and ending on August 27, 2028. In addition, a warrant issued by the Company to WOMF in August 2022 was amended to change the exercise price of the warrant from $5.40 per share to the lower of $5.40 per share or the lowest volume weighted average price of the common stock during the five trading days preceding its exercise.

The Company has entered into a Registration Rights Agreement with WOMF pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission to register the shares of common stock issuable upon the conversion of the Note and the exercise of the Warrant for public resale. The Company filed the registration statement on May 12, 2023 and it was declared effective on May 22, 2023. WOMF has also been granted piggyback registration rights with respect to the shares of common stock issuable upon the conversion of the Note and the exercise of the Warrant. Each of the Note and Warrant grants full ratchet anti-dilution protection to WOMF in the event that the Company issues common stock or rights to purchase common stock at a price less than the conversion or exercise price then in effect.

In May 2023, the Company issued a promissory note to WOMF in the principal amount of $437,500. The purchase price of the note was $350,000, representing a 20% original issue discount. The note is non-interest bearing except in the event of a default, in which case interest will accrue at a rate of 40% per annum in the event of a payment default and 18% per annum in the event of other defaults. The note became due on October 15, 2023. The principal balance outstanding at December 31, 2023 was $256,893.

F-20

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Forbearance and Amendment of Outstanding Notes.

Contemporaneous with the sale of the Note and Warrant to WOMF, ASOP and ASOF (collectively, “Arena”), who hold promissory notes with an unpaid principal balance of approximately $3,877,000 which became due on April 30, 2022 (the “Arena Notes”), entered into a Forbearance Agreement with the Company pursuant to which they agreed to forbear from exercising remedies under the Arena Notes until December 31, 2024 provided that the Company does not default on its obligations under the Forbearance Agreement. In September 2023, Arena notified the Company that it was in default of certain obligations under the Forbearance Agreement but did not declare an acceleration of the indebtedness.

The Forbearance Agreement requires the Company and/or Company’s subsidiaries, Duramed, Inc. and Duramed MI, LLC (together the “Duramed Subsidiaries”) to remit to Arena on a monthly basis certain accounts receivable collected by the Company and/or the Duramed Subsidiaries until the total amount collected is $5,700,000. After the amount collected is $5,700,000, additional collections of these receivables are shared equally between the Company and Arena. The Company and the Duramed Subsidiaries have assigned their rights to these receivables to Arena.

In December 2023Arna notified the Company that it intended to conduct an auction of certain of the Company’s assets under Article 9 of the Uniform Commercial Code due to the alleged breaches of the Forbearance Agreement. See Note 14.

As a condition to the closing of the sale of the Note and Warrant to the WOMF, certain terms of certain promissory notes previously issued by the Company were amended, including the following:

	●	in consideration of an increase in the aggregate principal amount by $10,000 and an increase in the interest rate to 18% per annum, the holder of notes in the aggregate principal amount of $150,000 agreed to waive his right to require the Company to repay a $50,000 note upon the Company’s receipt of $1,500,000 of financing and extend maturity dates from November 18, 2021 and January 22, 2023 to September 1, 2023;

	●	in consideration of the Company’s agreement to provide a product credit for future orders of $50,000, the holder of a promissory note in the principal amount of $150,000 agreed to extend the maturity date from August 10, 2022 to September 1, 2023;

	●	the maturity date of a promissory note in the principal amount of $1,250,000 was extended from August 12, 2022 until the earlier of September 1, 2023 or the date that the Company completes an offering resulting in an uplisting of its common stock to the Nasdaq Capital Market; and

	●	in consideration of the repayment of a total of $232,500 under the notes, the holders of promissory notes in the aggregate principal amount of $435,000 issued in October and November 2022 that bore interest at 18% per annum and were past due agreed to exchange the notes for new notes that matured on September 1, 2023 and bear interest at 15% per annum;

F-21

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, 2023 and 2022

TWS Note

On August 12, 2021, pursuant to an Equipment Acquisition Agreement, the Company entered into a twelve-month promissory note of $1,250,000 with payments of $100,000 per month and interest at 6% (See Note 5). As of December 31, 2022, the total amount outstanding was $1,050,000.

WOMF October 2023 Note

On October 27, 2023, the Company completed the sale of a promissory note (the “Initial Note”) in the principal amount of $156,250 to WOMF pursuant to a Securities Purchase Agreement between the Company and the WOMF (the “Stock Purchase Agreement”). The purchase price of the Note was $125,000, representing a 20% original issue discount. The Initial Note is non-interest bearing, except in the case of the event of a default, in which case interest will accrue from the date of the default at a rate equal to the lower of 18% per annum or the maximum rate permitted by law. The Initial Note becomes due on October 27, 2024.

F-22

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

September 30, 2023

WOMF may elect to convert the principal amount of the Initial Note and default interest, if any, subject to adjustment at a price equal to 90% of the lowest daily volume weighted average price of the common stock during the fifteen trading days preceding the conversion date.

WOMF and/or investors introduced by WOMF may purchase up to an additional $1,693,750 aggregate principal amount of notes having terms substantially similar to the Initial Note (the “New Notes” and collectively with the Initial Note, the “Notes”). In addition to the principal and interest payment obligations under the Notes, the Company has agreed to pay and/or cause its newly formed 70% owned subsidiary, Nascent Pharma, LLC (“Nascent”,) to pay WOMF fifteen percent (15%) of all amounts that would otherwise be distributable to the Company by Nascent until WOMF receives distributions in the aggregate amount that equal the sum of (a) 200% of the purchase price of notes previously issued by the Company to WOMF plus (b) 200% of the principal amount of certain notes previously issued by the Company and acquired by WOMF from a third party plus (c) 100% of the purchase price of Notes purchased pursuant to the Stock Purchase Agreement; provided, however, if WOMF and/or other investors purchase $1,875,000 aggregate principal amount of Notes pursuant to the Stock Purchase Agreement, the obligation to pay 100% of the purchase price of the Notes shall be increased to 200% of the purchase price of such Notes. The amounts distributable by Nascent to the Company, if any, will represent the proceeds of Nascent’s enforcement of certain patents it is seeking to acquire. Nascent has not yet acquired such patents and no assurance can be given that it will be able to complete such acquisition. Under the terms of the Stock Purchase Agreement, the purchase of New Notes by WOMF and/or investors introduced by WOMF is subject to, among other things, Nascent’s acquisition of the patents. If Nascent does not complete the acquisition of the patents, the Company does not expect that any New Notes will be purchased and the Company will have no obligation to pay additional consideration to WOMF.

In the event of a default under a Note, the Company shall be required to pay the holder of the Note an amount equal to the amount determined by multiplying the principal amount of the Note then outstanding plus default interest by 135%, plus costs of collection. WOMF may elect to accept payment of any such amount in cash and/or shares of the Company’s common stock, valued for this purpose at the lower of the conversion price then in effect or a 60% discount to the lowest volume weighted average price of the common stock during the five trading days preceding the conversion date.

WOMF has been granted a right of first refusal to participate in future financing transactions conducted by the Company.

The Company has entered into a Registration Rights Agreement with WOMF pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission by December 11, 2023 to register for public resale the shares of common stock issuable upon the conversion of the Note and a consolidated note issued to WOMF in the principal amount of $1,354,210 (the “Consolidated Note”) which combined certain notes held by WOMF into a single Note. If the Company fails to file the registration statement by December 11, 2023 or have the registration statement declared effective by the deadlines set forth in the Registration Rights Agreement, the Company will be required to make a payment of 2% of the amount then owed under the Note and the Consolidated Note for each 30 day period after the applicable deadline that the Company does not file the registration statement or the registration statement is not declared effective. WOMF has also been granted piggyback registration rights with respect to the shares of common stock issuable upon the conversion of the Notes it acquires and the Consolidated Note. Each of the Initial Note and Consolidated Note grants full ratchet anti-dilution protection to WOMF in the event that the Company issues common stock or rights to purchase common stock at a price less than the conversion or exercise price then in effect.

F-23

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, 2023 and 2022

The Initial Note contains and the New Notes will contain a provision which provides that the holder will not be converted if the conversion would result in the holder becoming the beneficial owner of more than 9.99% of the Company’s outstanding common stock.

ClearThink Notes

The Company issued a convertible note in the principal amount of $15,000 to ClearThink Capital Partners, LLC (“ClearThink”) in September 2023 for a purchase price of $10,000. The note has a six month term and is past due. A note in the principal amount of $75,000 was issued to ClearThink for a purchase price of $50,000 in December 2023. This note has a nine month term. Each of the notes bears interest at a rate of twelve percent (12%) per annum and is convertible into the Company’s common stock at a conversion price of $.0772 per share

Other Loans

On November 18, 2021, the Company entered into a $100,000 unsecured promissory note agreement with a lender. The promissory note ~~accrues~~accrued interest at a rate of 10% per annum and iswas due within twelve months of issuance or due on demand ~~subsequently~~subsequent to any major funding received by the Company in excess of $3,000,000. As of ~~December~~September 3130, ~~2022~~2023 ~~the~~there ~~total~~was ~~amount~~no ~~outstanding~~principal ~~was $100,000~~outstanding.

During the year ended December 31, 2022, the Company entered into various agreements relating to the sales of future receivables for an aggregate purchase amount of approximately $450,000. The aggregate principal amounts are payable in weekly installments ranging from $2,917 through $453 until such time the obligations are fully satisfied. As of December 31, ~~2022~~2023, the total amounts outstanding were approximately $6595,000.

On February 11, 2022, the Company entered into a $175,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of 16% per annum and is due within six months or due on demand subsequently to any major funding received by the Company in excess of $2,000,000. As of December 31, ~~2022~~2023 the total amount outstanding was $175,000.

On August 18, 2022, the Company entered into a $250,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of 16% per annum and is due within three months or due on demand subsequently to any major funding received by the Company in excess of $1,000,000. As of December 31, ~~2022~~2023 the ~~total~~note ~~amount~~has ~~outstanding~~been ~~was~~satisfied ~~$250,000~~in full.

On October 14, 2022, the Company entered into a $115,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of 18% per annum and was due on October 31, 2022. As of December 31, ~~2022~~2023 the total amount outstanding was $~~115~~65,000.

On October 14, 2022, the Company entered into a $230,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of 18% per annum and was due on October 31, 2022. As of December 31, ~~2022~~2023 ~~the~~no ~~total~~principal ~~amount outstanding~~ was ~~$230,000~~outstanding.

On November 17, 2022, the Company entered into a $200,000 unsecured promissory note agreement with a lender. The promissory note accrues interest at a rate of 18% per annum and was due on December 17, 2022. As of S December 31, ~~2022~~2023 the total amount outstanding was $~~200~~125,000.

Note 109 – Stockholders’ Equity

Preferred Stock

Each share of Series A Preferred Stock is convertible into 218 shares of CANB common stock and is entitled to 4,444 votes. All Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu to all current and future series of preferred stock, unless otherwise stated in the certificate of designation for such preferred stock. In the event of a Liquidation Event, whether voluntary or involuntary, each holder may elect (i) to receive, in preference to the holders of Common Stock, a one-time liquidation preference on a per-share amount equal to the per-share value of preferred shares on the issuance date, as recorded in the Company’s financial records, or (ii) to participate pari passu with the Common Stock on an as-converted basis. Subject to any adjustments, the Series A holders shall be entitled to receive such dividends paid and distributions made to the holders of shares of Common Stock on an as converted basis. During the year ended December 31, 2022, the Company converted 15 shares of Series A preferred stock to 33,345 shares of common stock.

Each share of Series B Preferred Stock has the first preference to dividends, distributions and payments upon liquidation, dissolution and winding-up of the Company, and is entitled to an accrued cumulative but not compounding dividend at the rate of 5% per annum whether or not declared. After six months of the issuance date, such share and any accrued but unpaid dividends can be converted into common stock at the conversion price which is the lower of (i) $0.0101; or (ii) the lower of the dollar volume weighted average price of CANB common stock on the trading day prior to the conversion day or the dollar volume weighted average price of CANB common stock on the conversion day. The shares of Series B Preferred Stock have no voting rights.

F-2124

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Each share of Series C Preferred Stock has preference to payment of dividends, if and when declared by the Company, compared to shares of our common stock. Each Preferred Series C share is convertible into 1,667 shares of common stock. The shares of Series C Preferred Stock have voting rights as if fully converted. During the year ended December 31, 2022 the Company issued 1,077 shares of Series C preferred stock.

Each share of Series D Preferred Stock has 667 shares of voting rights only pari passu to common shares voting with no conversion rights and no equity participation. The Company can redeem Series D Preferred Stock at any time for par value.

On February 8, 2021, the Company’s Board of Directors approved the designation of the Series D Preferred Shares and the number of shares constituting such series, and the rights, powers, preferences, privileges and restrictions relating to such series. On March 27, 2021, the Company filed an amendment to its articles of incorporation to authorize 4,000 shares of a new Series D Preferred Stock with a par value of $0.001 each. All Series D Preferred Shares shall rank senior to all shares of Common Stock of the Company with respect to liquidation preferences and shall rank pari passu to all current and future series of preferred stock, unless otherwise stated in the certificate of designation for such preferred stock. Each Series D Preferred Share shall have voting rights equal to 667 shares of Common Stock, adjustable at any recapitalization of the Company’s stock. In the event of a liquidation event, whether voluntary or involuntary, each holder shall have a liquidation preference on a per-share amount equal to the par value of such holder’s Series D Preferred Shares. The holders shall not be entitled to receive distributions made or dividends paid to the Company’s other stockholders. Except as otherwise required by law, for as long as any Series D Preferred Shares remain outstanding, the Company shall have the option to redeem any outstanding share of Series D Preferred Shares at any time for a purchase price of par value per share of Series D Preferred Shares (“Price per Share”). Should the Company desire to purchase Series D Preferred Shares, the Company shall provide the Holder with written notice and a check or cash in an amount equal to the number of shares of Series D Preferred Shares being purchased multiplied by the Price per Share. The shares of Series D Preferred Shares so purchased shall be deemed automatically cancelled and the Holder shall return the certificates for such share to the Corporation. During the year ended December 31, 2022 the Company issued 2,050 shares of Series D preferred stock.

Common Stock

For the year ended December 31, 2022, the Company issued an aggregate of 51,282 shares of Common Stock under its Offering Statement on Form 1-A (File No. 024-11233) (the “Regulation A Offering”).

In addition, for the year ended December 31, ~~2022~~2023, the Company issued an aggregate of ~~190~~28,~~505~~330,612of ~~13,704, 1,270,616, 18,227, and 10,150 of~~ Common Stock for ~~asset~~the ~~acquisitions,~~acquisition ~~property~~of inventory and equipment, services rendered, ~~exercise~~legal ~~of warrants~~settlements, ~~and~~accrued inpayroll, ~~lieu~~conversion of promissory notes and principal and interest ~~repayments, respectively.~~payments

F-2225

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Note 1110 – Stock Options

The Company has an employee share option plan, which is shareholder-approved, permits the grant of share options and shares to its employees. The Company believes that such awards better align the interests of its employees with those of its shareholders. Option awards are generally granted with an exercise price equal to the market price of the Company’s stock at the date of grant. Share awards generally vest over five years.

The fair value of each option award is estimated on the date of grant using a lattice-based option valuation model that uses the assumptions noted in the following table. Because lattice-based option valuation models incorporate ranges of assumptions for inputs, those ranges are disclosed. Expected volatilities are based on implied volatilities from traded options on the Company’s stock, historical volatility of the Company’s stock, and other factors. The expected term of options granted is derived from the output of the option valuation model and represents the period of time that options granted are expected to be outstanding; the range given below results from certain groups of employees exhibiting different behavior. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

	December 31, 2022			December 31, 2021
	December 31, 2023			December 31, 2022
Per share fair value at grant date	$	30.5113		$	83.0251
Risk free interest rate		34.0036			13.0200
Expected volatility		~~226~~206	%		~~201~~226	%
Dividend yield		0	%		0	%
Expected life in years		5			5

A summary of stock options activity for the year ended December 31, 2022 and 2021 is as follows:

~~Summary~~Schedule of Stock Options Activity

	Option Shares		Weighted Average Exercise Price		Weighted Average Remaining Contractual Life (Years)
Outstanding, January 1, 2021		79,147	$	5.37		3.92
Granted		298,507	$	6.30		4.61
Outstanding, December 31, 2021		377,654	$	6.11		3.97
Granted		679,012	$	2.86		4.02
Exercised		-		-		-
Forfeited		-		-		-
Expired		-		-		-
Outstanding and exercisable, December 31, 2022		1,056,666	$	4.02		3.82
Granted		11,166,665	$	0.12		4.88
Outstanding and exercisable, December 31, 2023		12,223,331	$	3.08		3.89

At December 31, ~~2022~~2023 all stock options are no intrinsic value.

As of December 31, ~~2022~~2023, there was no unrecognized compensation cost related to nonvested stock-based compensation arrangements granted under the share option plan. The Company recognized$1,451,665 and $2,371,819 of stock-based compensation expense during the ~~year~~ years ended December 31, 2023 and December 31, 2022., respectively

F-2326

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Note 1211 – Income Taxes

The provision for income taxes consisted of the following:

Schedule of Provision For Income Taxes

	December 31,		December 31,
	December 31, 2023		December 31, 2022
	2022		2021
State franchise tax	$	9,596	$	793
State franchise tax	$	793	$	1,075

The Company’s effective income tax rate differs from the federal statutory rate primarily as a result of certain expenses being deductible for financial reporting purposes that are not deductible for tax purposes, the existence of research and development tax credits, operating loss carryforwards, and adjustments to previously recorded deferred tax assets and liabilities due to the enactment of the Tax Cuts and Jobs Act in 2017.

The difference in the provision for income taxes and the amount computed by applying the statutory federal income tax rates consists of the following:

	December 31,			December 31,
	December 31, 2023			December 31, 2022
	2022			2021
Expected income tax benefit	$	(1,647,456	)	$	(3,042,141	)
Expected income tax benefit	$	(3,042,141	)	$	(2,034,215	)
State franchise tax		9,596			793
State franchise tax		793			1,075
Non-deductible stock-based compensation		648,286			942,867
Non-deductible stock-based compensation		942,867			252,205
Non-deductible stock-based interest		69,076			15,346
Non-deductible stock-based interest		15,346			41,856
Increase in deferred income tax assets valuation allowance		930,094			2,083,928
Increase in deferred income tax assets valuation allowance		2,083,928			1,740,154
Provision for income taxes	$	9,596		$	793
Provision for income taxes	$	793		$	1,075

Principal components of the Company’s deferred tax assets as of December 31, 2022 and December 31, 2021 were as follows:

Schedule of Deferred Income Tax Assets

	December 31,			December 31,
	December 31, 2023			December 31, 2022
	2022			2021
Net operating loss carryforward	$	(6,685,532	)	$	(5,755,437	)
Net operating loss carryforward	$	(5,755,437	)	$	(3,671,509	)
Valuation allowance		6,685,532			5,755,437
Valuation allowance		5,755,437			3,671,509
Net	$	-		$	-

At December 31, ~~2022~~2023, the Company had net operating loss carryforwards of approximately $2731,~~407~~836,000 that begin to expire in 2025.

The Company files a federal income tax return and separate income tax returns in various states. For federal and certain states, the 2019 through 2022 tax years remain open for examination by the tax authorities under the normal three-year statute of limitations.

The Company assesses available positive and negative evidence to estimate whether sufficient future taxable income will be generated to permit use of the existing deferred tax assets. A significant component of objective negative evidence identified during management’s evaluation was the cumulative loss incurred over the three-year period ended December 31, ~~2022~~2023. Such objective evidence limits the ability to consider other subjective evidence, such as our forecasts of future taxable income and tax planning strategies. On the basis of this evaluation as of December 31, ~~2022~~2023 and ~~2021~~2022, the Company recognized a full valuation allowance against its net deferred tax assets, pursuant to ASC 740, as of December 31, 2023 and December 31, 2022. Based on the Company’s evaluation, it was determined that no uncertain tax positions existed as of December 31, ~~2022~~2023 or December 31, ~~2021~~2022.

Note 1312 – Related Party Transactions

For the ~~years~~year ended December 31, 2022 ~~and 2021,~~ the Company paid fees to a service provider that is a relative of a director for professional ~~services~~ services in the amount of $17,100 ~~and $28,100, respectively~~.

At December 31, 2023 and 2022, the Company has amounts due to directors of the Company of ~~approximately~~$357,243 and $295,243, respectively, which are expected to be repaid in the next twelve months.

F-2427

Can B̅ Corp. and Subsidiaries

Notes to Consolidated Financial Statements

December 31, ~~2022~~2023 and ~~2021~~2022

Note 1413 – Commitments and Contingencies

Employment Agreements

On December 28, 2020, the Company entered into new three-year Employment Agreements with CEO Marco Alfonsi, CFO Stanley Teeple, and ~~Pure~~ Pure Health Products LLC Pasquale Ferro. Under these agreements, they are to receive a i) base salary of fifteen thousand dollars ($15,000.00) per month, ii) is eligible to receive cash and or stock bonuses, iii) shall receive a stock bonus in accordance with the Company’s Incentive Stock Option Plan (“ISOP”) in an amount of one-hundred thousand dollars ($100,000) per year of the Agreement, iv) ~~200~~ 200 shares of the Company’s Series C Preferred stock, v) usual and customary benefits including expense reimbursement, health and life insurance plan reimbursements and allowances. Phil Scala. Interim COO also received a similar agreement with a base ~~compensation~~ compensation of fifty-two thousand annually, $100,000 in ISO, and 20 Preferred C shares. These agreements were replaced by new agreements effective February 8, 2024.

Consulting Agreements

On July 15, 2020, we engaged an advisor to provide consulting services under an Investor Relations and Advisory Agreement (the “Advisory Agreement”). Pursuant to the Advisory Agreement, we agreed to pay the Consulting Firm a restricted common stock monthly fee of $5,000 per month for the initial 3 months., $6,250 per month for months 4-6., $7,500 per month for month 7 and after. At CANB’s option, the monthly fee may be payable in part or in whole in cash. Monthly Fee, such amount shall be paid via issuance of restricted common shares of the Company. The shares are to be issued in the name of Tysadco Partners. The number of common shares earned each month shall be calculated and issued on a quarterly basis prior to each 90-day period and based on the value at the closing price on the last day of the preceding period. All common shares earned by the Consultant pursuant to this Agreement shall be issued by CANB on a quarterly basis.

Lease Agreements

The Company leases office space in numerous medical facilities offices under month-to-month agreements. The Company determines if a contract contains a lease at inception. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date of the lease based on the present value of lease payments over the lease term. The Company uses the incremental borrowing rate to determine the present value of lease payments, as the implicit rate is not readily determinable. The ROU asset also includes any lease payments made. Lease expense for lease payments is recognized on a straight-line basis over the lease term.

~~Rent~~At ~~expense for the years ended~~ December 31, ~~2022~~2023, ~~and~~the ~~2021~~total ~~was~~future ~~$768,829~~minimum ~~and~~lease ~~$614,779,~~payments ~~respectively.~~were as follows:

At December 31, 2022, the total future minimum lease payments were as follows:

		2022
2024	$	294,818
2023	$	740,852
Total future minimum lease payments	$	294,818
2024		469,818
Less: Interest		(40,427	)
Total future minimum lease payments	$	1,210,670
Total present value of lease liabilities	$	254,391
Less: Interest		(120,394	)
Total present value of lease liabilities	$	1,090,276

As of December 31, ~~2022~~ 2023, the Company had a weighted average remaining lease term of 1.3 1 years and a weighted average discount rate of 8.92%.

Note 1514 – Subsequent Events

~~Issuance~~In February 2024, the Company’s 67% owned subsidiary, Nascent Pharma, LLC (“Nascent”), acquired composition of ~~OID~~matter and ~~Note~~use patents covering liquid formulations of cannabis, including, among other things, beverages, tinctures, vape pen liquids and ~~Warrant~~liquid filled capsules. Patented uses include using the liquid formulations to manage numerous debilitating conditions, including cancer, irritable bowel syndrome, chronic pain, post-traumatic stress disorder, anxiety, sleep disorders and opioid dependencies. Through Nascent, the Company plans to pursue opportunities to license and develop uses for the patents.

OnIn ~~March~~connection 2,with ~~2023,~~ the ~~Company~~assignment ~~completed the sale~~ of ~~a promissory note (~~the ~~“Note”)~~patents into ~~the~~Nascent, ~~principal~~Nascent ~~amount~~has ofagreed ~~$1,823,529~~ to an ~~investor~~distribute ~~(the “Investor”) pursuant~~ to acreditors ~~Securities Purchase Agreement dated as~~ of ~~February~~a ~~27,~~prior ~~2023.~~owner ~~The purchase price~~ of the ~~Note~~patents five ~~was~~percent ~~$1,550,000, representing a 15~~(5%) ~~original~~of ~~issue~~the ~~discount.~~Company’s ~~The~~share ~~Note~~of isNascent’s ~~non-interest bearing~~revenues, ~~except~~less ~~in the case of the event of~~ a ~~default,~~reserve infor ~~which~~Nascent’s ~~case~~operating ~~interest~~expenses ~~will~~and amounts ~~accrue~~repaid ~~from~~to ~~the~~Nascent ~~date~~investors, ofuntil the ~~default~~creditors athave areceived ~~rate~~aggregate ~~equal~~payments ~~to the lower~~ of ~~18% per annum or the maximum rate permitted by law~~$10,000,000.

The ~~Note is payable in nine (9) monthly installments of $232,500 each, consisting of a $227,941 principal reduction payment and a $4,559 redemption fee, commencing on April 27, 2023. The~~ Company’s ~~obligations~~has ~~under~~entered ~~the~~into ~~note are secured by~~ a ~~security~~consulting ~~interest~~agreement inwith the ~~Company’s~~ ~~deposit~~inventor ~~accounts~~who ~~and~~assigned the ~~deposit~~patents ~~accounts~~to ofNascent ~~the~~which ~~Company’s~~provides ~~subsidiaries. In addition, each the Company’s subsidiaries has agreed~~ that ~~if an event of default occurs under~~ the ~~Note, the subsidiary~~ consultant will ~~pay~~be entitled to ~~the~~fifty ~~Investor~~percent ~~an amount equal to 10~~(50%) of ~~revenues~~distributions received ~~during~~by ~~the~~Company ~~prior month~~ from ~~the sale of goods or services or collections of accounts receivable~~Nascent.

~~The~~In ~~Note~~February ~~requires~~2024, the Company toissues ~~use~~options ~~reasonable commercial efforts~~ to ~~complete~~purchase an25,264,463 ~~offering~~shares ~~which will result in an uplisting~~ of ~~its~~it ~~common~~ commo stock toat aan ~~national~~exercise ~~securities~~price ~~exchange within a reasonable time following the issuance~~ of ~~the Note~~$.05 ~~The~~per ~~Note~~share ~~contains certain negative covenants, including a prohibition on the incurrence of debt that is senior or pari passu~~ to ~~the indebtedness represented by the Note~~officers, ~~the creation of liens on the Company’s assets, the payment of dividends and other distributions on the Company’s~~ ~~common stock~~directors, ~~the~~employees ~~repurchase of the Company’s common stock, the sale of a significant portion of the Company’s assets~~ and ~~the~~ ~~repayment of indebtedness other than existing indebtedness~~consultants.

~~F-25~~On February 29, 2024, the Company completed the sale of a promissory note in the principal amount of $75,000 to ClearThink. The purchase price of the note was $50,000, representing a 33.33% original issue discount. The note becomes due on November 29, 2024 and bears interest, payable upon maturity, at a rate of 12% per annum. ClearThink may convert the purchase price of the note and accrued and unpaid interest into shares of the Company’s common stock at any time at a conversion price of $0.0772 per share. The proceeds of the loan were used for general working capital purposes.

~~The~~On ~~Company~~March ~~may~~14, ~~elect~~2024, tothe ~~pay~~previously ~~all~~announced orauction ~~a portion~~ of aassets ~~monthly installment due under the Note by converting such amount into shares~~ of the ~~Company’s common~~hemp ~~stock~~division ~~at a price~~ of ~~$4.00~~Can ~~per~~B ~~share, subject to adjustment in accordance with the terms of the Note~~Corp. If (the “Company”) ~~does~~under ~~not pay~~Article an9 ~~installment~~of ~~when due it is deemed an election by~~ the ~~Company~~Uniform toCommercial ~~convert~~Code ~~the~~was ~~installment~~completed. ~~payment~~The ~~into~~auction ~~common~~resulted ~~stock~~in atproceeds ~~a price equal to the lower~~ of approximately $~~4.00~~300,000 ~~per~~from ~~share or 90% of~~ the ~~lowest~~sale ~~daily volume weighted average price~~ of ~~the~~certain ~~common stock during the five trading~~equipment ~~days~~to ~~preceding~~multiple ~~the~~bidders, ~~conversion~~which ~~date.~~has ~~The~~been ~~Investor~~applied ~~may elect at any time~~ to ~~convert~~the ~~amounts~~Company’s ~~payable~~obligations under ~~the~~Convertible ~~Note~~Notes ~~into~~held ~~shares~~by ofArena ~~the~~Special ~~Company’s~~Opportunities ~~common~~Partners ~~stock~~I, ~~at a conversion price of $4~~L.~~00 per share~~P., ~~subject~~Arena toSpecial ~~adjustment~~Opportunities inFund, ~~accordance~~LP ~~with~~and ~~the~~Arena ~~terms~~Investors, ~~of the Note~~L.P.

IfOn ~~the~~April ~~Company~~7, ~~receives~~2024, ~~cash~~Arena ~~proceeds~~filed ~~from~~a ~~any~~complaint ~~source~~in the Court against the Company, ~~including~~it ~~payments~~subsidiaries ~~from~~and ~~customers~~certain orofficers ~~from~~of the ~~issuance~~Company ofand ~~equity~~its subsidiaries oralleging ~~debt,~~tortious interference with the ~~Investor can~~auction ~~require~~and seeking a declaratory judgment that the Company tois ~~apply~~in ~~100%~~breach of ~~such~~the Arena ~~proceeds~~notes and the Forbearance Agreement and that Arena has the right to auction certain equipment held at a Company facility that is not owned by the ~~repayment~~Company or any of ~~the~~its ~~Note~~subsidiaries. The Company believes that Arena’s claims are without merit and intends to vigorously defend Arena’s claims.

If the Company completes a placement of securities, the Investor will have the right to accept such new securities in lieu of the Note and Warrant. For so long as the Note is outstanding, if the Company issues a security or amends the terms of a security issued before the issue date of the Note, and the Investor believes that terms of the new or amended security are more favorable to the holder than the terms provided to the Investor, the Investor may require that such terms become part of Investor’s transaction documents with the Company.F-28

In the event of a default under the Note, the Company shall be required to pay the Investor an amount equal to the amount determined by multiplying the principal amount then outstanding plus default interest by 135%, plus costs of collection. The Investor may elect to accept payment of any such amount in cash and/or shares of the Company’s common stock, valued for this purpose at the lower of the conversion price then in effect or a 60% discount to the lowest volume weighted average price of the common stock during the five trading days preceding the conversion date.

The Investor has been granted a right of first refusal to participate in future financing transactions conducted by the Company.

As additional consideration for the purchase of the Note, the Company issued the Investor a warrant (the “Warrant”) to purchase 1,307,190 shares of the Company’s common stock at an exercise price equal to 90% of the lowest volume weighted average price of the common stock during the five trading days preceding the date of exercise. The Warrant contains a cashless exercise provision and is exercisable at any time during the period beginning on August 27, 2023 and ending on August 27, 2028. In addition, a warrant issued by the Company to the Investor in August 2022 was amended to change the exercise price of the warrant from $5.40 per share to the lower of $5.40 per share or the lowest volume weighted average price of the common stock during the five trading days preceding its exercise.

The Company has entered into a Registration Rights Agreement with the Investor pursuant to which the Company has agreed to file a registration statement with the Securities and Exchange Commission by April 13, 2023 to register the shares of common stock issuable upon the conversion of the Note and the exercise of the Warrant for public resale. If the Company fails to file the registration statement by April 13, 2023 or have the registration statement declared effective by the deadlines set forth in the Registration Rights Agreement, the Company will be required to make a payment of 2% of the amount then owed under the Note for each 30 day period after the applicable deadline that the Company does not file the registration statement or the registration statement is not declared. The Investor has also been granted piggyback registration rights with respect to the shares of common stock issuable upon the conversion of the Note and the exercise of the Warrant. Each of the Note and Warrant grants full ratchet anti-dilution protection to the Investor in the event that the Company issues common stock or rights to purchase common stock at a price less than the conversion or exercise price then in effect.

F-26

Each of the Note and Warrant contains provisions pursuant to which the Investor has agreed not to effect a conversion of the Note or exercise of the Warrant if the conversion or exercise would result in the Investor becoming the beneficial owner of more than 9.99% of the Company’s outstanding common stock.

Forbearance and Amendment of Outstanding Notes.

As a condition to the closing of the sale of the Note and Warrant to the Investor, certain terms of certain promissory notes previously issued by the Company were amended, including the following:

● the maturity date of a promissory note in the principal amount of $62,500 was extended from June 6, 2023 to September 1, 2023; provided, however, that the holder can require full payment if the Company completes an offering of its common stock that results in an uplisting of its common stock to a national securities exchange; ● in consideration of the Company repaying an aggregate of $200,000 under notes issued in March 2022, the holders of the notes agreed to extend the maturity dates of the notes until September 1, 2023 and reduce the percentage of the cash proceeds received by the Company from the issuance of equity or debt that the holders of the notes can require the Company to apply to the repayment of the notes from 50% to 33%; ● in consideration of an increase in the aggregate principal amount by $10,000 and an increase in the interest rate to 18% per annum, the holder of notes in the aggregate principal amount of $150,000 agreed to waive his right to require the Company to repay a $50,000 note upon the Company’s receipt of $1,500,000 of financing and extend maturity dates from November 18,2021 and January 22,2023 to September 1, 2023; ● in consideration of the Company’s agreement to provide a product credit for future orders of $50,000, the holder of a promissory note in the principal amount of $150,000 agreed to extend the maturity date from August 10,2022 to September 1, 2023; ● the maturity date of a promissory note in the principal amount of $1,250,000 was extended from August 12, 2022 until the earlier of September 1, 2023 or the date that the Company completes an offering resulting in an uplisting of its common stock to the Nasdaq Capital Market; ● in consideration of the repayment of a total of $232,500 under the notes, the holders of promissory notes in the aggregate principal amount of $435,000 issued in October and November 2022 that bore interest at 18% per annum and were past due agreed to exchange the notes for new notes that mature on September 1, 2023 and bear interest at 15% per annum; and ● in consideration of an increase in the aggregate principal amount to $937,000, the holder of notes in the aggregate principal amount of $852,000 having maturity dates between August 24, 2022 and April 12, 2023 agreed to exchange the notes for a single note that matures on September 1, 2023.

F-27

Filing Compare · Can B Corp